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ABSTRACT 
 
 Amphotericin B (AmB) represents a clinically vital but toxic antibiotic that additionally 
has the ability to form ion channels in biological membranes, a capacity normally associated 
with proteins. Better understanding the dynamics of channel formation and how it relates to 
AmB’s antifungal activity would stand to enable both the rational development of derivatives 
that have a better therapeutic index, and the design of the small molecule prosthetics with the 
capacity to treat currently incurable human diseases. Efficient access to derivatives of AmB 
would greatly facilitate these goals.  
In this context, several methodological advances have been made that were stimulated by 
studies toward an efficient and flexible total synthesis of AmB. In response to challenges 
encountered in the construction of the AmB polyene, a new cross-coupling protocol was 
developed whereby N-methyliminodiacetic acid (MIDA) boronates can be used directly in 
Suzuki-Miyaura cross-coupling (SMC) reactions, enabling air-stable MIDA boronates to act as 
surrogates for boronic acids. Additionally, conditions were identified under which MIDA 
boronates could be slowly hydrolyzed in the SMC reaction, enabling an in situ “slow-release” of 
the boronic acid. This slow release effect enables the efficient cross-coupling of a variety of 
otherwise unstable boronic acids. The synthesis and isolation of 2-pyridyl MIDA boronate and 
its derivatives demonstrates that even the most unstable boronic acids may be rendered stable 
and competent cross coupling partners by conversion to the corresponding MIDA boronates. 
Further, the use of “fast-release” conditions enabled the construction of the AmB heptaene as 
well as a variety of polyenyl natural products both within and outside our research group.  To 
overcome the challenging 1,2-cis glycosidic bond found in AmB a mycosamine sugar donor 
synthesis was developed incorporating a new directing group for neighboring group 
participation. The use of this new directing group enabled efficient glycosylation of, and 
ultimately the completion of, a critical building block in the context of the iterative cross-
coupling (ICC)-based synthesis of AmB. The potential of this glycosylation strategy for rapidly 
accessing AmB derivatives was also demonstrated in the synthesis of a C3’-deaminomycosamine 
sugar donor and its efficient attachment to a protected amphotericin aglycone. 
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CHAPTER 1 	
 
Understanding of Mycosamine-Containing Polyene Macrolides 
 
 
1-1 TOTAL SYNTHESIS AS A STIMULUS FOR NEW SYNTHETIC METHODOLOGY 
 The remarkable complexity and variety of molecular structures found in nature forces the 
synthetic chemist to consider new tactics and strategies for their synthesis in the laboratory. For 
this reason natural product synthesis has historically led to the development of a large number of 
new chemical methods, ranging from new carbon-heteroatom and carbon-carbon bond-forming 
reactions, to new techniques to control the stereochemical outcome of existing reactions, and 
even to the discovery of entirely new reactions. The continued discovery and challenge of natural 
products with difficult-to-access architectures suggests that the potential of small molecules to 
stimulate new methodology remains high. 
 Mycosamine-containing polyene macrolides constitute one such class of natural products. 
Despite being known for more than 60 years, members of this class still pose a formidable 
synthetic challenge. Polyene macrolides are also notable for their biological activity. They are 
potent antimycotics, and the most prominent member of the class, amphotericin B, remains the 
last line of defense against systemic fungal infections in humans. Furthermore, some members, 
including amphotericin B, are capable of forming ion-channels in biological membranes, a 
function normally reserved for proteins. We believe this ability to perform protein-like activity 
represents untapped potential in this class of compounds, but harnessing that potential will 
require a better understanding of its mechanism of action, something that has eluded the 
scientific community for more than half a century. The following sections describe the historical 
context of this remarkable small molecule, the current understanding of its mechanism of action, 
and some new synthetic methodologies that have been stimulated by our own efforts toward its 
synthesis and study. 
 
1-2 AMPTHOTERICN B: A CLINICALLY VITAL SMALL MOLECULE 
Systemic fungal infections represent a serious and expanding threat to human health. In 
the United States, the occurrence of fungal septicemias increased by 207% between the years of 
1979 and 2000,1 fungal pathogens account for approximately 10% of all reported hospital 
acquired infections, and  Candida species alone are statistically tied for the third most common 
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source of microbial bloodstream infection.2 Further, the prevalence of fungal infections may be 
significantly underestimated due to the challenges inherent to their diagnosis, as well as the high 
frequency of false-negative results in fungal blood-cultures.3 For those infected, mortality rates 
are high, ranging from 30–80%.4 The associated burden to the U.S. healthcare system is also 
high, with reports of total cost ranging from $1–4 billion annually.5-7  Additionally, demographic 
trends that are associated with an increased risk of fungal septicemia such an aging population, 
an increase in the length of hospital stays, and a growing population of immunocompromised 
individuals due to organ transplants and stem cell therapies, are only expected to continue.8 
Further exacerbating this situation is the growing problem of microbial resistance which has 
narrowed the range of viable treatments.9 Mirroring the trends seen in bacterial antibiotics,10 the 
development of new classes of antifungal agents has also been slow, making microbial resistance 
an even more serious concern. 
Despite these troubling statistics, prior to 1950 the situation was even more dire, with the 
mortality rate of blood borne fungal infections at nearly 100% due to the lack of any effective 
treatment.11 The isolation of the potent antifungal polyene macrolide nystatin (initially named 
fungicidin) from the soil bacterium Streptomyces noursei in 195012-13 revolutionized the 
treatment of fungal infections. Commercialized in 1954, nystatin was the first broad spectrum 
antifungal agent. In the years following nystatin’s isolation, intense research unearthed a number 
of additional polyene macrolides, including rimocidin in 1951,14 perimycin in 1952,15 candicidin 
in 1953,16 amphotericin in 1955,17 and natamycin in 1957.18 
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Figure 1.1. Chemical structure of amphotericin B (AmB) 
 
Today, amphotericin B (AmB) (Figure 1.1), also a member of this class, represents the 
standard of care for systemic fungal infections. First introduced in the clinic in 1958, AmB has 
enjoyed continuous clinical use for over 50 years. The remarkable success of this antibiotic can 
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be attributed to two factors: its broad spectrum of activity19 and its relative insusceptibility to 
microbial resistance.20 However, despite its potent antifungal activity, the effective clinical use 
of AmB has been hampered by its severe dose-limiting toxicity. Specifically, the use of AmB is 
associated with significant cardiac and renal toxicity, as well as hemolytic anemia. 21 These 
effects have been partly reduced by liposome formulations,22 but an unclear understanding of 
AmB’s mechanism of action has to date hampered further improvement of the therapeutic index, 
or the design of more effective derivatives, of this vital antibiotic. 
AmB is also notable for its capacity for form discrete ion-channels in lipid bilayers, a 
phenomenon that we find to be extremely provocative. Specifically, it suggests to us that AmB 
might serve as the foundation for the development of “molecular prosthetics,” small molecules 
designed to mimic the function of proteins in living systems. There exist a number of diseases 
that stem from an acute lack of protein function, including channelopathies like cystic fibrosis.23 
These diseases are essentially untreatable via the current pharmacological paradigm: that of 
using a small molecule to inhibit a protein target. The use of a molecular prosthetic that could 
even partially restore the function of a missing or dysfunctional protein might represent a 
fundamentally new way to treat these diseases.24-26 We therefore propose that an atomistic 
understanding of this remarkable small molecule-based channel stands to not only enable the 
pursuit of less toxic AmB derivatives, but might also enable the development of a new class 
drugs targeting currently incurable diseases. 
 
1-3 STRUCTURAL CHARACTERISTICS OF THE POLYENE MACROLIDES 
 AmB belongs to a class of natural products called mycosamine-containing polyene 
macrolides. Since the discovery of AmB, more than 200 mycosamine-containing polyene 
macrolides have been reported, though to date only 36 have been structurally characterized to a 
reasonable degree of certainty.27-50 Their structural similarity is a consequence of their common 
biosynthetic origin; all are products of type I polyketide synthase (PKS) machinery found in their 
producing organisms.51 Further, this class of natural products is characterized by several notable 
structural features, all found on the “eastern end” of the molecules. As shown in Figure 1.2, these 
include a 6-membered endocyclic hemiketal, an exocyclic carboxylic acid, and a mycosamine 
sugar appendage. The carboxylic acid and mycosamine sugar are both installed by dedicated 
tailoring enzymes after the parent macrolide is released from the PKS machinery.52 Interestingly, 
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within this class of natural products, mycosamine attachment is always accompanied by the 
presence of the neighboring carboxylic acid, which is itself installed by P-450 mediated 
oxidation of an exocyclic methyl group. These two functional groups are also notable in their 
rarity outside of the polyene macrolide family. The only other natural products known to contain 
a mycosamine sugar are the fluvaricins,53-55 and the tetramic acid derivative vancoresmycin.56 
Exhaustive oxidation of exocyclic methyl groups is also extremely rare.52 
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Figure 1.2. Structural features common to mycosamine-containing polyene macrolides, as shown on AmB. 
Together, these features comprise a highly conserved motif, which is highlighted in blue. 
 
 Collectively, these structural features form a highly conserved motif common to all 
mycosamine-containing polyene macrolides that have been structurally characterized thus far 
(Figure 1.2). Given the ubiquity of this structural motif across all members of the polyene 
macrolide family, we hypothesized that these natural products share a common mechanism of 
action, and that this motif might represent the structural features critical for that mechanism.  
 
1-4 MECHANISTIC UNDERSTANDING OF POLYENE MACROLIDE ANTIBIOTICS 
 Understanding the mechanism of antifungal activity of AmB and other members of the 
polyene macrolide family is key to the development antimycotics with improved therapeutic 
indexes. Additionally, a thorough understanding of AmB’s mechanism of action might shed light 
on how it is uniquely insusceptible to microbial resistance. Such an understanding could enable 
the design of a new class of pharmaceuticals better able to avoid the growing problem of 
microbial resistance, which would have a substantial impact beyond just fungal infections. With 
this potential in mind it is therefore not surprising that a tremendous amount of effort has been 
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directed at understanding the mechanism of action of polyene macrolides over the last half 
century. 
 Initial studies on the mechanism of polyene macrolides were performed in 1958 by 
Osteux and coworkers, who observed that nystatin induced leakage of low molecular weight 
contents from C. albicans, but that larger contents were retained.57 Similarly, in 1961 Kinsky and 
coworkers found that treatment of N. crassi with AmB resulted in a significantly reduced dry 
weight of mycelial mats.58 Kinsky proposed that AmB permeabilizes membranes, and that this 
permeabilization is the source of its activity. Since that time, membrane permeabilization has 
been the general mechanism most often implicated as the mode of activity and toxicity in these 
compounds.51,59-60 Indeed, a significant amount of data over the years has correlated the 
membrane permeabilizing properties of AmB and related polyene macrolides with their 
biological activity. de Kruijff and co-workers showed that cholesterol laden A. laidlawii, known 
to be sensitive to AmB, lost intracellular potassium when exposed to AmB.61 Correspondingly, 
the eubacterium B. megaterium, which is completely resistant to AmB, showed no efflux of 
cellular material.62-64 In 1976, electrophysiology experiments with black planar lipid bilayers 
(BLM)65 showed unequivocal channel formation in both AmB and nystatin.66 Remarkably, these 
channels displayed characteristics, such as gating, more generally associated with protein ion 
channels. Further, it was demonstrated that these channels could be reversibly blocked with 
tetraethylammonium cation,67 also similar to known protein ion channels. With evidence 
mounting for a existence of a discrete channel, Andreoli and coworkers investigated the ability 
of small solutes to pass through membranes permeabilized with AmB.68 They found that AmB 
increased the membrane permeability of small molecules like urea and glycerol, but not larger 
molecules like glucose. Correlating the hydrodynamic radii of these small molecules with their 
ability to transit membranes in the presence of AmB, Andreoli and coworkers estimated an AmB 
pore size of 7–10 Å. 
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Figure 1.3. (A) Top down view of the barrel-stave channel model proposed for AmB. (B) Side on view of the 
channel complex double-barrel channel with one half of the barrel in each leaflet of the membrane, stacked on top of 
one another. (C) The single-barrel channel model, in which one barrel pinches the membrane together. 
 
Collectively, these results led to the now classic barrel-stave channel model, proposed 
independently by de Kruijff,69 Andreoli,70-71 and Finklestein72 (Figure 1.3). In this model, eight 
monomers of AmB assemble into a membrane-spanning complex, each with their hydrophilic 
polyol projecting inward toward the interior of a water-filled pore, and the hydrophobic polyene 
exposed to the exterior lipid environment. Additionally, there are two basic proposals for how 
this channel might span a lipid bilayer. In the first, single barrel-hypothesis, a single AmB 
octomeric complex, or barrel, spans the membrane directly, forcing the surrounding 
phospholipids to pinch together. In the double-barrel hypothesis, two barrels stack on top of one 
another to span the bilayer.73 The double-barrel model appears particularly attractive for AmB, 
given that the length of the AmB macrolactone (21 Å) is conspicuously almost exactly one half 
the length of a lipid bilayer (43 Å). Nevertheless, these two models remain debated in the 
literature.74 
 Several interactions have been predicted to play a key role in the stabilization of this 
barrel-stave complex. All three involve the mycosamine sugar and C41’-carboxylate, the very 
same conserved functionality shown previously as unique to mycosamine-containing polyene 
macrolides. In the first proposal, the C41-carboxylate and the C3’-ammonium of the 
mycosamine interact to form a stabilizing ring of salt bridges around the periphery of the 
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channel.75-77 In the second proposal, the C41-carboxylate and mycosamine sugar have been 
implicated in intermolecular polar interactions with the head groups of nearby lipids, thereby 
anchoring the channel in the membrane.76-78 Finally, it has also been proposed that the 
mycosamine sugar may engage in a direct binding interaction with membrane sterols, 
specifically to the C3-β-hydroxyl of the A ring in ergosterol and cholesterol.76-77,79-82 It should be 
noted, however, that a competing hypothesis proposes that AmB does not interact directly with 
membrane embedded sterols at all.83-84 In this indirect sterol model, sterols change the global 
membrane properties, thereby creating more favorable conditions for AmB activity. 
 While there was clear evidence for channel formation, the existence or nature of a direct 
binding interaction with sterols was more controversial in the literature. Despite this lack of 
clarity, the dependence of AmB activity on the presence of sterols was well known even in the 
1950’s. In 1958, Carter and coworkers found that the addition of exogenous sterols isolated from 
carrots effectively inhibited the activity of many polyene macrolide antibiotics against yeast,85 
though at the time it was not clear why. Kinsky and coworkers noted that rat erythrocytes, which 
contain cholesterol, and N.Crassa protoplasts, which contain ergosterol are both sensitive to 
AmB, while B. megaterium, which lacks any membrane sterols, is completely resistant.62-64 
Further evidence came in comparative studies with the mycobacterium, A. laidlawii, which lack 
the protein machinery to manufacture their own membrane sterols. They will readily incorporate 
environmental sterols into their own membranes, but the presence of sterols is not necessary for 
their survival.  Feingold and coworkers observed that laidlawii grown in strictly sterol-free 
media were insensitive to AmB, but that they became sensitive upon addition of exogenous 
sterol.61 Similar results were observed with the S. japonicus, a yeast strain which modulates its 
ergosterol production based on the availability of oxygen. When these yeast are grown under 
strictly anaerobic conditions produce no sterols, and when grown as such were found to be 
insensitive to natamycin. When grown under aerobic conditions, the yeast produce ergosterol, 
and become sensitive.86 Additionally, in BLM studies the presence of sterols (ergosterol or 
cholesterol) is necessary for AmB channel formation.87 Collectively, these experiments 
demonstrated a clear dependence of AmB activity on the presence of sterol, but the exact nature 
of that dependence remained unclear. 
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1-5 PROBING AMB VIA A FUNCTIONAL GROUP-DELETION APPROACH 
 Traditionally, attempts to directly probe the nature of the AmB ion channel interaction 
have relied upon covalent modification of AmB and/or lipids.88-89 This strategy suffers from 
fundamental experimental complications, in that covalent attachment of a bulky group to either 
AmB or a lipid can dramatically alter its conformation and/or chemical reactivity, making the 
functional effects of the modifications difficult to interpret. Even small changes, such as the 
inversion of the 3-β-hydroxyl group on a sterol can dramatically alter the effects the sterol has on 
a lipid bilayer.90-91 We envisioned a different approach, whereby we would delete protic 
functional groups from AmB and then assay the functional consequence of the deletion in a 
manner similar to “alanine scanning” in protein science.92-93 In this functional group-deletion 
approach there is no complication from introducing added steric bulk or new reactivity, and 
assuming that deletion does not change the gross conformation of the target molecule, any 
change in function would be directly attributable to the excised group.  
 Palacios and coworkers successfully demonstrated this approach in a study probing the 
importance of the mycosamine sugar and C41-carboxylate to the antifungal activity of AmB.94 
AmB derivatives MeAmB (lacking the C41-carboxylate), AmdeB (lacking mycosamine) and 
MeAmdeB (lacking both) were prepared, and the consequences of these modifications were 
investigated (Figure 1.4). The mycosamine sugar was observed to be required for antifungal 
activity, as both derivatives lacking the sugar were inactive against yeast strain C. albicans and 
S. cerevesiae. Surprisingly though, deletion of the C41-carboxylate alone yielded a compound 
that was equipotent to AmB. Since a methyl group cannot donate or accept a hydrogen bond, this 
derivative cannot participate in the intermolecular interaction proposed to stabilize the channel 
complex. Therefore, either this polar interaction is not required for the channel formation, and/or 
channel formation is not required for cell killing. 
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Figure 1.4. Functional group deletion strategy applied to the AmB carboxylate and mycosamine sugar. 
  
The power of this approach was further demonstrated when combined with an isothermal 
titration calorimetry (ITC) assay that enabled interrogation of a direct binding interaction 
between AmB and ergosterol.95 Using the same set of functional group-deficient derivatives, 
Palacios and coworkers demonstrated that the mycosamine sugar is critical for a direct binding 
interaction between AmB and ergosterol in lipid bilayers, as well as for channel formation. 
Interestingly, it was known that some mycosamine-containing polyene macrolides, including 
natamycin and rimocidin, are potent antimycotics, but do not permeabilize membranes.69,96-97 
Also, in some mutated yeast strains the anti-fungal and membrane permeabilizing effects of 
mycosamine-containing polyene macrolides is disconnected.98 Collectively, the above data led to 
the hypothesis that mycosamine-containing polyene macrolides operate by two distinct 
mechanisms: sterol-sequestration and membrane-permeabilization via channel formation, both of 
which require mycosamine-mediated sterol binding as enabled by the conserved structural motif 
found in all members of this class of natural products (Figure 1.5B). 
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Figure 1.5. (A) Structures of AmB and ergosterol. (B) While the C35-hydroxyl of AmB was not predicted to be 
necessary for mycosamine mediated sterol binding, it was predicted to be critical for either of the two leading 
models of channel formation. 
 
In a subsequent study,99 Gray and coworkers prepared a new functional group deficient 
probe, C35deOAmB. The C35 hydroxyl group of AmB is not predicted to be critical for the 
proposed mycosamine-mediated binding of ergosterol (Figure 1.5A), but the C35-hydroxyl is 
expected to be critical for the formation of the AmB channel complex by either of the two 
leading models for channel formation in lipid bilayers (Figure 1.5B). In the single barrel model, 
the C35 hydroxyl is expected to participate in polar interaction with the neighboring 
phospholipid head groups, while in the double-barrel model, the C35 hydroxyl is expected to 
mediate dimerization of the individual barrel units via a network of intermolecular hydrogen 
bonds.  Deletion of the C35 hydroxyl therefore provides a way of discriminating between these 
two mechanisms, sterol binding and channel formation. Indeed, C35deOAmB was found to be 
incapable of permeabilizing membranes, yet retained the ability to bind ergosterol, as determined 
by ITC. Importantly, C35deOAmB also retained potent antifungal activity. Thus, it was 
concluded that direct sterol binding, not channel formation, is primarily responsible for the 
antifungal activity of AmB. 
This conclusion has several important implications. First, efforts to date to improve the 
therapeutic index of AmB have largely focused on the challenging task of promoting the 
assembly of a multimeric channel in the lipid bilayers of yeast cells over those of human cells. 
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The identification of ergosterol-binding as the primary mode of cell killing makes the task of 
finding more effective derivatives, at least in principle, simpler. To find a less toxic derivative of 
AmB, one needs simply to create an AmB derivative that more selectively binds ergosterol, the 
principle sterol in yeast, over cholesterol, the principle sterol in humans. 
Second, the development of microbial resistance represents a globally emerging threat to 
human health. The existence of drugs like AmB  that have been in continual use for over 50 
years without significant microbial resistance suggests that antimicrobial mechanisms exist 
which are inherently refractory to resistance. AmB kills yeast cells primarily by binding and 
sequestration of ergosterol, a critical membrane lipid, and this might represent a general strategy 
for the design of new, more enduring drugs. It should be noted that AmB may also benefit from a 
dual mode of antimicrobial action. While sterol binding is the primary mechanism of cell killing, 
channel formation likely contributes as a secondary mechanism, making the development of the 
microbial resistance even more challenging. This dual mechanism parallels the activity observed 
in the antibiotic nisin, which displays a similar dual mode of action.100 
Finally, the ability of C35deOAmB to bind ergosterol without forming channels 
demonstrates that the two modes of action of AmB are not inextricably linked. This suggests that 
derivatives might be possible which readily form channels, but do not significantly bind to 
cholesterol. Discovering such derivatives would be a crucial first step in developing a molecular 
prosthetic which could mimic the function of a protein ion-channel without the toxicity 
associated with sterol-binding. 
 Ultimately, all of the above goals necessitate a still deeper understanding of the principles 
underlying sterol binding and channel formation. Fortunately, the deletion-based approach 
represents a powerful way to interrogate the mechanism of small molecules. Further, the now 
clarified sterol binding model plainly identifies the next targets for study. While the mycosamine 
sugar is necessary for sterol binding, the functional group(s) responsible for this binding event 
remain unclear. Future functional deletion targets include AmB derivatives lacking individual 
hydrogen bonding group on the mycosamine to identify specifically which group(s) are involved 
in sterol binding. Specifically, individual deletion of the C2’ and C4’-hydroxyls and the C3’-
amine would provide insight into which of these functional groups is involved in sterol binding. 
Unfettered access to these derivatives would enable a deeper understanding of this important 
small molecule-small molecule interaction 
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1-6 ICC APPROACH TO THE SYNTHESIS OF AMB 
 In the context of the functional group deletion strategy, synthesizing the defunctionalized 
probes is by far the hardest step. Once a functionally deficient probe is in hand, the assays 
necessary to test its activity are relatively straightforward. For example, the synthesis of the key 
deoxygenated derivative C35deOAmB described in the previous section required the combined 
contributions of six graduate students over more than 5 years. In contrast, once C35deOAmB 
was in hand, biological experiments required to assess its activity required less than 4 months, 
including significant time spent developing a new ITC assay. The development of a more 
efficient route to small molecules would dramatically speed up the scientific process. Of more 
fundamental concern, in the context of AmB, many defunctionalized derivatives of interest are 
not accessible from a degradative approach. As part of a systematic approach to the atomistic 
dissection of AmB, a synthetic strategy was needed to access derivatives potentially lacking any 
protic functional group. With this aim in mind, we decided that an efficient, bottom-up synthesis 
of AmB would greatly facilitate the preparation of new derivatives. 
 AmB represents a formidable synthetic target, and to date only one total synthesis has 
been achieved, by Nicolaou and coworkers in 1988.101-103 Nicolaou’s synthesis is undoubtedly a 
classic, but it lacks the efficiency and flexibility required to generate multiple deoxygenated 
derivatives in quantities necessary for study. To realistically have a chance at accessing 
derivatives by total synthesis another approach would be required. To enable a more 
systematized and efficient approach toward AmB, and small molecules in general, Gillis and 
coworkers reported in 2007 the development of a system for the iterative cross-coupling (ICC) of 
bifunctional haloboronic acid building blocks.104 Complexation of a boronic acid with N-
methyliminodiacetic acid (MIDA) renders the boron center inert to anhydrous Suzuki-Miyaura 
cross-coupling (SMC) conditions, as well as a variety of other synthetic transformations.105 
Despite this stability, MIDA boronates can be deprotected under aqueous basic conditions to 
yield the corresponding boronic acids, which can then be subjected to another SMC reaction, 
thus enabling an iterative cycle (Figure 1.6). 
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Figure 1.6. (A) The ICC strategy was inspired by the facile manner by which polypeptides are assembled from pre-
formed bifunctional building blocks using a single reaction. (B) In ICC, the stability of the MIDA protecting group 
to anhydrous base enables cross-coupling of a boronic acid selectively to a bifunctional building block containing a 
halide and a protected boronic acid. Subsequent deprotection of MIDA reveals a new boronic acid, enabling the 
process to be iterated. 
  
Applying Suzuki transforms to AmB enables it to be deconstructed into four smaller, 
much more synthetically manageable building blocks. This building block approach is also 
highly desirable in the context of the synthesis of derivatives, as for any given derivative, only 
one of the four building blocks needs to be modified. Also notable is BB2, a building block that 
incorporates all of the conserved functionality inherent to mycosamine-containing polyene 
macrolide antibiotics. This particular building block would be especially useful, as it could be 
applied to the ICC-based synthesis of any of the known polyene macrolides. 
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Figure 1.7. ICC-based retrosynthesis of AmB. 
 
 
 
Figure 1.8. The synthesis of AmB has stimulated two important new synthetic methodologies in addition to the 
general ICC strategy described by Gillis and coworkers: slow-release cross-coupling and TDMB-directed β-
glycosylation. The development of these two methodologies is detailed in the following chapters. 
 
The following chapters describe new synthetic methodologies borne out of efforts to 
overcome synthetic challenges encountered in the synthesis of AmB by this ICC strategy (Figure 
1.8). Specifically, the proposed assembly of the AmB polyene by ICC, which requires the cross-
O
O
OH
OH
OHOH
OH
OHOHO
Me
HO
Me
Me
O
O
H Me
OH
NH2
HO
CO2H
   
Slow-release cross-coupling
TDMB-directed β-glycosylation 
 
 
15 
 
coupling of unstable boronic acids, stimulated the development of a new cross-coupling 
methodology involving the slow release of unstable boronic acids from air-stable MIDA 
boronates. Additionally, attachment of the critical mycosamine appendage to BB2 proved to be 
very challenging and stimulated the development of new glycosylation methodology involving 
the use of a new directing group for 1,2-trans-glycosidations. Importantly, in several cases, the 
solutions to above problems proved highly useful outside of the context of synthesizing AmB 
and its derivatives. 
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CHAPTER 2 	
 
Direct-Release Cross-Coupling of MIDA Boronates 
 
 
 The SMC reaction was chosen as the basis for the ICC platform due to its well-
demonstrated power in the construction of complex small molecules. Nevertheless, the synthesis 
of AmB and its derivatives presents an exceptional challenge that ultimately demanded the 
development of new methodology. This chapter describes such methodology; i.e. a new SMC 
reaction protocol based on the in situ release of boronic acids from their corresponding MIDA 
boronates under aqueous basic cross-coupling conditions. The author’s contribution to the 
development was inspired by challenges encountered in work toward the AmB total synthesis, 
but the developed methodology has proven to be much more generally useful, enabling the 
efficient cross-coupling of a range of classes of otherwise unstable boronic acids. Efficient cross-
coupling of polyenyl, vinyl, cyclopropyl, and 2-heterocyclic MIDA boronates is described, as 
well as the notoriously challenging 2-pyridyl motif. Eric P. Gillis contributed the results 
presented in Figure 2.2, Table 2.5, Table 2.6, and Table 2.7. Graham R. Dick contributed all of 
the results presented in section 2-6. 
 
2-1 BACKGROUND 
 Boronic acids are highly desirable building blocks due to their low cost, minimal 
environmental impact and lack of toxicity,1 as well as the relatively mild conditions necessary to 
activate them for cross-coupling.2 They serve as excellent building blocks for the synthesis of a 
wide range of natural products, pharmaceuticals, and materials, and with the development of 
MIDA boronates and the ICC platform the utility of boronic acids in the construction of complex 
small molecules has been even further extended.3-10 Yet, boronic acids are not without their 
limitations. Most notably, some are highly susceptible to protodeboronation, oxidation, and/or 
polymerization11-12 which preclude their benchtop storage and/or efficient coupling, particularly 
with aryl chlorides. 
In light of this, the assembly of the AmB polyene by iterative SMC reactions was 
anticipated to be a challenging portion of the synthesis, due to the necessity of working with 
highly conjugated polyenylboronic acid intermediates. Polyenylboronic acids are notoriously 
unstable,13-14 which has to some extent precluded their general use in organic synthesis. This 
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possible hurdle was confirmed in an experiment modeling the final coupling reaction of the AmB 
polyene synthesis using the ICC strategy (Scheme 2.1). Deprotection of pentaenyl-MIDA 
boronate 2.1 with aqueous sodium hydroxide and subsequent cross-coupling with dienyl chloride 
2.2 proved to be very challenging. This challenge was attributed to the very sensitive nature of 
the required polyenyl boronic acid intermediate. 
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Me
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Scheme 2.1. Deprotection of pentaenyl MIDA boronate 2.1 to the corresponding boronic acid and subsequent 
exposure to SMC reaction conditions with dienyl chloride 2.2 was extremely challenging 
  
This result highlights one of the principal challenges associated with boronic acids: Many 
of the most desirable boronic acids, including polyenyl, 2-heterocyclic,15-24 vinyl,12,25-26 and 
cyclopropyl27-30 derivatives are inherently unstable. This instability manifests in two important 
ways. First, these boronic acids tend to be unstable to storage. Second, protodeboronation, a 
common decomposition pathway, is known to be accelerated by heat, base, polar solvents and 
palladium catalysts, making these compounds unstable to the conditions of the SMC reaction 
itself.31 To address these challenges, a number of important surrogates for boronic acids have 
been developed for use in the SMC reaction, including trialkoxy32-35 or trihydroxyborate salts,36 
diethanolamine adducts,37-40 sterically bulky boronic esters,41-43 and boroxines.44-46 Perhaps the 
most notable boronic acid substitute is the trifluoroborate salt developed by Molander and co-
workers.47-49 In contrast to boronic acids, trifluoroborate salts are generally air-stable monomeric 
crystalline solids. In addition, they are capable of direct use in SMC reactions and have been 
successfully used as surrogates for unstable boronic acids.50-54 However, trifluoroborate salts 
suffer from a number of key limitations. Incompatibility with silica gel limits the available 
options for their isolation and purification.55 The use of trifluoroborate salts has also been 
associated with the release of HF, which is both toxic and damaging to glassware.11,56 Also, 
while there are a few examples of SMC reactions between heteroaromatic trifluoroborate salts 
and sterically encumbered and electron rich aryl chlorides,52 it has not been generally established 
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that trifluoroborate salts are effective cross-coupling partners with electron rich aryl chlorides. 
Finally, some very unstable boronic acids, notably 2-pyridylboronic acid, are not effective 
coupling partners as the corresponding trifluoroborate salts.50 The apparent lack of a robust, 
generally effective surrogate for unstable boronic acids struck us as an important unmet need in 
synthetic methodology. We therefore reasoned that the development of such a reagent could 
potentially not only address the problems we had encountered with polyene construction in the 
context of the AmB synthesis, but might also have a profound impact on the state of the art of the 
SMC reaction in general. 
 
2-2 STABILITY OF BORONIC ACIDS 
 While the stability of boronic acids has been described anecdotally in the literature, there 
have been few quantitative reports to date. Therefore, to ground ourselves in a better 
understanding of this phenomenon we sought to rigorously test the air-stability of a variety of 
boronic acids. To this end we synthesized a collection of boronic acids representing several 
classes known to have stability problems (Table 2.1). To maximize their starting purity, each was 
synthesized via hydrolysis from the corresponding MIDA boronate and determined by 1H-NMR 
to be >95% pure at the start of the experiment. A sample of each boronic acid was then stored 
sealed under air at room temperature for a period of 15 days, after which the quantity of 
remaining boronic acid was determined by 1H-NMR using 4-bromoacetophenone as an internal 
standard. Every boronic acid tested exhibited some degree of decomposition within this time 
frame. The 2-furyl, 2-pyrrole-, 2-indole- and vinylboronic acid (2.4a, 2.4e, 2.4f, and 2.4g) were 
observed to be particularly unstable, with very little of the original boronic acid left in the 
sample. In follow-up experiments vinylboronic acid (2.4g) was observed to undergo nearly 
complete (>95%) decomposition in only two days. In sharp contrast, identical experiments 
performed with the corresponding MIDA boronates (2.5a, 2.5e, 2.5f, and 2.5g) showed the 
MIDA boronates to completely air-stable, with no decomposition observed even after sixty days. 
For 2.5a, 2.5d, and 2.5g, no decomposition was detectable even after more than 15 weeks at 
ambient conditions. This remarkable stability is consistent with previous reports3 and suggests 
that, at the very least for the purpose of addressing benchtop instability, MIDA boronates may be 
effective surrogates for unstable boronic acids. 
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Table 2.1 
d
S
S
O
a
Me
g
O
S
Boc
N
N
PhO2S
b
c
e
f
h
1
2
3
4
5
6
7
8
entry R
R B O
O O
O
MeN
R B(OH)2
THF, 23 °C, 20 min
NaOH (1M)
2.5 2.4
7
88
80
80
<5
<5
5
31
>95b
>95
>95
>95b
>95
>95
>95b
>95
aFreshly prepared boronic acids 2.4 and MIDA boronats 2.5 were stored as solids on the benchtop
under air for 15 and 60 days, respectively. bStored for 107 days.
% remaining after storage
under air at 23 °Ca
2.4 (15 days) 2.5 (60 days)
Reproduced in part with permission from Knapp, D. M.; Gillis, E. P.; Burke, M. D. J. Am.
Chem. Soc. 2009, 131, 6961-6963. Copyright 2009 American Chemical Society.  
 
2-3 DIRECT-RELEASE CROSS-COUPLING OF MIDA BORONATES 
 Having established that complexation with MIDA effectively renders otherwise unstable  
boronic acids stable to storage, we next investigated whether we could harness this phenomenon 
to improve the efficiency with which these boronic acids could be utilized in the SMC reaction. 
Traditionally, using a MIDA boronate as surrogate for an unstable boronic acid would involve 
deprotection with aqueous sodium hydroxide, isolation of the resulting boronic acid, and then 
exposure of that boronic acid to SMC reaction conditions. We recognized that SMC reaction 
conditions, i.e. palladium catalyst and aqueous or anhydrous base, and the unique stability profile 
of MIDA boronates might provide an opportunity to streamline this process. While MIDA 
 
 
23 
 
boronates are quite stable to anhydrous bases, they are labile to aqueous bases. Thus, we 
reasoned that by subjecting a MIDA boronate directly to aqueous basic SMC reaction conditions 
we might achieve in situ hydrolysis of the MIDA boronate, revealing the boronic acid which 
would subsequently undergo cross-coupling. If successful, such a direct addition would 
completely eliminate the need to handle the unstable boronic acid, and would thus minimize time 
available for decomposition since the boronic acid would capable of reacting immediately upon 
MIDA boronate deprotection.  
It should be noted that this “direct-release” protocol would be incompatible with the 
selective cross-coupling of MIDA-protected haloboronic acids as part of an ICC sequence, due to 
the necessity of preserving the integrity of the MIDA ligand in such a reaction. However, this 
protocol could be quite useful for any aqueous non-selective coupling. Further, direct-release 
coupling would be compatible with the final step of an ICC sequence, a useful feature given that 
the last cross-coupling in an ICC sequence is often the most challenging due to the highly 
conjugated nature of the boronic acid involved. 
 The success of a direct-release coupling requires that the MIDA ligand released upon 
MIDA boronate hydrolysis does not interfere with the subsequent cross-coupling reactions. 
MIDA is known to be a competent ligand for a number of transition metals, including 
palladium(II) species,57 and the amount of MIDA present in the SMC reaction would far exceed 
the amount of the palladium catalyst. Thus, to test the viability of using MIDA boronates directly 
in SMC reactions, we exposed MIDA boronate 2.6 directly to bromoacetophenone (2.7) under 
standard aqueous cross-coupling conditions (Scheme 2.2). By 1H-NMR we observed complete 
consumption of 2.7, and after column chromatography obtained the desired biaryl cross-coupling 
product 2.8 in 97% yield, suggesting that the presence of stoichiometric quantities of MIDA had 
no deleterious impact on the reaction. 
 
B O
O O
O
MeN
Me
+
Br
Me
O
Me
O
Me
Pd(PPh3)4
NaOH
THF:H2O 5:1
60 °C, 24 h, 97%2.6 2.7 2.8  
Scheme 2.2. Direct exposure of MIDA boronate 2.6 to bromoacetophenone (2.7) and standard SMC reaction 
conditions resulted in a 97% yield of biaryl product 2.8, suggesting that the MIDA released from in situ hydrolysis 
of the MIDA boronate was not detrimental to the activity of the catalyst. 
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To better assess the generality of direct-release coupling, we next synthesized a collection 
of simple MIDA boronates, and compared their efficiency in direct release cross-coupling 
reactions to the corresponding boronic acids (Table 2.2). Note that these otherwise standard 
SMC reaction conditions included an increased amount of base to account for the hydrolysis of 
the MIDA boronate. As seen in Table 2.2 there was little difference in yields between the MIDA 
boronates and boronic acids, with only some variation involving boronic acids 2.9c and 2.9d. 
This may have been a result of imperfect purity of these boronic acids, as these were obtained 
commercially and used as received without further purification. Collectively, these results added 
additional evidence that the MIDA ligand does not significantly reduce the activity of the 
palladium catalyst under direct release SMC conditions. 
 
Table 2.2 
O O
B O O
MeN
RR B(OH)2 or
R'
RPd(PPh3)4, NaOH
THF/H2O 5:1, 60 oC, 24hr
R'
Br
Entry R
% Yield from
2.9 2.10
2.9 2.10
1
5
3
Me
Me
3
9690
96 97
MeO 98 98
Reaction conditions: 1.0 equiv 2.11, 1.5 equiv 2.9 or 2.10, 7.5 equiv NaOH.
2 93
2.11a
2.11b
956 87
96
2.12
R'
C(O)Me
OMe
4 9694
Halide
2.11a
2.11a
2.11a
2.11a
2.11b
2.11b
Product
Me
R'
R'
MeO
R'
Me
3 R'
a
b
c
d
2.12a
2.12b
2.12c
2.12d
2.12e
2.12f
 
  
Hydrolysis of MIDA boronates with strong bases such as sodium hydroxide proceeds in 
under 10 minutes at room temperature.3 For the purpose of clarity, such direct-release conditions 
employing strong bases such as sodium hydroxide, potassium hydroxide, etc. will hereafter be 
referred to as “fast-release” conditions. An important consequence of this phenomenon is that, if 
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the released MIDA ligand acts as a spectator, within several minutes at 60 °C there is essentially 
no difference between fast-release conditions and conditions using boronic acids, assuming the 
latter are pure.  The fast-release protocol has the clear advantage of mitigating the problems 
associated with boronic acid storage, and it ensures the delivery of pure boronic acid to the SMC 
reaction. However, we would not expect fast-release conditions to effectively address the 
problem of boronic acids which exhibit significant instability to the conditions of the SMC 
reaction itself. 
This hypothesis was confirmed when we attempted SMC reactions using more unstable 
boronic acids and slower reacting aryl chlorides. For example, even when using the powerful 
biaryldialkylphosphine ligands developed by Buchwald and co-workers,58 the reaction of 2.4a 
with the deactivated aryl chloride 2.13 proceeded in modest yield, (Scheme 2.3), despite the 
boronic acid having been freshly prepared prior to the reaction. An identical experiment carried 
out using the corresponding MIDA boronate (2.5a) under fast-release conditions resulted in a 
similar yield. These results are consistent with the known challenge of using 2-heterocyclic 
boronic acids in SMC reactions with aryl chlorides,31 and our own experiments have shown that 
2.4a undergoes protodeboronation when exposed to the aqueous basic conditions of the  SMC 
reaction (vide infra). These results demonstrate that fast-release conditions, while beneficial to 
the handling and storage of boronic acids, do not fully address the challenges associated with the 
use of unstable boronic acids. 
 
B O
O O
O
MeN
OorB(OH)2O O
Ot-Bu
Cl
Ot-Bu
Pd(OAc)2/S-Phos (5/10%)
NaOH, dioxane:H2O (5:1)
60 °C, 6 h
2.4a 2.5a
2.13
2.14a
64% from 2.4a
59% from 2.5a  
Scheme 2.3. Both 2-furylboronic acid (2.4a) and 2-furyl MIDA boronate (2.5a) gave similarly modest yields in an 
attempted cross-coupling with 2.13, showing that direct couplings of MIDA boronates using strong bases like NaOH 
may not be more effective than using the corresponding boronic acid in reactions involving slower reacting aryl 
chlorides. 
 
2-4 SLOW-RELEASE CROSS-COUPLING OF MIDA BORONATES 
 A likely reason for the low yields in Scheme 2.3 is that decomposition of the boronic acid 
by protodeboronation is competitive with productive cross-coupling. One factor that likely 
exacerbates this problem is the low catalyst loading typical in the SMC reaction. For example, 
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with a 5% catalyst loading, at the start of the reaction, only 5% of the boronic acid is able to react 
productively with the catalyst, while the remaining 95% must wait for the catalytic cycle to turn 
over, during which time it is free to undergo other competing, non-productive pathways. One 
obvious way to address this problem is to increase the catalyst loading, thereby increasing the 
ratio of catalyst to boronic acid, and speeding up productive coupling over protodeboronation. 
Intuitively, it seemed that a reasonable alternative would be to decrease the concentration of the 
boronic acid, achieving a similar change in the ratio of catalyst to boronic acid. For example, if 
the boronic acid were added to the reaction at a rate slower than the turn-over frequency (TOF) 
of the catalyst, then the catalyst would at all times remain superstoichiometric to the boronic 
acid, enabling the boronic acid to most efficiently undergo productive coupling. This hypothesis 
is consistent with a literature report by Buchwald and coworkers, whereby the yield of an SMC 
reaction was improved by the slow addition of an unstable boronic acid to the reaction mixture.31  
 Additionally, it is worth considering the resting state of the catalyst. The SMC reaction 
proceeds through a three-step catalytic cycle, involving oxidative addition, transmetallation, and 
reductive elimination (Figure 2.1). Keeping the concentration of the boronic acid very low forces 
the turnover limiting step of the catalytic cycle to be transmetallation, and in the presence of a 
still high concentration of halide, the resting state of the catalyst will be at the oxidative addition 
product (2). Thus, at very low boronic acid concentrations, virtually all of the catalyst will be 
sitting at 2, primed to immediately undergo transmetallation with the boronic acid as it is added 
to the reaction. If one assumes that protodeboronation is a first order process with respect to the 
boronic acid, then the relative rates of transmetallation vs. protodeboronation are directly 
dependent on the concentration of species 2. Increasing the concentration of species 2 by forcing 
a change in the catalyst resting state will increase the rate of transmetallation, but have no impact 
on the competing protodeboronation. A similar resting state analysis was recently employed by 
researchers at GlaxoSmithKline in an elegant process-level optimization of an SMC reaction 
plagued by undesired homocoupling.59 
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Figure 2.1. A proposal to explain the beneficial nature of slow-release cross-coupling. The low concentration of 
boronic acid in solution forces the catalyst resting state to [2]. The increased concentration of [2] correspondingly 
accelerates the rate of transmetallation with the boronic acid. This resting state proposal also helps to explain why 
slow-release phenomenon has been show to limit other SMC byproducts like oxidative homocoupling. 
 
 To test the hypothesis that slow addition of an unstable boronic acid would improve the 
efficiency of the SMC reaction, we repeated the experiment shown in Scheme 2.3, adding the 
boronic acid slowly via syringe pump over three hours. Despite only using a single equivalent of 
unstable 2.4a, a 98% yield of the desired product 2.14a was obtained after column 
chromatography. While the use of a syringe pump is not overly challenging, it does introduce 
undesired complexity to the reaction setup, and again necessitates the isolation and handling of 
the unstable boronic acid. Instead, we proposed that a similar effect could be achieved if the 
boronic acid were delivered to the reaction internally, via a slow hydrolysis from the 
corresponding MIDA boronate. 
 
B(OH)2O O
Ot-Bu
Cl
Ot-Bu Pd(OAc)2/S-Phos (5/10%)
2.4a2.13 2.14a
+
K3PO4, dioxane:H2O (5:1)
60 °C, 6 h
98%added via syringe-
pump over 3 h  
Scheme 2.4. The use of a syringe pump to deliver 1.0 equiv of boronic acid 2.4a steadily over 3 h enabled a nearly 
quantitative yield of the biaryl product 2.14a. We attribute this high yield to slow addition of the boronic acid. 
 
 To test whether a “slow-release” of an unstable boronic acid from the corresponding 
MIDA boronate could improve the efficiency of a cross-coupling reaction, we needed to identify 
conditions that would still promote efficient cross-coupling, but that would result in a much 
 
 
28 
 
slower hydrolysis of the MIDA boronate. Ideally, the rate of hydrolysis would be slower than the 
turnover-rate of the catalyst used in the SMC reaction. Before investigating potential conditions, 
we needed to accurately determine the rate of the reaction in question. Therefore, we again set up 
the reaction of boronic acid 2.4a with 2.13, under our standard SMC conditions, and monitored 
the course of the reaction by analyzing aliquots taken from the reaction by GC (Figure 2.2). As 
seen in Figure 2.2, the reaction appears to reach a maximum conversion of the halide of 62% 
within one hour, which is consistent with the yield obtained in Scheme 2.3. It is likely that the 
halide ceases to convert after one hour due to the fact that all of boronic acid has been consumed, 
either via productive conversion to 2.14a or destructive protodeboronation. To test if 
protodeboronation occurs under these conditions at a rate commensurate with this hypothesis, we 
set up an experiment wherein boronic acid 2.4a was exposed to mock cross-coupling conditions 
(aqueous K3PO4 in dioxane at 60 ˚C) and the amount of boronic acid remaining in the mixture 
was determined over the course of six hours by 1H-NMR (Figure 2.3). Consistent with our 
hypothesis, the amount of 2.4a decreased steadily over six hours as it converts to furan (2.15), 
demonstrating its instability to aqueous base at elevated temperature. The amount of 2.4a 
remaining after one hour, ~40%, is also roughly consistent with the conversion of halide 
obtained in the actual SMC reaction in Figure 2.2. Collectively, these experiments suggested to 
us that in order to match the catalyst TOF a MIDA boronate would need to be hydrolyzed over at 
least 30 minutes at 60 ˚C.  
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Reproduced with permission from Knapp, D. M.; Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2009, 131, 6961-
6963. Copyright 2009 American Chemical Society.  
Figure 2.2. The reaction of 2.13 with 2.4a, when monitored by GC, was seen to stalls out at ~60% conversion of 
halide, consistent with the observation that under similar conditions this reaction affords 2.14a in 64% yield. 
 
Reproduced with permission from Knapp, D. M.; Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2009, 131, 6961-
6963. Copyright 2009 American Chemical Society.  
Figure 2.3. Exposure of boronic acid 2.4a to mock cross-coupling conditions results in steady decomposition via 
protodeboronation. The progress of decomposition was monitored by 1H-NMR over the course of 6 h. 
B(OH)2O
O
Ot-Bu
Cl
Ot-Bu Pd(OAc)2/S-Phos (5/10%)
2.4a2.13 2.14a
+
K3PO4, dioxane:H2O (5:1)
60 °C, 6 h
B(OH)2O
2.4a 2.15
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 Previous experiments in our laboratory had demonstrated that weak bases hydrolyze 
MIDA boronates more slowly than strong bases such as sodium hydroxide,60 so we tested 
K3PO4, an inexpensive base commonly employed in SMC reactions, at a variety of temperatures 
to evaluate its suitability for use in slow-release SMC reaction (Figure 2.4). When MIDA 
boronate 2.5a was exposed to aqueous K3PO4 in dioxane at 60 ˚C we observed that hydrolysis 
was greater than 95% complete after two hours, well above the target of thirty minutes that we 
had previously established. Notably, even at 100 ˚C, complete hydrolysis took longer than thirty 
minutes, suggesting that slow-release conditions might be effective even at significantly elevated 
temperatures. Deprotection at room temperature was considerably slower, requiring greater than 
24 hours to complete (Figure 2.5). Based on these results, K3PO4 appeared very suitable for use 
in slow-release SMC reactions performed between 23 and 100 °C.  
 
Reproduced with permission from Knapp, D. M.; Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2009, 131, 6961-
6963. Copyright 2009 American Chemical Society.  
Figure 2.4. Exposure of MIDA boronate 2.5a to mock cross-coupling conditions demonstrates a steady release of 
the boronic acid in a temperature-dependent fashion. These results suggest that the slow-release effect may be useful 
even at temperatures up to 100 °C, and that temperatures below room temperature are likely to be impractical with 
this particular base due to the long time necessary to achieve full deprotection. 
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Reproduced with permission from Knapp, D. M.; Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2009, 131, 6961-
6963. Copyright 2009 American Chemical Society.  
Figure 2.5. The deprotection of MIDA boronate 2.5a under mock reaction conditions takes approximately 24 hours 
at room temperature. 
 
We also investigated the sensitivity of the MIDA boronate hydrolysis kinetics to the 
organic group appended to boron. We exposed several different MIDA boronates containing 
vinyl, cyclopropyl, aryl and heteroaryl moieties to aqueous K3PO4 in dioxane at 60 ˚C. 
Remarkably, the deprotection rates were very similar for all MIDA boronates tested. This 
suggested to us that any improvement in SMC reaction efficiency imparted by the slow-release 
conditions might be quite general. Notably, it has recently been demonstrated that the release 
rates for trifluoroborate salts vary substantially as a function of the organic group.56 
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2.4a
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Reproduced with permission from Knapp, D. M.; Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2009, 131, 6961-
6963. Copyright 2009 American Chemical Society.  
Figure 2.6. The rate of deprotection of MIDA boronates does not seem to be dependent on the nature of the organic 
group appended to boron as seen in the above substrates representing aryl, heteroaryl, vinyl and cyclopropyl 
functionalities. 
 
To test whether the candidate slow-release conditions could improve the efficiency of 
SMC reactions involving unstable boronic acids, we repeated the experiment from Scheme 2.4, 
using MIDA boronate 2.5a directly in the reaction with K3PO4 as a base (Table 2.3, entry 1). 
Strikingly, the product was obtained in a very high 94% yield after chromatography, matching 
the result obtained with the syringe pump.  
To better understand the generality of this approach, a collection of additional MIDA 
boronates were synthesized, representing several classes of boronic acids previously described to 
exhibit significant instability. MIDA boronates 2.5a-h were thus exposed to the slow-release 
SMC conditions, and the yields obtained were compared to those obtained with the 
corresponding boronic acids (Table 2.3). Importantly, all boronic acids were freshly prepared 
immediately before use by hydrolysis from the corresponding MIDA boronate and confirmed to 
be ≥95% pure by 1H NMR. Additionally, only a single equivalent of MIDA boronate or boronic 
acid was used relative to the halide coupling partner, so that any decomposition of the 
organoborane in the reaction would manifest as a decrease in yield. The yields obtained with the 
R B(OH)2R B O
O O
O
MeN K3PO4
dioxane-d8:D2O (5:1), 60 °C
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MIDA boronates were uniformly high (≥90%), despite the use of only a single equivalent of 
organoborane, while the yields obtained with boronic acids 2.4a-h were much lower. In some 
cases the differences were striking. For example, thiophenylboronic acid 2.4c generated a 37% 
yield, compared to a 94% yield from corresponding MIDA boronate 2.5f. Similarly, 
indolylboronic acid 2.4f generated only a 14% yield, compared to a 93% yield from the 
corresponding MIDA boronate 2.5f. Interestingly, there was not a significant difference between 
2.4h and 2.5h, suggesting that difficulties with 2.4h noted in the literature are due to its 
instability to storage. Collectively, these results clearly demonstrate that MIDA boronates can 
not only serve as effective direct surrogates for boronic acids in SMC reactions, but that under 
slow-release conditions they can effectively improve the efficiency with which one can use 
otherwise unstable boronic acids. 
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Table 2.3 
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9645
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S
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2.14d
Ot-Bu
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a
Ot-Bu
O 2.14a 68 94
Me Me
g 2.14g
Ot-Bu
O
S
Boc
N
N
PhO2S
3
4
6
7b
8b
O
Ot-Bu
Ot-Bu
S 2.14c
Ot-Bu
Boc
N 2.14e
2.14b
N
PhO2S
2.14f
Ot-Bu
2.14h
Ot-Bu
50 92
37 94
b
c
e
f
h
9061
9314
9879
9695
Entry
RR
B(OH)2 or
Pd(OAc)2, SPhos
K3PO4, dioxane:H2O 5:1
60 °C, 6 h
Ot-Bu
Cl
2.4 2.5
MeN
O
OB
O
O
2.14
Ot-Bu
R
2.13
1.0 equiv 1.0 equiv
1 mmol
R Product Isolated yield
a from:
2.4 2.5
aReaction conditions: 1.0 equiv 2.13, 1.0 equiv 2.5 (freshly prepared, >95% purity) or 1.0 equiv 2.4, 5 mol%
Pd(OAc)2, 10 mol% S-Phos, 7.5 equiv K3PO4, 0.07M in dioxane:H2O 5:1, 60 °C, 6 h.bCross-couplings performed
at 100 °C.
Reproduced with permission from Knapp, D. M.; Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2009, 131, 6961-6963.
Copyright 2009 American Chemical Society.  
 
 While the generality of the slow-release SMC reaction conditions appeared quite good 
with respect to the identity of the organoborane, we were still interested in further exploring the 
scope of this protocol with respect the identity of the halide. We had attempted to set a high bar 
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for ourselves by performing all initial experiments with an electronically deactivated aryl 
chloride (2.13), and so chose maintain that level of rigor by testing the same MIDA boronates 
from Table 2.3 against a variety of aryl chlorides (2.15a-h) encompassing substrates that were 
electron-rich (2.15a, 2.15c, 2.15e, 2.15f, 2.15g), electron-poor (2.15d, 2.15h), sterically 
encumbered (2.15a, 2.15b, 2.15d) and heteroaromatic (2.15c, 2.15e, 2.15f, 2.15g, 2.15h) (Table 
2.4). Across 21 examples, the average yield was 92%, demonstrating the efficiency and 
generality of the slow-release protocol. Reactions were set up without the use of a glovebox, 
using the same standard conditions developed in Table 2.3 and 1.2 equivalents of the MIDA 
boronates, and used only a single catalyst system. Reactions were generally complete within six 
hours. Some exceptions were as follows: The best results for vinyl MIDA boronate (2.5g) and 
cyclopropyl MIDA boronate (2.5h) were obtained at 100 ˚C (entries 16 -21), and entries 7, 8 and 
20 used 1.5 equivalents of MIDA boronate. Interestingly, in contrast to results reported for 
potassium vinyltrifluoroborate, for SMC reactions performed with vinyl MIDA boronate (2.5g), 
in no case did we observe byproducts from a competitive Heck coupling reaction.  
It should also be noted that during the course of our experimentation with the slow-
release SMC conditions we attempted to reduce the amount of base used in the reaction. While 
isolated experiments showed that as few as 3 equivalents of K3PO4 could sometimes give full 
conversion and high yields, extensive attempts to optimize the protocol with between 3 to 5 
equivalents of base inevitably gave highly irreproducible results. In contrast, using 7.5 
equivalents of base appears to render the protocol robust and highly reproducible. 
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Table 2.4 
aGeneral reaction conditions: 1 equiv of aryl halide (1 mmol), 1.2 equiv of MIDA boronate, 5 mol % Pd(OAc)2, 10 mol %
SPhos, 7.5 equiv of K3PO4, 0.07 M in dioxane:H2O 5:1, 60 °C, 6 h. b1.5 equiv of MIDA boronate. c0.5 mmol of aryl
halide, 0.6 mmol of MIDA boronate (1.2 equiv). d100 °C . e2 h. f24 h
Pd(OAc)2, SPhos, K3PO4
dioxane:H2O 5:1, 60 °C, 6 h
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O
OMe
1
2
3
9
10
2.15a 94
2.5b
2.15e
O
94
5
O
OMe
2.5a
2.5a
O
99
97
N
O
MeO 99
2.15a
N
O
Me
Cl
Cl
OMe
2.15b
2.15c
2.15a
MeO OMe
2.16iS
N
O
MeS2.15c2.5c
98
99
H
N
MeO
MeOMeO
Cl
MeMe
Me Me
Me Me
N
NMe
MeCl
2.15d
2.5a4 O
N
NMe
Me
91
MeN
O
OB
O
O
2.16a
2.16b
Cl
H
N
2.16c
2.16d
2.16e
2.16f
2.16j
11 2.5c 97
2.16k
N
N
Cl
2.15h
N
N
S
N NH2
O 857b 2.5b
N NH2
Cl
2.15f
O
S
S
Cl
8b 2.5b 85
2.15
2.16g
2.16h
2.15g
Cl
2.5
2.5a
2.5b
2.5c
Reproduced with permission from Knapp, D. M.; Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2009, 131, 6961-6963.
Copyright 2009 American Chemical Society.
Entry 2.5 isolated yield (%)2.15 2.16
 
 
 
37 
 
 
Table 2.4 cont.  
20b,d,f
17d,e
19d,e
12c
14
18d,e
2.15a
OMe
Boc
N
2.5e N
O
MeBocN
N
2.16n
PhO2S
OMe
OMe
81
98
97
N
2.16o
PhO2S
93N
O
Me2.5f
2.15c
2.15a
2.15c15
16d,e
2.16t
Me Me
Me
2.5g
2.15b
2.16p
Me Me
Me
N
N
2.16q
91
872.5g
13c
2.5h
2.15b 79
2.15h
2.16l
2.16m
N NH2
76
2.5g 96
N
O
Me2.15c
OMe
2.15f
2.16r
2.16s
OMe
21d
MeO
972.15a
2.16u
2.5h
2.5g
2.5f
2.5e
aGeneral reaction conditions: 1 equiv of aryl halide (1 mmol), 1.2 equiv of MIDA boronate, 5 mol % Pd(OAc)2, 10 mol %
SPhos, 7.5 equiv of K3PO4, 0.07 M in dioxane:H2O 5:1, 60 °C, 6 h. b1.5 equiv of MIDA boronate. c0.5 mmol of aryl
halide, 0.6 mmol of MIDA boronate (1.2 equiv). d100 °C . e2 h. f24 h
Reproduced with permission from Knapp, D. M.; Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2009, 131, 6961-6963.
Copyright 2009 American Chemical Society.
Entry 2.5 isolated yield (%)
Pd(OAc)2, SPhos, K3PO4
dioxane:H2O 5:1, 60 °C, 6 h
2.15 2.16
2.16
MeN
O
OB
O
O
2.15Cl
2.5
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2-5 SYNTHESIS AND CROSS-COUPLING OF 2-PYRIDYL MIDA BORONATE 
 Encouraged by the success of the slow-release SMC protocol, we wished to explore the 
limits of the methodology. In this vein, 2-pyridylboronic acid presented itself as a worthy target. 
From an applications standpoint, the 2-pyridyl subunit is a very important motif found in a 
variety of pharmaceuticals,61-62 natural products,63-65 unnatural nucleotides,66-67 fluorescent 
probes,68 materials,69-71 and metal-complexing ligands.71-73 Unfortunately, 2-pyridyl boronic is 
extremely unstable,74-75 precluding its use in SMC reactions. As a testament to its potential value, 
however, tremendous effort has been directed over the past several decades toward the 
development of a 2-pyridyl organometallic equivalent that can be efficiently used in cross-
coupling reactions.32,37-40,50,76-78 Unfortunately, each of these methods suffers from one or more 
important limitations, including a lack of air-stability,32,50,78 use of toxic metals,76-77 an inability 
to fully characterize or isolate the building block in a chemically pure form,37-38 and/or 
inefficiency in couplings with more challenging yet desirable halide coupling partners like 
deactivated aryl chlorides.37-40 
 Recognizing a challenging and unmet need in the synthetic methodology, we first 
questioned if we could synthesize 2-pyridyl MIDA boronate (2.19), and if so, whether it might 
exhibit the same degree of air-stability that had to date appeared ubiquitous to the MIDA 
boronate class. Consistent with its reported instability, we initially had considerable difficulty 
isolating 2.19. Traditional Dean-Stark complexation was not possible due to our inability to 
access the free boronic acid, and attempts to transmetallate from silicon to boron9,79 were 
unsuccessful, despite numerous variations of the procedure (Brice Uno, unpublished results). 
Alternatively, we were intrigued by several reports of the modest stability of 2-
pyridyltrialkoxyborate salts like 2.18.32,75 We reasoned that a transligation from the relatively 
stable alkoxyborate salt directly to the MIDA boronate might be possible. Indeed, preparation of 
2.18, followed by reaction with MIDA in DMSO and azeotropic removal of i-PrOH with 
refluxing toluene afforded our first successful synthesis of 2.19, albeit in only 2% yield (Table 
2.5). Further optimization by employing low pressure vacuum distillation, and finally portion-
wise solid addition of a mixture of 2.18 and Celite to a mixture of DMSO and MIDA at 45 ˚C 
and 1 Torr increased the yield to 13% and 27% respectively. While we remained far from 
satisfied with this yield, it did enable us access to gram-quantities of 2.19. Remarkably, in stark 
contrast to 2-pyridylboronic acid, 2.19 was isolated as a colorless, free-flowing crystalline solid, 
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in terms of its physical characteristics no different than the other MIDA boronates described 
above. Its high crystallinity enabled X-ray crystallographic analysis, which afforded an 
unambiguous structural confirmation (Figure 2.7), though surprisingly it also showed good 
solubility in acetone, MeCN and DMF. Additionally, 2.19 was also observed to be stable under 
air at room temperature for at least two months. To the best of our knowledge, 2-pyridyl MIDA 
boronate (2.19) represents the first example of an air-stable 2-pyridyl borane that can be isolated 
in chemically pure form. 
 
Table 2.5 
N Br B(Oi-Pr)3
n-BuLi
THF
N B(Oi -Pr)3
- HOi-Pr
DMSO
HO N OH
O Me O MeN
O
OB
O
ON
Li
Entry Distillation temp (°C) Distillation Pressure (Torr)
2.17
1
2
3
110
45
45
740
1
1
% Yield of 2.18
2
18
27a
2.19(via distillation)
a 2.18 was added portion-wise as mixture adsorbed onto Celite
2.18
 
 
 
Figure 2.7. Crystal structure of 2-pyridyl MIDA boronate (2.19). 
 
 Having developed a preparative synthesis of 2.19, we next sought to explore whether it 
could be an effective cross-coupling partner using the slow-release SMC methodology. Using 
conditions similar to those from Table 2.4, when 2.19 was exposed to 4-bromoacetophenone 
(2.7), no conversion to the desired SMC product was observed (Table 2.6, entry 1). Copper has 
been shown to be useful in promoting SMC reactions.34,40,43 The addition of 0.2 equivalents of 
CuI afforded 11% conversion as determined by 1H NMR (entry 2). Switching to a more polar 
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solvent, DMF with K2CO3 improved the yield to 30% (entry 3). Finally, changing the ratio of 
DMF:IPA to 1:1 and changing to the catalyst Pd(dtbpf)Cl2 improved conversion to 100% (entry 
4). Unfortunately, applying these conditions to activated aryl chloride 4-chloroacetophenone 
(2.20a) afforded a rather poor 21% conversion (entry 5).  
 
Table 2.6 
MeN
O
OB
O
ON
2.19 X
Me
O
+
Pd(OAc)2 (2%), S-Phos (4%)
60 °C, 24 h
N
Me
O
1
2
3
THF:H2O (5:1)
THF:H2O (5:1)
DMF:i-PrOH (5:1)
0
0.2
0.2
0%
11%
30%
4a DMF:i-PrOH (1:1) 0.2 100%
Entry Solvent Base Equiv CuI Conversion to 2.21a
K3PO4
K3PO4
K2CO3
K2CO3
a In place of Pd(OAc)2 and S-Phos, Pd(dtbpf)Cl2 was used
X
5a DMF:i-PrOH (1:1) 0.2 21%K2CO3
Br (2.7)
Br (2.7)
Br (2.7)
Br (2.7)
Cl (2.20a)
2.21a
 
 
It became clear that for the more difficult aryl chlorides a broader, more systematic 
screening effort would be necessary. Therefore we surveyed a range of copper sources (CuI, 
CuSO4, CuO, Cu2O, CuNO3, CuTC), bases (Ba(OH)2, KOAc, K2CO3, Cs2CO3, CaCO3, TBAF, 
CsF, K3PO4), temperatures, solvents and catalysts. From these experiments we identified 
Cu(OAc)2 as being more effective than CuI in promoting the desired reaction. CsCO3 and K2CO3 
were equally superior to the rest of the bases, and the combination of the X-Phos and Pd2dba3 
was uniquely effective, as was the solvent combination of DMF:IPA (4:1) at 100 ˚C. Combining 
these results we were able to identify optimal conditions for the reaction of 2.20a with 2.19, 
which gave the desired product after column chromatography in 72% yield (Table 2.7, entry 1). 
We next tested these conditions with a variety of aryl and heteroaryl chlorides and bromides, and 
found them to be fairly general (Table 2.7). Interestingly, yields with aryl bromides 2.20f-h were 
not significantly better than the aryl chlorides (2.20a-e), though it is possible that after such 
intense optimization for reaction with 2.20a we had arrived at conditions imperfectly suited for 
bromides, especially given the excellent earlier result with bromoacetophenone (Table 2.6, entry 
4). Also worth noting are bipyridine 2.21h, isoquinoline 2.21e, pyrazine 2.21d and quinoxaline 
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2.21c. In each of these products, cross-coupling has formed a bond between two carbons each 
adjacent to nitrogen. Through the use of cross-coupling, these products could only be obtained 
by using an inherently unstable nitrogen 2-heterocyclic nucleophile. Collectively, these results 
strongly suggest that 2-pyridyl MIDA boronate (2.19) is a stable and efficient surrogate for the 
highly unstable 2-pyridyl boronic acid in SMC reactions. It should be noted that using these 
reaction conditions, limitations still existed in cross-coupling to deactivated aryl chlorides. A 
recent publication80 by Dick and coworkers, addresses this limitation through the use of a 
diethanolamine additive. This is clearly an important advance but lies outside the scope of this 
dissertation. 
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Table 2.7 
MeN
O
OB
O
ON
2.19
Cu(OAc)2, K2CO3
DMF:IPA 4:1, 100 °C, 4 h
N
1
2
3
72
60
79
4 52
Entry 2.20 2.21 Isolated yield of 2.21 (%)a
5 74
2.21
2.20X
Pd2(dba)3, X-Phos
6
7
57
42
8 66
9 41
N
Me
O
N
CN
N
N
N
N
N
NMe
Me
N
N
N
OMe
N S
N
N
2.21a
2.21a
2.21b
2.21c
2.21d
2.21e
2.21f
2.21g
2.21h
Cl
Me
O
Cl
CN
Cl N
N
Cl N
NMe
Me
Cl
N
Br
OMe
Br
Me
O
S
Br
NBr
2.20a
2.20b
2.20c
2.20d
2.20e
2.20f
2.7
2.20g
2.20h
aReaction conditions: 1.0 equiv halide 2.20 (1 mmol), 1.5 equiv MIDA boronate 2.19, 1.5 mol% Pd2(dba)3,
6 mol% X-Phos, 50 mol% Cu(OAc)2, 5 equiv K2CO3, 0.1 M in DMF:IPA 4:1, 100 °C, 4h.
Reproduced in part with permission from Knapp, D. M.; Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2009, 131, 6961-
6963. Copyright 2009 American Chemical Society.  
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2-6 IMPROVED SYNTHESIS OF 2-PYRIDYL MIDA BORONATE AND DERIVATIVES 
 Having demonstrated the utility of 2.19, we returned our attention to the unfinished 
problem of its synthesis. While the current synthesis (Table 2.5, entry 3) enabled the generation 
of small amounts of material, the yield remained poor, and the reaction was operationally 
challenging, difficult to scale, and involved arduous column chromatography which ideally 
would be eliminated. Initial experimentation involved elimination of the technically challenging 
solid addition of 2.18, instead adding it as a suspension in THF. Additionally, we attempted 
lowering the temperature of the distillation with the goal of suppressing undesired 
protodeboronation of 2.18 and/or the corresponding diisopropylboronic ester. This strategy had 
previously seemed beneficial (Table 2.5, entries 1 and 2), but the yields for reactions run 
between 23 and 55 ˚C were low and inconsistent. A breakthrough was subsequently made in the 
discovery that 2.19 can be heated in anhydrous DMSO for greater than one hour without 
detectable decomposition by 1H NMR. This result prompted us to investigate higher 
temperatures (Figure 2.8). Surprisingly, we found that the reaction performed much better at 
higher temperatures, with the highest observed yield at 130 ˚C. In practice, we found 115 ˚C to 
be an acceptable compromise between yield and practicality.  
 
N Br
B(Oi-Pr)3
n-BuLi
THF
N B(Oi-Pr)3
MIDA
DMSO
MeN
O
OB
O
ON
Li
2.17 2.18
internal
reaction
temperature 2.19  
Reproduced with permission from Dick, G. R.; Knapp, D. M.; Gillis, E. P.; Burke, M. D. Org. Lett. 2010, 12, 2314-
2317. Copyright 2010 American Chemical Society.  
Figure 2.8. Yield of 2.19 as a function of temperature (each bar represents the average of two runs) 
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 Application of this optimized procedure, semi-officially dubbed the “hot protocol” 
enabled isolation of 2.19 in 59% yield (Table 2.8, entry 1), a significant improvement over the 
previous-generation synthesis. Additionally, a procedure was developed whereby the product 
could be purified by trituration and subsequent re-crystallization, with no need for SiO2 
chromatography. In light of the significantly improved efficiency of this reaction, we were 
prompted to investigate whether derivatives of 2.19 might be accessible. Beginning with 2-
pyridyl bromides 2.22a-i, application of the hot protocol enabled isolation of 2-pyridyl MIDA 
boronate derivatives 2.23a-i in fair to good yield (Table 2.8, entries 2-10). Furthermore, 
beginning with bromides 2.24 and 2.26, we were able obtain 2-thiazole MIDA boronate (2.25) 
and pyrazinyl MIDA boronate (2.27) in 30% and 43% yields, respectively (Scheme 2.5). To our 
knowledge 2.27 represents the first example of an air-stable pyrazinyl organoborane. 
 
  
 
 
45 
 
Table 2.8 
N Br
n-BuLi, B(i-PrO)3
THF, -78 °C
MeN
O
OB
O
ON
2.23
MIDA, DMSO
115 °C
RR
2.22
Entry 2.22 2.23 Isolated Yield (%)
1
2
3
4
5
6
7
8
9
10
59
58
51
42
81
89
56
53
47
69
N Br
N BrMe
N Br
Me
N Br
Me
N BrMeO
N BrF3C
N Br
F3C
N Br
CF3
N BrBr
N Br
Br
MeN
O
OB
O
ON
MeN
O
OB
O
ONMe
MeN
O
OB
O
ON
Me
MeN
O
OB
O
ON
Me
MeN
O
OB
O
ONF3C
MeN
O
OB
O
ON
F3C MeN
O
OB
O
ON
CF3 MeN
O
OB
O
ONBr
MeN
O
OB
O
ON
Br
MeN
O
OB
O
ONMeO
Reproduced with permission from Dick, G. R.; Knapp, D. M.; Gillis, E. P.; Burke, M. D. Org. Lett . 2010, 12, 2314-2317.
Copyright 2010 American Chemical Society.
2.17
a
b
c
d
e
f
g
h
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a
b
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n-BuLi; B(i-PrO)3;
MeN
O
OB
O
ON
N
MIDA, DMSO
115 °C, 43%N
N Br
n-BuLi; B(i-PrO)3;
MeN
O
OB
O
O
MIDA, DMSO
115 °C, 30%
Br
N
S
N
S
2.24 2.25
2.272.26  
Reproduced with permission from Dick, G. R.; Knapp, D. M.; Gillis, E. P.; Burke, M. D. Org. Lett. 2010, 12, 2314-
2317. Copyright 2010 American Chemical Society.  
Scheme 2.5. Synthesis of 5-thiazole MIDA boronate (2.25) and 2-pyrazinyl MIDA boronate (2.27). Also shown are 
the corresponding crystal structures obtained via X-ray crystallography. 
 
2-7 APPLICATION OF DIRECT-RELEASE SMC REACTIONS TO NATURAL PRODUCT 
SYNTHESIS 
 Given the positive results obtained with vinyl, cyclohexyl and heterocyclic boronic acids 
in the direct release SMC protocol, we wanted to see if this methodology might offer a solution 
to one of the synthetic problems that originally stimulated the project. Repeating the coupling 
from Scheme 2.1, instead using the MIDA boronate directly with aqueous NaOH (Scheme 2.6), 
the desired heptaene product (2.3) was obtained in 48% yield. 2.3 represents fully one half of the 
AmB macrolactone, and at the time of this result represented, to our knowledge, the longest 
polyene ever synthesized via an SMC reaction. Since then that record has been surpassed, first 
by Eric Woerly in his synthesis of the carotenoid peridinin also using a direct-release SMC 
reaction,10 and later by Seiko Fujii in her synthesis of the carotenoid synechoxanthin using a 
novel bidirectional variation of the direct-release protocol.81 
 
NMe
O
O B
O
O
Me Cl
OAc
Me
TESO
Me
Me
Pd(OAc)2, X-Phos
aqueous NaOH
THF, 45 °C, 48%
OAc
Me
TESO
Me
Me
Me
2.1 2.3  
Scheme 2.6. Application of the “fast-release” cross-coupling conditions enabled synthesis of the previously 
inaccessible heptaene 2.3. 
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 In addition to the AmB polyene and the aforementioned carotenoids, peridinin and 
synechoxanthin, the direct release protocol has found use in a number of other natural product 
syntheses, both within and outside of our laboratory, including crocacin C,5 myxalamide A,82 
methyl-eicosapentaenoate,83 renierapurpurin (Hannah Haley, unpublished results), the polyene 
core of vacidin A,6 and a deoxygenated derivative of AmB84 (Figure 2.9).  Interestingly, despite 
the clear benefit of the slow-release conditions for SMC reactions involving heterocyclic, 
cyclopropyl and vinyl boronic acids, fast-release conditions with sodium hydroxide have 
repeatedly proven to be superior for the construction of extended polyenes. This may be because 
the longer reaction times necessitated by the slow-release conditions allow time for 
decomposition of either the unstable vinyl halide substrate or the polyene product. The number 
of examples of syntheses incorporating direct-release coupling of MIDA boronates at the end of 
an ICC sequence, particularly in the context of polyenes, clearly demonstrates the utility of this 
methodology in natural product synthesis. 
 
Me
Me
Me Me Me
Me Me
Me
Me
Me
O
HO
Me
Me Me Me
Me Me
OH
O
Me
Me
OAc
Me
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Me
Me
Me
O
O
OHOH
OHOH
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OHOHO
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Me
Me
O
CO2H
Me Me
Me
Me
HO
Me
Me
O
NH
Me OH
H2N
O Me
Me Me
OMe OMe
Me
Me
OTBS
Me
Me
OAcMeMe
MeHO
Me
HO
O
MeMe
O
MeHO
O MeOH
NH2HO
Myxalamide-A
crocacin-C
AmB polyene core
vacidin A polyene core
(-)-peridinin
synechoxanthin
renierapurpurin
C-35 deoxy AmB
Me
O
OMe
methyl-eicosapentaenoate
Me
 
Figure 2.9. Examples of natural product-based syntheses which have utilized the direct release cross-coupling 
protocol. The relevant bond disconnection(s) are noted for each molecule. 
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2-8 SUMMARY   
 Stimulated by challenges encountered in the AmB polyene synthesis, it has been 
demonstrated that MIDA boronates can be utilized as direct surrogates for unstable boronic 
acids. Unlike many of their boronic acid counterparts, MIDA boronates are uniformly air-stable, 
free-flowing, crystalline solids, completely stable to storage under ambient conditions. Further, a 
new SMC reaction protocol has been developed in which MIDA boronates can be directly 
utilized in aqueous basic SMC reactions, whereby in situ hydrolysis of the MIDA boronate 
generates the boronic acid for cross-coupling. The use of weak bases like K3PO4 promotes a 
slow-release of the boronic acid, which minimizes competitive protodeboronation and allows for 
very efficient cross-coupling compared to reactions using unprotected free boronic acids, even in 
couplings to deactivated and/or sterically encumbered aryl chlorides. Alternatively, the use of 
“fast-release” conditions using strong bases like NaOH has been identified as particularly useful 
in the context of polyene construction, where the stability of the polyenyl halide coupling partner 
or polyene product is as much of a concern as that of the polyenylboronic acid. This 
methodology has also been extended to include the notoriously unstable 2-pyridylboronic acid, 
which as the corresponding MIDA boronate represents the first air-stable and chemically pure 2-
pyridyl organoborane. The necessity of aqueous or protic co-solvents restricts this direct-release 
protocol to the final step of an ICC sequence (often the most challenging), but makes it very 
useful for the cross-coupling of any monofunctional halide or pseudohalide. By taking advantage 
of their favorable physical properties, uniform air stability, and their capacity for in situ slow-
release in SMC reactions, MIDA boronates thus fully address both of the key problems 
associated with the use of unstable boronic acids in the SMC reaction, i.e. their instability to 
storage and instability under SMC reaction conditions. This advance stands to not only greatly 
expand the range of useful organoboranes available for use in cross-coupling but also to 
generally enhance the utility of the SMC reaction in organic synthesis. Additionally, following 
the publication of these results, others have found the slow-release approach useful in the 
synthesis and cross-coupling of other heterocyclic organoboranes85-86 unnatural amino acids,87 
and in the context of other reactions.11,88-90  
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2-9 EXPERIMENTAL SECTION 
Materials.   
Commercial reagents were purchased from Sigma-Aldrich, Fisher Scientific, Alfa Aesar, 
TCI America Frontier Scientific, Oakwood Products or Combi-Blocks and were used without 
further purification unless otherwise noted. Solvents were purified via passage through packed 
columns as described by Pangborn and coworkers91 (THF, Et2O, MeCN, DCM: dry neutral 
alumina; hexane, benzene, and toluene: dry neutral alumina and Q-5 reactant (copper(II) oxide 
on alumina); DMSO, DMF: activated molecular sieves). All water was deionized prior to use. 
Triethylamine, diisopropylamine, diethylamine, pyridine, and 2,6-lutidine were freshly distilled 
under an atmosphere of nitrogen from CaH2. The following compounds were prepared according 
to procedures reported in the literature: N-methyliminodiacetic acid,4 4-tolyl MIDA boronate 
(2.10a),3 vinyl MIDA boronate (2.5g),9 and 5-bromo-2-thiopheneboronic acid MIDA ester.3  
 
General Experimental Procedures.   
 Unless otherwise noted, all reactions were performed in flame-dried glassware under 
argon. Organic solutions were concentrated via rotary evaporation under reduced pressure with a 
bath temperature of 35-40 ºC. Reactions were monitored by analytical thin layer chromatography 
(TLC) performed using the indicated solvent on E. Merck silica gel 60 F254 plates (0.25mm). 
Compounds were visualized by: exposure to a UV lamp (λ = 254 or 366 nm), incubation in a 
glass chamber containing iodine, and/or treatment with a solution of KMnO4, an acidic solution 
of p-anisaldehyde or a solution of ceric ammonium molybdate (CAM) followed by brief heating 
with a Varitemp heat gun. MIDA boronates are compatible with standard silica gel 
chromatography, including standard loading techniques. Column chromatography was performed 
using standard methods92 or with a Teledyne-Isco CombiFlash Rf purification system. Both 
methods were performed using Merck silica gel grade 9385 60 Å (230-400 mesh).  
 
Structural analysis.   
1H-NMR spectra were recorded at 23 °C on a Varian Unity or a Varian Unity Inova 500 
MHz spectrometer. Chemical shifts () are reported in parts per million (ppm) downfield from 
tetramethylsilane and referenced to residual protium in the NMR solvent (CHCl3, = 7.26; 
CD2HCN, = 1.93, center line; acetone-d6 = 2.04, center line). Alternatively, NMR-solvents 
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designated as “w/ TMS” were referenced to tetramethylsilane (δ = 0.00 ppm) added as an 
internal standard. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, quint = quintet, sept = septet, m = multiplet, br = broad, app = 
apparent), coupling constant (J) in Hertz (Hz), and integration.  13C NMR spectra were recorded 
at 23 °C on a Varian Unity 500 MHz spectrometer. Chemical shifts () are reported in ppm 
downfield from tetramethylsilane and referenced to carbon resonances in the NMR solvent 
(CDCl3, = 77.0, center line; CD3CN, = 1.30, center line, acetone-d6 = 29.80, center line) or 
to added tetramethylsilane (= 0.00).  Carbons bearing boron substituents were not observed 
(quadrupolar relaxation). 11B NMR were recorded using a General Electric GN300WB 
instrument and referenced to an external standard of (BF3·Et2O). High resolution mass spectra 
(HRMS) were performed by Furong Sun and Dr. Steve Mullen at the University of Illinois 
School of Chemical Sciences Mass Spectrometry Laboratory.  Infrared spectra were collected 
from a thin film on NaCl plates or as KBr pellets on a Perkin-Elmer Spectrum BX FT-IR 
spectrometer, a Mattson Galaxy Series FT-IR 5000 spectrometer or a Mattson Infinity Gold FT-
IR spectrometer.  Absorption maxima (max) are reported in wavenumbers (cm-1).  X-ray 
crystallographic analysis of 2.19 was carried out by Dr. Scott Wilson and Dr. Danielle Gray at 
the University of Illinois George L. Clark X-Ray facility. 
 
Kinetics of boronic acid cross-coupling (Figure 2.3).  
 Under ambient atmosphere, to a 25 mL Schlenk flask equipped with a stir bar was added 
2-dicyclohexylphosphino-2’,6’-dimethoxybiphenyl (S-Phos) (41 mg, 0.10 mmol), Pd(OAc)2 (11 
mg, 0.050 mmol) and freshly-prepared 2-furylboronic acid (2.4a) (106 mg, 0.949 mmol). The 
flask was placed under argon atmosphere and to the flask was added dioxane (12.5 mL). To the 
solution was added dodecane (100 L, internal standard) and 1-tert-butoxy-4-chlorobenzene 
(2.13) (175 L, 0.980 mmol), and the solution was stirred at 23 C for 10 minutes. The solution 
was sampled and analyzed by GC to determine the ratio of halide:internal standard. To the dark 
amber solution was added aq K3PO4 (3.0 M, 2.5 mL, degassed by sparging with argon for 30 
min) and the dark mixture was stirred for 5 minutes. The organic phase was sampled as the initial 
time-point (t=0), and the mixture was then immediately placed in a 60 C oil bath with stirring. 
The organic phase was sampled periodically and the consumption of the halide was determined 
by GC analysis versus the internal standard. 
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Rates of in-situ boronic acid decomposition (Figure 2.4). 
 A stock solution of 2-furylboronic acid (2.4a) and 4-bromoanisole (internal standard) in 
dioxane-d8 was prepared as follows: 2-furylboronic acid (9 mg, 0.08 mmol) and 4-bromoanisole 
(15 mg, 0.080 mmol) were dissolved in dioxane-d8 (1.0 mL). To each of eight argon-filled 1.5 
mL vials, equipped with stir bars and sealed with PTFE-lined septum-screw caps was added the 
boronic acid stock solution (100 μL), followed by a solution of K3PO4 in D2O (3.0 M, 20 μL) by 
syringe. The mixtures were maintained, with stirring at 60 °C for the specified time (10 min, 20 
min, 30 min, 1 h, etc.) The mixtures were then immediately quenched by the addition of  a 
solution of pH 7 potassium phosphate buffer in D2O (2M, 120 μL) allowed to cool to 23 °C and 
diluted with DMSO-d6 (0.5 mL, containing TMS internal standard). The resulting solutions were 
immediately analyzed by 1H-NMR. The percent boronic acid remaining was calculated by 
comparing the ratio of the integrated 4-bromoanisole C-H signal (doublet, 7.41 ppm) to that of 
the boronic acid C-H signal (doublet, 7.74 ppm). 
 
Rates of slow-release of boronic acids from MIDA boronates (Figures 2.5-2.7). 
 Stock solutions of the MIDA boronate and 4-bromoanisole (internal standard) in dioxane-
d8 were prepared as follows: 4-tolyl MIDA boronateError! Bookmark not defined. (16 mg, 0.064 mmol) 
and 4-bromoanisole (12 mg, 0.065 mmol) were dissolved in dioxane-d8 (800 μL); 2-furyl MIDA 
boronate (2.5a) (54 mg, 0.24 mmol) and 4-bromoanisole (45 mg, 24 mmol) were dissolved in 
dioxane-d8 (3.0 mL); vinyl MIDA boronate (2.5g) (11.7 mg, 0.064 mmol) and 4-bromoanisole 
(12 mg, 0.065 mmol) were dissolved in dioxane-d8 (800 μL); cyclopropyl MIDA boronate (2.5h) 
(12.8 mg, 0.065 mmol) and 4-bromoanisole (12.0 mg, 0.064 mmol) were dissolved in dioxane-d8 
(800 μL). To each 1.5 mL vial equipped with a small stir bar was added the boronate stock 
solution (100 μL) followed by a solution of K3PO4 in D2O (3.0 M, 20 μL). The mixtures were 
stirred at the specified temperature (23 °C, 60 °C, or 100 °C) for the specified time (0.5 h, 1.0 h, 
2.0 h, etc.). The mixtures were then immediately cooled to room temperature and were diluted 
with CD3CN (0.5 mL containing TMS internal standard). The solutions were immediately 
analyzed by 1H-NMR. The percent MIDA boronate remaining was calculated by comparing the 
ratio of the integrated 4-bromoanisole OCH3 singlet (3.76 ppm, internal standard) to that of the 
MIDA boronate NCH3 singlet (tolyl = 2.47 ppm; furyl = 2.60 ppm; vinyl = 2.77 ppm; 
cyclopropyl = 2.98 ppm). 
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Yield of 2-pyridyl MIDA based on internal reaction temperature (Figure 2.9). 
To a 25 mL Schlenk flask equipped with a stir bar was added 2-bromopyridine (0.30 mL, 
3.1 mmol), triisopropylborate (0.70 mL, 3.0 mmol), and THF (6 mL). The resulting stirred 
solution was cooled to -78 °C. To the cooled solution was added dropwise over 5 min n-
butyllithium (2.58 M in hexanes, 1.2 mL, 3.1 mmol). Following the addition, the reaction was 
stirred at -78 °C for 1 h, then warmed to 23 °C with stirring for 3 h. Separately, to a 3-neck 50 
mL flask equipped with a 25 mL pressure equalizing addition funnel, a water-cooled short-path 
distillation apparatus, a thermometer, and a stir bar was added N-methyiminodiacetic acid (0.75 
g, 5.1 mmol) and DMSO-d6 (6 mL). The mixture was heated with stirring to the internal 
temperature as indicated (25 °C, 40 °C, 55 °C, 70 °C, 85 °C, 100 °C, 115 °C, or 130 °C). The 
borate mixture contained in the Schlenk flask was transferred to the addition funnel, washing 
with THF (6 mL). To the hot, stirred DMSO solution was added dropwise the borate solution at a 
rate necessary to maintain the internal temperature ± 5 °C from the indicated temperature (ca. 30 
min.). Following the addition, the mixture was cooled to room temperature. Where necessary, 
residual THF was removed in vacuo. To the DMSO-d6 solution was added 4-bromoanisole 
(0.190 mL, internal standard). The mixture was filtered through a short pad of Celite and the 
filtrate was then analyzed by 1H-NMR to find the yield of 2.18 as determined by reference to the 
internal standard. Specifically, the H3C-N resonance of 2.18 at 2.53 ppm was compared to the 
aromatic resonance of 4-bromoanisole at 6.88 ppm. 
 
Syringe pump addition of boronic acid (Scheme 2.4). 
Under ambient atmosphere, to a 40 mL I-Chem vial equipped with a stir bar was added 1-
tert-butoxy-4-chlorobenzene (2.13) (0.185 g, 1.00 mmol), dicyclohexylphosphino-2’,6’-
dimethoxy-1,1’-biphenyl (S-Phos) (41 mg, 0.10 mmol) and Pd(OAc)2 (11 mg, 0.050 mmol). The 
vial was sealed with a PTFE-lined septum screw-cap, and then placed under an argon 
atmosphere. To the vial was added dioxane (9.5 mL) and the resulting mixture was stirred at 23 
°C for 10 min. To the vial was added aq K3PO4 (3.0 M, 2.5 mL, degassed by sparging with argon 
for 30 min). The vial was placed in a 60 °C oil bath, and to the stirring mixture was added  
dropwise over 3 h via syringe pump freshly prepared 2-furylboronic acid (2.4a) (0.112 g, 1.00 
mmol) as a solution in dioxane (3.0 mL). After the addition was complete, the reaction mixture 
was stirred at 60 °C for an additional 3 h. The mixture was cooled to room temperature and was 
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then transferred to a 60 mL separatory funnel and was diluted with aq NaOH (1.0 M, 10 mL). 
The mixture was extracted with Et2O (3 × 10 mL). The combined organic fractions were dried 
over MgSO4, filtered and then concentrated in vacuo. The resulting residue was purified by flash 
chromatography (hexanes:EtOAc, 100:0 → 9:1) to afford a colorless oil (0.213 g, 98%). (see 2.3 
for characterization of product). 
 
Benchtop stability of boronic acids and MIDA boronates (Table 2.1). 
 To quantify the stability of boronic acids or MIDA boronates to storage on the benchtop 
as solids under air at 23 C, the following general procedure was followed: Two 7-mL vials were 
charged with 10 mg of freshly prepared boronic acid or MIDA boronate at 23 C under ambient. 
The vials containing these solid samples were then sealed with PTFE-lined screw caps under 
ambient atmosphere and placed on the benchtop at 23 ºC. The solid sample present in one of the 
two vials was then immediately analyzed via 1H NMR to verify the purity and quantity of 
boronic acid present at time zero (see below for details of NMR assay). After 15 days (boronic 
acids) or 60 days (MIDA boronates), the solid sample in the second vial was then analyzed via 
1H NMR, again by the method described below, to determine the quantity of boronic acid 
remaining at the indicated time. The NMR assay was performed as follows: An NMR stock 
solution was prepared as follows: To a 25 mL volumetric flask was added bromoacetophenone 
(0.336 g, 1.69 mmol) as an internal standard for quantification of the boronic acid, 
tetramethylsilane (1 mL) as an internal standard for the NMR shifts, and DMSO-d6:D2O 95:5 to 
a final solution volume of 25.00 mL. To a vial containing solid boronic acid or solid MIDA 
boronate (see above) was added 1.00 mL of this NMR stock solution, and  the resulting solution 
was analyzed by 1H NMR. The mmol of boronic acid or MIDA boronate present in the sample 
was determined by comparing the ratio of the integrated 4-bromoacetophenone aryl C–H 
doublets (7.90 ppm relative to TMS) to that of the boronic acid or MIDA boronate C–H signals.  
 
Synthesis of MIDA boronates (Table 2.1). 
 
B(OH)2
MeN
O
OB
O
O
toluene:DMSO
Dean-Stark
HO
N
OH
O Me O
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General procedure for the synthesis of MIDA boronates.  To a round-bottom flask equipped 
with a stir bar was added the boronic acid (1 equiv), N-methyliminodiacetic acid (1-1.5 equiv), 
DMSO and either toluene or benzene. The flask was fitted with a Dean-Stark trap and the Dean-
Stark trap was fitted with a reflux condenser vented to ambient atmosphere. The stirred mixture 
was heated to reflux with azeotropic removal of water for 2-18 h. The solution was concentrated 
in vacuo (1 Torr, 100 °C). Unless otherwise noted, the resulting residue was adsorbed onto Celite 
in vacuo from an acetone suspension and the resulting powder was subjected to flash 
chromatography (Et2O → Et2O:MeCN). 
 
2-furyl MIDA boronate (2.5a). The general procedure was followed using furan-2-boronic acid 
(5.029 g, 44.95 mmol, purchased from Sigma-Aldrich), N-methyliminodiacetic acid (7.275 g, 
49.44 mmol), toluene (210 mL) and DMSO (40 mL). The mixture was refluxed for 8 h. The 
product was eluted with Et2O → Et2O:acetone 1:1. The solid thus obtained was dissolved in a 
minimum of acetone to which Et2O was slowly added to promote crystallization. Filtration of the 
mixture afforded 2.5a as an off-white crystalline solid (8.98 g, 90%). 
 
B O
O O
O
MeN
O
2.5a  
TLC (EtOAc) 
 Rf = 0.33, stained with KMnO4 
 
1H-NMR (500 MHz, CD3CN) 
 δ 7.66 (dd, J = 2.0, 1.0 Hz, 1H), 6.71 (dd, J = 3.0, 1.0 Hz, 1H), 6.43 (dd, J = 3.0, 2.0 Hz, 
1H), 4.06 (d, J = 17 Hz, 2H), 3.89 (d, J = 17 Hz, 2H), 2.60 (s, 3H) 
 
13C-NMR (125 MHz, CD3CN) 
 δ 169.2, 147.0, 119.1, 110.8, 62.4, 47.9 
 
11B-NMR (96 MHz, CH3CN) 
 δ 9.5 
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HRMS (EI+) 
 Calculated for C9H10BNO5 (M)+: 223.0652  
 Found:     223.0651 
 
IR (thin film, cm-1) 
3136, 3109, 3002, 2990, 2962, 1751, 1570, 1481, 1457, 1419, 1346, 1336, 1302, 1245, 
1227, 1197, 1153, 1085, 1057, 1004, 965, 932, 873, 839, 828, 823 
 
 
2-benzofuranyl MIDA boronate (2.5b). The general procedure was followed using benzofuran-
2-boronic acid (5.247 g, 32.39 mmol, purchased from Sigma-Aldrich), N-methyliminodiacetic 
acid (5.005 g, 34.02 mmol), toluene (135 mL) and DMSO (15 mL). The mixture was refluxed 
for 8 h. The product was eluted with Et2O → Et2O:MeCN 2:1. The solid thus obtained was 
dissolved in a minimum of acetone to which Et2O was slowly added to promote crystallization. 
Filtration of the mixture afforded 2.5b as a colorless crystalline solid (7.61 g, 86%). 
 
MeN
O
OB
O
O
O
2.5b  
TLC (EtOAc) 
 Rf = 0.45, visualized by UV (λ = 254 nm) and KMnO4 stain 
 
1H-NMR (500 MHz, CD3CN) 
 δ 7.63 (app dq, J = 7.5, 1.0 Hz, 1H), 7.51 (app. dt, J = 8.5, 1.0 Hz, 1H), 7.30 (m, 1H), 
7.22 (app tt, J = 7.5, 0.5 Hz, 1H), 7.11 (s, 1H), 4.14 (d, J = 17 Hz, 2H), 3.97 (d, J = 17 
Hz, 2H), 2.69 (s, 3H) 
 
13C-NMR (125 MHz, CD3CN) 
 δ 169.2, 158.2, 129.1, 125.7, 123.6, 122.4, 115.8, 112.2, 62.6, 48.1 
 
11B-NMR (96 MHz, CD3CN) 
 δ 9.5 
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HRMS (EI+) 
 Calculated for C13H12BNO5 (M)+: 273.0809 
 Found:     273.0810 
 
IR (thin film, cm-1) 
 3008, 2956, 1765, 1560, 1448, 1335, 1282, 1249, 1191, 1157, 1138, 1052, 1005, 942, 853 
 
 
2-thiophenyl MIDA boronate (2.5c). The general procedure was followed using thiophene-2-
boronic acid (4.871 g, 38.06 mmol, purchased from Sigma-Aldrich), N-methyliminodiacetic acid 
(5.884 g, 39.99 mmol), benzene (180 mL) and DMSO (20 mL). The mixture was refluxed for 8 
h. The product was eluted with Et2O → Et2O:MeCN 2:1. The solid thus obtained was dissolved 
in a minimum of acetone to which Et2O was slowly added to promote crystallization. Filtration 
of the mixture afforded 2.5c as a colorless crystalline solid (7.13 g, 78%). 
 
MeN
O
OB
O
OS
2.5c  
TLC (EtOAc) 
 Rf = 0.34, visualized by UV (λ = 254 and 366 nm) and KMnO4 stain 
 
1H-NMR (500 MHz, CD3CN) 
 δ 7.62 (dd, J = 5.0, 1.0 Hz, 1H), 7.28 (dd, J = 3.5, 1.0 Hz, 1H), 7.19 (dd, J = 5.0, 3.5 Hz, 
1H), 4.07 (d, J = 17 Hz, 2H), 3.90 (d, J = 18 Hz, 2H), 2.58 (s, 3H) 
 
13C-NMR (125 MHz, CD3CN) 
 δ 169.1, 134.2, 130.7, 129.5, 62.4, 48.3 
 
11B-NMR (96 MHz, CD3CN) 
 δ 11.2 
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HRMS (EI+) 
 Calculated for C9H10BNO4S (M)+: 239.0424   
Found:     239.0432 
 
IR (thin film, cm-1) 
 3007, 2954, 1773, 1704, 1514, 1457, 1421, 1337, 1285, 1226, 1172, 1029, 979, 894, 860, 
814, 713 
 
 
MeN
O
OB
O
OSBr
MeN
O
OB
O
OS
S
Me
S
Me
B(OH)2
Pd(OAc)2, SPhos
K3PO4, THF, 45°C
2.5d  
 
bis-thiophenyl MIDA boronate (2.5d). 
Preparation of catalyst stock solution: In a glove box, to a 40 mL vial equipped with a stir bar 
was added Pd(OAc)2 (0.137 g, 0.610 mmol), dicyclohexylphosphino-2’,6’-dimethoxy-1,1’-
biphenyl (S-Phos) (0.502 g, 1.22 mmol) and THF (25 mL). The solution was stirred for 30 
minutes upon which the color of the solution changed from orange to yellow. 
Cross-coupling reaction: To a 500 mL two-neck flask equipped with a stir bar was added 2-
bromothiophene-5-MIDA boronate ester3 (4.862 g, 15.29 mmol), 4-methylthiophene-2-boronic 
acid (4.808 g, 30.58 mmol) and K3PO4 (anhydrous, finely ground, 9.739 g, 45.89 mmol). The 
flask was fitted with a reflux condenser and the second arm was fitted with a rubber septum. The 
flask was placed under argon atmosphere and to the flask was added THF (150 mL). To the flask 
was added via cannula the catalyst stock solution (25 mL). The mixture was heated to 45 °C with 
stirring for 12 h. The mixture was cooled to room temperature and then was filtered through a 
thin pad of silica gel eluting with a copious volume of MeCN. The filtrate was concentrated in 
vacuo and the crude residue was adsorbed onto Celite from an acetone solution. The resulting 
powder was subjected to flash chromatography on silica gel (Et2O, then Et2O:MeCN 2:1) to 
afford a green foam, which was further purified by dissolving the product in a minimum of 
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acetone followed by slow addition of Et2O to promote crystallization. Filtration of the resulting 
mixture afforded 2.5d as a pale green solid (3.744 g, 73%). 
 
 
MeN
O
OB
O
OS
S
Me
2.5d  
TLC (EtOAc) 
 Rf = 0.38, visualized by UV (λ = 254 and 366 nm) and KMnO4 stain 
 
1H-NMR (500 MHz, CD3CN) 
 δ 7.24 (d, J = 3.5 Hz, 1H), 7.17 (d, J = 3.5 Hz, 1H), 7.09 (d, J = 1.5 Hz, 1H), 6.91 (app 
quint, J = 1.0 Hz, 1H), 4.07 (d, J = 17 Hz, 2H), 3.91 (d, J = 17 Hz, 2H), 2.66 (s, 3H), 2.22 
(d, J = 1.0 Hz, 3H) 
 
13C-NMR (125 MHz, CD3CN) 
 δ 169.1, 142.5, 139.8, 137.6, 135.3, 127.3, 125.9, 121.2, 62.4, 48.4, 15.7 
 
11B-NMR (96 MHz, CD3CN) 
 δ 10.9 
 
HRMS (EI+) 
 Calculated for C14H14BNO4S2 (M)+:  335.0457  
Found:      335.0457 
 
IR (thin film, cm-1) 
 3004, 2953, 1773, 1453, 1419, 1336, 1285, 1231, 1193, 1169, 1037, 980, 858, 806 
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B(Oi-Pr)3
LDA
THF - HOi-Pr
DMSO
HO
N
OH
O Me O
Boc
N
Boc
N B(Oi -Pr)3Li
MeN
O
OB
O
O
Boc
N
2.5e  
 
2-(N-tert-butoxycarbonyl)pyrrole MIDA boronate (2.5e). In an unoptimized procedure, to a 
50 mL Schlenk flask equipped with a stir bar was added THF (15 mL) and diisopropylamine 
(920 μL). The solution was cooled to -78 °C and then to the stirred solution was added dropwise 
n-BuLi (2.5 M in hexanes, 2.75 mL). The solution was maintained at -78 °C for 10 min, and then 
was allowed to warm to room temperature with stirring for 3 h. The solution was cooled to -78 
°C, and to the stirred solution was added dropwise via cannula N-tert-butoxycarbonylpyrrole 
(1.016 g, 6.074 mmol) as a solution in THF (15 mL + 10 mL washing). The solution was stirred 
for 30 min. To the yellow solution was added dropwise triisopropylborate (1.40 mL, 6.07 mmol). 
The solution was stirred for 10 min at -78 °C and then was allow to warm to room temperature 
with stirring overnight (11 h). To the near-black solution was added DMSO (15 mL). The THF 
was then removed in vacuo and the resulting DMSO solution was transferred to a 50 mL 
pressure-equalizing addition funnel. The funnel was fitted onto a 100 mL 3-neck round-bottom 
flask charged with N-methyliminodiacetic acid (1.407 g, 9.563 mmol) and DMSO (20 mL). To a 
second neck was fitted a short-path distillation apparatus connected to vacuum. The third neck of 
the flask was sealed with a septum. The system was placed under vacuum (1 Torr) and the 
mixture was heated to 75 °C upon which the DMSO began to distill. The DMSO solution of 
lithium triisopropyl 2-(N-tert-butoxycarbonyl)pyrrole borate was added to the distilling mixture 
dropwise over 1 h. The mixture was further distilled to near dryness (1 h). The resulting residue 
was suspended in acetone and concentrated in vacuo onto Celite (10 g). The resulting powder 
was lyophilized for one day to remove additional DMSO and then was subjected to flash 
chromatography on silica gel (Et2O:MeCN, 100:0 → 80:20) to afford 2.5e as an off-white 
crystalline solid (565 mg, 29%). 
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MeN
O
OB
O
O
Boc
N
2.5e  
TLC (EtOAc) 
Rf = 0.35 stained with KMnO4 
 
1H-NMR (500 MHz, CD3CN)  
δ 7.38 (dd, J = 3.0, 1.5 Hz, 1H), 6.61 (dd, J = 3.0, 1.5 Hz, 1H), 6.20 (t, J = 3.0 Hz, 1H), 
4.09 (d, J = 17 Hz, 2H), 4.05 (d, 17 Hz, 2H), 2.79 (s, 3H), 1.54 (s, 9H) 
 
13C-NMR (125 MHz, CD3CN) 
 δ 169.9, 151.2, 126.2, 124.9, 112.1, 84.9, 65.9, 49.9, 28.0 
 
11B-NMR (96 MHz, CD3CN) 
 δ 11.1   
 
HRMS (ESI+) 
 Calculated for C14H20BN2O6 (M+H)+: 323.1414 
 Found:     323.1414 
 
IR (KBr, cm-1) 
3174, 3118, 3012, 2982, 2941, 1743, 1457, 1337, 1304, 1296, 1253, 1235, 1146, 1027, 
1008, 815, 747 
 
 
1-(Phenylsulfonyl)-2-indole MIDA boronate (2.5f). The general procedure was followed using 
1-(phenylsulfonyl)-2-indoleboronic acid (1.396 g, 4.64 mmol, purchased from Sigma-Aldrich), 
N-methyliminodiacetic acid (0.717 g, 4.88 mmol), toluene (30 mL) and DMSO (15 mL). The 
mixture was refluxed for 3 h. The mixture was cooled to room temperature and the toluene was 
removed in vacuo. The resulting DMSO solution was transferred to a separatory funnel and was 
diluted with H2O (50 mL). The aqueous phase was extracted with THF:Et2O (1:1, 3 × 25 mL). 
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The combined organics were washed with brine (2 × 25 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The residue was adsorbed onto Celite from an acetone solution and the 
resulting powder was subjected to flash chromatography on silica gel (Et2O:MeCN 100:0 → 2:1) 
to afford 2.5f as a colorless crystalline solid (1.326 g, 69%). 
 
MeN
O
OB
O
O
N
SO2Ph
2.5f  
TLC (EtOAc) 
 Rf = 0.42, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CD3CN) 
 δ 8.18 (d, J = 8.5 Hz, 1H), 7.99 (d, J = 7.0, 2H), 7.59 (m, 2H), 7.49 (t, J = 8.5 Hz, 2H), 
7.36 (ddd, J = 8.5, 7.5, 1.5 Hz, 1H), 7.26 (app. td, J = 7.0, 1.0 Hz, 1H), 7.16 (d, J = 0.5 
Hz, 1H), 4.16 (d, J = 18 Hz, 2H), 4.11 (d, J = 18 Hz, 2H), 3.00 (s, 3H) 
 
13C-NMR (125 MHz, CD3CN) 
 δ 140.4, 139.7, 135.3, 131.3, 130.4, 127.8, 126.6, 124.8, 123.8, 122.6, 115.7, 65.9, 50.7 
 
11B-NMR (96 MHz, CD3CN)   
 δ 10.9 
 
HRMS (EI+)   
 Calculated for C19H17O6N2SB (M)+: 412.0900 
 Found:     412.0897 
 
IR (KBr, cm-1) 
 3068, 3014, 1769, 1528, 1469, 1448, 1363, 1340, 1299, 1228, 1176, 1124, 1091, 1042, 
1010, 966, 865, 750, 727, 686, 656, 589, 573, 561 
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cyclopropyl MIDA boronate (2.5h). The general procedure was followed using cyclopropyl 
boronic acid (5.139 g, 59.82 mmol, purchased from Oakwood Products), N-methyliminodiacetic 
acid (10.56 g, 71.79 mmol), DMSO (20 mL) and toluene (20 mL). The mixture was refluxed for 
2 h. The mixture was cooled to room temperature and then was concentrated in vacuo (1 Torr, 
100 °C). Although the product is stable to chromatography, for convenience the purification step 
was modified to employ crystallization. The residue oil was suspended in EtOAc (500 mL) and 
was transferred to a 2 L separatory funnel. The mixture was washed with water (250 mL). The 
aqueous phase was extracted with EtOAc (3 × 250 mL). The combined organics were washed 
with brine (50 mL) and then were dried over MgSO4, filtered, and concentrated in vacuo. The 
resulting crude product was dissolved in acetone (app. 100 mL), and then was diluted slowly 
over 1 h with Et2O (1.5 L) to promote crystallization of the product. The mixture was filtered to 
isolate 2.5h as a colorless, crystalline solid (8.775 g, 74%). 
 
MeN
O
OB
O
O
2.5h  
TLC (EtOAc)  
 Rf = 0.21, stained with KMnO4 
 
1H-NMR (500 MHz, CD3CN) 
 δ 3.92 (d, J = 17 Hz, 2H), 3.80 (d, J = 17 Hz, 2H), 2.98 (s, 3H), 0.46 (dq, J = 9.5, 3.0 Hz, 
2H), 0.12 (m, 2H), -0.33 (m, 1H) 
 
13C-NMR (125 MHz, acetone-d6) 
 δ 169.0, 62.7, 46.8, 1.2 
 
11B-NMR (96 MHz, CD3CN) 
 δ 13.2 
 
HRMS (FAB+) 
 Calculated for C8H13BNO4 (M+H)+: 198.0938 
 Found:     198.0937 
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IR (thin film, cm-1) 
 2998, 1744, 1457, 1358, 1337, 2197, 1246, 1129, 1048, 985, 956, 892, 880, 845, 704 
 
 
Synthesis of boronic acids (Table 2.1). 
 
MeN
O
OB
O
O
23 °C, 20 min
aq. NaOH
THF
B(OH)2
 
 
General Procedure for the synthesis of boronic acids.  Under ambient atmosphere, to a 100 
mL flask equipped with a stir bar and charged with MIDA boronate (2.5) (5 mmol) as a solution 
in THF (50 mL) was added aq NaOH (1.0 M, 15 mL). The mixture was vigorously stirred for 20 
min. The mixture was then transferred to a separatory funnel and was diluted with Et2O (50 mL) 
and 0.5 M pH 7 sodium phosphate buffer (50 mL). The mixture was shaken, and the phases were 
separated. The aqueous phase was extracted with THF:Et2O (1:1, 2 × 25 mL). The combined 
organics were dried over MgSO4, filtered and concentrated in vacuo. Residual solvent was co-
evaporated with MeCN, and the resulting solid was placed under vacuum (~1 Torr) for 30 min. 
All boronic acids thus obtained were judged to be >95% pure by 1H-NMR (See accompanying 
1H NMR spectra) and were utilized in cross-coupling reactions immediately after preparation. 
 
Boronic acid 2.4a. The general procedure was followed using MIDA boronate 2.5a (1.127 g, 
5.002 mmol) to yield the 2.4a as an off white solid (0.531 g, 95%). 
 
O B(OH)2
2.4a  
TLC (EtOAc) 
Rf = 0.46, stained with KMnO4 
 
1H-NMR (500 MHz, DMSO-d6:D2O 95:5 w/ TMS)  
δ 7.81 (dd, J = 1.5, 0.5 Hz, 1H), 7.07 (dd, J = 3.0, 0.5 Hz, 1H), 6.48 (dd, J = 3.5, 2.0 Hz, 
1H) 
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13C-NMR (125 MHz, DMSO-d6:D2O 95:5 w/ TMS) 
 δ 146.4, 121.5, 110.3 
 
HRMS (EI+) 
 Calculated for C4H5O3B (M)+: 112.0332 
 Found:   112.0332 
 
 
 
 
 
 
 
 
 
1H NMR Spectrum of 2.4a 
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Boronic acid 2.4b. The general procedure was followed using MIDA boronate 2.5b (1.374 g, 
5.033 mmol) to yield 2.4b as an off white solid (0.728 g, 89%). 
 
B(OH)2
O
2.4b  
TLC (EtOAc) 
Rf = 0.14, visualized by UV (λ = 254 and 366 nm) and KMnO4 stain 
 
1H-NMR (500 MHz, DMSO-d6:D2O 95:5 w/ TMS)  
δ 7.71 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 7.50 (s, 1H), 7.37 (t, J = 8.0 Hz, 1H), 
7.26 (t, J = 7.5 Hz, 1H) 
 
13C-NMR (125 MHz, DMSO-d6:D2O 95:5 w/ TMS) 
 δ 156.4, 127.6, 125.3, 122.5, 121.8, 117.5, 111.4 
 
1H NMR Spectrum of 2.4b 
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Boronic acid 2.4c. The general procedure was followed using MIDA boronate 2.5c (1.207 g, 
5.048 mmol) to yield 2.4c as a white solid (0.641 g, 99%). 
 
S B(OH)2
2.4c  
TLC (EtOAc) 
Rf = 0.23, visualized by UV (λ = 254 nm) and KMnO4 stain 
 
1H-NMR (500 MHz, DMSO-d6:D2O 95:5 w/ TMS)  
δ 7.75 (d, J = 5.0 Hz, 1H), 7.69 (d, J = 3.5 Hz, 1H), 7.18 Hz (app t, J = 4.0 Hz, 1H) 
 
13C-NMR (125 MHz, DMSO-d6:D2O 95:5 w/ TMS) 
 δ 135.9, 131.5, 128.1 
1H NMR Spectrum of 2.4c 
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Boronic acid 2.4d. The general procedure was followed using MIDA boronate 2.5d (1.099 g, 
3.277 mmol) and aq NaOH (1.0 M, 10 mL) to yield 2.4d was as a green solid (0.667 g, 91%). 
B(OH)2S
S
Me
2.4d  
TLC (EtOAc) 
Rf = 0.34, visualized by UV (λ = 254 and 366 nm) and KMnO4 stain 
 
1H-NMR (500 MHz, DMSO-d6:D2O 95:5 w/ TMS)  
δ 7.59 (d, J = 3.5 Hz, 1H), 7.29 (d, J = 3.5 Hz, 1H), 7.17 (d, J = 1.0 Hz, 1H), 7.08 (s, 1H), 
2.22 (s, 3H) 
 
13C-NMR (125 MHz, DMSO-d6:D2O 95:5 w/ TMS) 
 δ 142.0, 138.3, 137.0, 136.3, 126.3, 124.6, 120.6, 15.3 
 
 
1H NMR Spectrum of 2.4d 
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Boronic acid 2.4e. The general procedure was followed using MIDA boronate 2.5e (0.691 g, 
2.144 mmol) and aq NaOH (1.0 M, 6.5 mL). Reaction volumes were scaled accordingly. After 
addition of NaOH, the reaction was stirred at 23 °C for 10 min. The reaction mixture was 
transferred to a separatory funnel and was diluted with Et2O (20 mL) and 1M aq NaOH (20 mL). 
The mixture was shaken and the organic phase was separated and discarded. The aqueous phase 
was diluted with THF:Et2O (1:1, 20 mL) and saturated aq NH4Cl (20 mL). The mixture was 
shaken and the phases were separated. The aqueous phase was extracted with THF:Et2O (1:1, 2 × 
10 mL). The combined organics were dried over MgSO4, filtered and concentrated in vacuo to 
afford 1e as a colorless solid (0.403 g, 89%). 
 
Boc
N B(OH)2
2.4e  
TLC (EtOAc) 
Rf = 0.50, visualized by UV (λ = 254 nm) and KMnO4 stain 
 
1H-NMR (500 MHz, DMSO-d6:D2O 95:5 w/ TMS)  
δ 7.34 (dd, J = 1.5 Hz, 1H), 6.46 (dd, J = 3.5, 2.0 Hz, 1H), 6.23 (t, J = 3.0 Hz, 1H), 1.54 
(s, 9H) 
 
13C-NMR (125 MHz, DMSO-d6:D2O 95:5 w/ TMS) 
 δ 149.8, 123.0, 120.6, 111.7, 84.1, 27.3 
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Boronic acid 2.4f. The general procedure was followed using MIDA boronate 2.5f (1.236 g, 
2.999 mmol) THF (30 mL), and aq NaOH (1.0 M, 9 mL). The mixture was stirred 5 min. The 
mixture was transferred to a separatory funnel and was diluted with Et2O (30 mL) and aq NaOH 
(1.0 M, 30 mL). The mixture was shaken and the organic phase was separated and discarded. 
The aqueous phase was diluted with THF:Et2O (1:1, 30 mL) and saturated aq NH4Cl (30 mL). 
The mixture was shaken and the phases were separated. The aqueous phase was extracted with 
THF:Et2O (1:1, 2 × 15 mL). The combined organics were dried over MgSO4, filtered and 
concentrated in vacuo to afford 2f as a pale yellow solid (584 mg, 65%). 
 
 
 
 
 
 
 
1H NMR Spectrum of 2.4e 
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B(OH)2
N
SO2Ph
2.4f  
TLC (EtOAc) 
Rf = 0.53, visualized by UV (λ = 254 and 366 nm)  
 
1H-NMR (500 MHz, DMSO-d6:D2O 95:5 w/ TMS)  
δ 8.02 (d, J = 7.5 Hz, 2H), 7.84 (d, J = 8.0 Hz, 1H), 7.65 (t, J = 7.5 Hz, 1H), 7.56 (t, J = 
7.5 Hz, 3H), 7.28 (t, J = 7.5 Hz, 1H), 7.20 (t, J = 8.0 Hz, 1H), 6.81 (s, 1H) 
 
13C-NMR (125 MHz, DMSO-d6:D2O 95:5 w/ TMS) 
 δ 137.1, 135.4, 134.2, 131.1, 129.4, 126.9, 124.3, 123.3, 121.1, 114.4, 113.3 
1H NMR Spectrum of 2.4f 
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Boronic acid 2.4g. The general procedure was followed using MIDA boronate 2.5g (0.915 g, 
5.00 mmol) and aq NaOH (1.0 mL, 15 mL). Due to the volatility of the product, solvent removal 
was performed at 23 °C. Residual solvent was co-evaporated with CH2Cl2. To further remove 
solvent, the product was briefly (< 1 minute) placed under vacuum (~1 Torr). Boronic acid 2.4g 
was isolated as a white solid (0.161 g, 45%). 
 
B(OH)2
2.4g  
TLC (EtOAc) 
Rf = 0.31, stained with KMnO4 
 
1H-NMR (500 MHz, DMSO-d6:D2O 95:5 w/ TMS)  
δ 6.01 (dd, J = 19, 5.5 Hz, 1H), 5.80 (m, 2H) 
 
13C-NMR (125 MHz, DMSO-d6:D2O 95:5 w/ TMS) 
 δ 133.7 
 
HRMS (CI+) 
 Calculated for C2H6O2B (M+H)+: 73.04609 
 Found:     73.04602 
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1H NMR Spectrum of 2.4g 
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Boronic acid 2.4h. The general procedure was followed using boronate 2.5h (0.789 g, 4.00 
mmol) and aq NaOH (1.0 M, 12 mL). Reaction and workup volumes were scaled accordingly. 
Boronic acid 2.4h was isolated as an off-white solid (0.183 g, 53%). 
 
B(OH)2
2.4h  
TLC (EtOAc) 
Rf = 0.22, stained with KMnO4  
 
1H-NMR (500 MHz, DMSO-d6:D2O 95:5 w/ TMS)  
δ 0.43 (m, 2H), 0.33 (m, 2H), -0.39 (m, 1H) 
 
13C-NMR (125 MHz, DMSO-d6:D2O 95:5 w/ TMS) 
 δ 3.29 
 
1H NMR Spectrum of 2.4h 
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Synthesis of MIDA boronates (Table 2.2) 
 
3-methoxyphenyl MIDA boronate (2.10b). A 500 mL flask equipped with a stir bar was 
charged with 3-methoxyphenylboronic acid (1.325 g, 8.72 mmol), N-methyliminodiacetic acid 
(1.290 g, 10.13 mmol), toluene (260 mL) and DMSO (26 mL). The flask was fitted with a Dean-
Stark apparatus filled with toluene and a reflux condenser open to ambient atmosphere, and the 
mixture was refluxed with stirring for 16 h, followed by concentration in vacuo (35 °C at 20 
mTorr, then 100 °C at 1 mTorr). The crude product was adsorbed onto Florisil® from an acetone 
solution, and the resulting powder was dry-loaded on top of a silica gel column slurry-packed 
with Et2O. The column was flushed with a copious volume of Et2O and eluted with Et2O:MeCN 
1:1 to yield the boronate ester 2.10b as a colorless, crystalline solid (2.25 g, 98%). 
 
MeN
O
OB
O
OMeO
2.10b  
TLC (EtOAc) 
 Rf = 0.33, visualized by UV (254 nm) and KMnO4 
 
1H-NMR (500 MHz, CD3CN) 
 δ 7.30 (ddd, J = 8.2, 7.3, 0.4, 1H), 7.03 (dt, J = 7.3, 1.2, 1H), 7.01 (dd, J = 2.5, 0.6, 1H), 
6.94 (ddd, J = 8.3, 2.8, 1.1, 1H), 4.05 (d, J = 17, 2H), 3.88 (d, J = 17, 2H), 3.78 (s, 3H), 
2.50 (s, 3H) 
 
13C-NMR (500 MHz, CD3CN) 
 δ 169.6, 160.3, 130.2, 125.5, 118.3, 115.8, 62.8, 55.7, 48.4 
 
11B-NMR (600 MHz, CD3CN) 
 δ 12.0 
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HRMS (EI+) 
 Calculated for C12H14BNO5 (M)+: 263.0965  
Found:     263.0963 
 
IR (thin film, cm-1) 
 3005, 2956, 1765, 1608, 1576, 1487, 1461, 1419, 1341, 1320, 1292, 1248, 1203, 1170, 
1149, 1094, 1050, 1030, 1014, 1002, 965, 896, 861 
 
 
trans-1-hexenyl MIDA boronate (2.10c). A 500 mL flask equipped with a stir bar was charged 
with E-hexen-1-ylboronic acid (0.457 g, 3.57 mmol), N-methyliminodiacetic acid (0.526 g, 3.58 
mmol), toluene (63 mL) and DMSO (7 mL). The flask was fitted with a Dean-Stark apparatus 
filled with toluene and a reflux condenser open to ambient atmosphere. The mixture was 
refluxed with stirring for 18 h, followed by concentration in vacuo (35 °C at 20 mTorr, then 100 
°C at 1 mTorr). The crude product was adsorbed onto Florisil® from an acetone solution, and the 
resulting powder was dry-loaded on top of a silica gel column slurry-packed with Et2O. The 
column was flushed with a copious volume of Et2O and eluted with Et2O:MeCN 1:1 to yield the 
boronate ester 2.10c as a colorless, crystalline solid (0.722 g, 85%). 
 
MeN
O
OB
O
OMe
2.10c  
TLC (EtOAc) 
 Rf = 0.37, visualized by KMnO4 
 
1H-NMR (500 MHz, CD3CN) 
 δ 6.06 (dt, J = 18, 6.5, 1H), 5.40 (dt, J = 18, 1.5, 1H), 3.92 (d, J = 17, 2H), 3.75 (d, J =17, 
2H), 2.74 (s, 3H), 2.11 (q, J = 7.1, 2H), 1.38 (quint, J = 7.1, 2H), 1.31 (sext, J = 7.2, 2H), 
0.89 (t, J = 7.3, 3H) 
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13C-NMR (500 MHz, CD3CN) 
 δ 169.5, 146.9, 62.2, 47.6, 35.8, 31.7, 22.9, 14.2. 
 
11B-NMR (600 MHz, CD3CN) 
 δ 11.1 
 
HRMS (CI+) 
 Calculated for C11H19BNO4 (M+H)+:  240.1407  
Found:      240.1406 
 
IR (thin film, cm-1) 
 2956, 2923, 1750, 1643, 1451, 1339, 1304, 1249, 1132, 1027, 995, 959, 867 
 
 
trans-styrenyl MIDA boronate (2.10d). A 500 mL flask equipped with a stir bar was charged 
with trans-2-phenylvinylboronic acid (3.27 g, 22.1 mmol, 1 equiv.), N-methyliminodiacetic acid 
(3.26 g, 22.2 mmol, 1 equiv), benzene (360 mL) and DMSO (40 mL). The flask was fitted with a 
Dean-Stark apparatus filled with benzene and a reflux condenser open to ambient atmosphere, 
and the mixture was refluxed with stirring for 18 h, followed by concentration in vacuo (35 °C at 
20 mTorr, then 100 °C at 1 mTorr). The crude product was adsorbed onto Florisil® from an 
acetone solution, and the resulting powder was dry-loaded on top of a silica gel column slurry-
packed with Et2O. The column was flushed with a copious volume of Et2O and eluted with 
Et2O:MeCN 1:1 to yield the boronate ester 2.10d as a colorless, crystalline solid (5.50 g, 96%). 
 
O O
B O O
MeN
2.10d  
TLC (EtOAc) 
 Rf =0.37, visualized by UV (254 nm) and KMnO4 
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1H-NMR (500 MHz, CD3CN) 
 δ 7.52 (app. d, J = 7.6, 2H), 7.35 (app. t, J = 7.5), 7.27 (app. t, J = 7.5, 1H), 6.97 (d, J = 
18, 1H), 6.30 (d, J = 18, 1H), 4.02 (d, J = 17, 2H), 3.86 (d, J = 17, 2H), 2.81 (s, 3H). 
 
13C-NMR (500 MHz, CD3CN) 
 δ 169.6, 143.2, 139.0, 129.5, 129.0, 127.6, 62.4, 47.7. 
 
11B-NMR (600 MHz, CD3CN) 
 δ 11.5 
 
HRMS (EI+) 
 Calculated for C13H14BNO4 (M)+: 259.1016 
 Found:     259.1017 
 
IR (thin film, cm-1) 
 2999, 1757, 1624, 1448, 1336, 1298, 1238, 1152, 1113, 1087, 1029, 998, 955, 874, 748, 
696. 
 
 
Fast-release cross-coupling of boronic acids and MIDA boronates (Table 2.2). 
 
O O
B O O
MeN
RR B(OH)2 or
R'
RPd(PPh3)4, NaOH
THF/H2O 5:1, 60 oC, 24hr
R'
Br
2.9 2.10
2.11a
2.11b
2.12
R'
C(O)Me
OMe
 
 
General procedures for the direct coupling of boronic acids or MIDA boronate esters. To a 
20 mL vial equipped with a stir bar was added the halide (1.0 mmol), solid base (7.5 mmol), and 
either the boronate ester (1.5 mmol) or the corresponding boronic acid (1.5 mmol). The vial was 
capped with a Kimwipe® and elastic band and brought into a glove box. To the vial was added 
0.02 mmol Pd(PPh3)4 from a 0.02 M stock solution in THF. Additional THF was added to bring 
 
 
78 
 
the total solvent volume to 10.0 mL. The vial was sealed with a PTFE-lined septum-screw cap 
and removed from the glove box. H2O (2 mL), degassed for 30 minutes by sparging with argon 
or nitrogen, was added by syringe, and the resulting biphasic mixture was maintained, with 
vigorous stirring, at 60°C for 24 h. The reaction mixture was allowed to cool to 23°C, and was 
diluted with 1M aq NaOH (10 mL) and Et2O (10 mL). The aqueous phase was separated and 
extracted with Et2O (3 × 10 mL). The combined organic fractions were washed with saturated aq 
NaCl (10 mL) and dried over MgSO4. Solvent was removed in vacuo. The resulting crude 
product was purified by flash column chromatography (SiO2). 
 
4'-Methyl-4-acetylbiphenyl (2.12b) [Table 2.2, Entry 1]. The general procedure was followed 
using 4-bromoacetophenone (0.201 g, 1.01 mmol), p-tolylboronic acid (0.206 g, 1.51 mmol), and 
NaOH (0.307 g, 7.68 mmol). Products were eluted with hexanes:EtOAc 6:1 to yield the title 
compound as a white crystalline solid (0.204 g, 96%). 
 
 A parallel reaction using 4-bromoacetophenone (0.201 g, 1.01 mmol), 2.10a (0.376 g, 1.52 
mmol), and NaOH (0.305 g, 7.62 mmol) afforded the title compound as a white crystalline solid 
(0.204 g, 96%). 
 
Me
O
Me
2.12a  
TLC (hexanes:EtOAc 6:1) 
 Rf = 0.26, visualized by UV (254 nm) and KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
 δ 8.02 (app. d, J = 8.4, 2H), 7.67 (app. d, J = 8.5, 2H), 7.54 (app. d, J = 8.0, 2H), 7.28 
(app. d, J = 7.9), 2.64 (s, 3H), 2.41 (s, 3H) 
 
13C-NMR (500 MHz, CDCl3) 
 δ 197.6, 145.6, 138.1, 136.8, 135.5, 129.6, 128.8, 127.0, 126.8, 26.5, 21.1 
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HRMS (CI+) 
 Calculated for C15H15O (M+H)+: 211.11230  
Found:     211.11214 
 
IR (thin film, cm-1) 
 1680, 1601, 1398, 1361, 1324, 1267, 1201, 1133, 959, 847 
 
 
4'-Methoxy-4-methylbiphenyl (2.12b) [Table 2.2, Entry 2]. The general procedure was 
followed using 4-bromoanisole (0.188 g, 1.01 mmol), 4-tolylboronic acid (0.205 g, 1.51 mmol), 
and NaOH (0.302 g, 7.55 mmol). The product was eluted with a gradient of hexanes:CH2Cl2 3:1 
→ 100% CH2Cl2 to yield the title compound as a colorless solid (0.195 g, 98%). 
 
A parallel reaction using 4-bromoanisole (0.188 g, 1.01 mmol), 2.10a (0.372 g, 1.51 mmol) and 
NaOH (0.301 g, 7.53 mmol) conditions afforded the title compound as a colorless solid (0.189 g, 
95%). 
 
Me
OMe
2.12b  
TLC (hexanes:EtOAc 6:1) 
 Rf = 0.47, visualized by UV (254 nm) and KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
 δ 7.52 (app. d, J = 8.8, 2H), 7.46 (app. d, J = 8.2, 2H), 7.24 (app. d, J = 7.8, 2H), 6.98 
(app. d, J = 8.8, 2H), 3.86 (s, 3H), 2.39 (s, 3H) 
 
13C-NMR (500 MHz, CDCl3) 
 δ 158.9, 137.9, 136.3, 133.7, 129.4, 127.9, 126.5, 114.1, 55.3, 21.0 
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HRMS (EI+) 
 Calculated for C14H14O (M)+:  198.1045  
Found:     198.1046 
 
IR (thin film, cm-1) 
 2957, 2836, 1608, 1502, 1288, 1269, 1252, 1183, 1038, 1012, 841, 807 
 
 
4-Acetyl-3'-methoxybiphenyl  (2.12c) [Table 2.2, Entry 3]. The general procedure was 
followed using 4-bromoacetophenone (0.200 g, 1.00 mmol), 3-methoxyphenylboronic acid 
(0.229 g, 1.51 mmol), and NaOH (0.303 g, 7.58 mmol). The product was eluted with 
hexanes:CH2Cl2:EtOAc 50:45:5 to yield the title compound as a clear colorless oil which 
crystallized under vacuum (0.222 g, 98%). 
 
A parallel reaction  using 4-bromoacetophenone (0.201 g, 1.01 mmol), 2.10b (0.397 g, 1.51 
mmol) and NaOH (0.303 g, 7.58 mmol) afforded the title compound as a clear colorless oil 
which crystallized under vacuum (0.219 g, 96%). 
 
Me
O
MeO
2.12c  
TLC (hexanes:EtOAc 6:1) 
 Rf = 0.19, visualized by UV (254 nm) and KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
 δ 8.03 (app. d, J = 8.3, 2H), 7.68 (app. d, J = 8.2, 2H), 7.39 (t, J = 7.8, 1H), 7.21 (app. d, J 
= 7.7, 1H), 7.15 (m, 1H), 6.95 (dd, J = 8.3, 2.6, 1H), 3.87 (s, 3H), 2.63 (s, 3H) 
 
13C-NMR (500 MHz, CDCl3) 
 δ 197.4, 159.9, 145.3, 141.1, 135.7, 129.8, 128.7, 127.0, 119.5, 113.3, 112.9, 55.1, 26.4 
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HRMS (CI+) 
 Calculated for C15H15O2 (M+H)+: 227.10721  
Found:     227.10732 
 
IR (thin film, cm-1) 
 2959, 2836, 1678, 1597, 1487, 1465, 1427, 1399, 1325, 1304, 1274, 1222, 1182, 1118, 
1049, 1030, 958, 831 
 
 
3,4'-Dimethoxybiphenyl (2.12d) [Table 2.2, Entry 4]. The general procedure was followed 
using 4-bromoanisole (0.187 g, 1.00 mmol), 3-methoxyphenylboronic acid (0.228 g, 1.50 mmol), 
and NaOH (0.300 g, 7.50 mmol). The product was eluted with hexanes:EtOAc 6:1 to yield the 
title compound as a clear colorless oil (0.201 g, 94%). 
 
A parallel reaction using 4-bromoanisole (0.188 g, 1.01 mmol), 2.10b (0.397 g, 1.51 mmol) and 
NaOH (0.302 g, 7.55 mmol) afforded the title compound as a clear colorless oil (0.208 g, 96%). 
 
OMe
MeO
2.12d  
TLC (hexanes:EtOAc 6:1) 
 Rf = 0.42, visualized by UV (254 nm) and KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
 δ 7.57 (app. d, J = 8.7, 2H), 7.37 (t, J = 7.9, 1H), 7.19 (d, J = 7.7, 1H), 7.14 (app. s, 1H), 
7.01 (app. d, J = 8.7, 2H), 6.90 (dd, J = 8.2, 2.4), 3.89 (s, 3H), 3.87 (s, 3H) 
 
13C-NMR (500 MHz, CDCl3) 
 δ 159.9, 159.2, 142.3, 133.5, 129.7, 128.1, 119.2, 114.1, 112.5, 111.9, 55.3, 55.2 
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HRMS (EI+) 
 Calculated for C14H14O2 (M)+: 214.0994  
Found:     214.0992 
 
IR (thin film, cm-1) 
 3010, 2962, 2938, 2836, 1598, 1591, 1570, 1517, 1488, 1463, 1401, 1323, 1309, 1288, 
1269, 1246, 1220, 1179, 1112, 1085, 1054, 1033, 870, 856, 828, 811 
 
 
1-[4-(1E)-1-hexenylphenyl]-ethanone (2.12e) [Table 2.2, Entry 5]. The general procedure was 
followed using 4-bromoacetophenone (0.200 g, 1.01 mmol), E-hexen-1-ylboronic acid (0.192 g, 
1.50 mmol), and NaOH (0.316 g, 7.65 mmol). The product was eluted with hexane:EtOAc 8:1 to 
yield the title compound as a clear colorless oil (0.183 g, 90%). 
 
A parallel reaction using 4-bromoacetophenone (0.200 g, 1.01 mmol), 2.10c (0.360 g, 1.51 
mmol), and NaOH (0.310 g, 7.75 mmol) afforded the title compound as a clear colorless oil 
(0.196 g, 96%). 
O
Me
Me
2.12e  
TLC (hexanes:EtOAc 6:1) 
 Rf = 0.43 visualized by UV and KMnO4 
 
1H-NMR (400 MHz, CDCl3) 
 δ 7.85 (app. d, J = 8.6, 2H), 7.36 (app. d, J = 8.4, 2H), 6.35 (m, 2H), 2.53 (s, 3H), 2.21 
(app. q,  J = 7.0, 2H), 1.44 (quint, J = 7.1, 2H), 1.35 (sext, J = 7.3, 2H), 0.91 (t, J = 7.3, 
3H) 
 
13C-NMR (500 MHz, CDCl3) 
 δ 197.2, 142.5, 135.2, 134.3, 128.8, 128.6, 125.7, 32.7, 31.1, 26.3, 22.1, 13.8 
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HRMS (CI+) 
 Calculated for C14H19O (M+H)+: 203.14360    
Found:     203.14360 
 
 
trans-4-acetylstilbene (2.12f) [Table 2.2, Entry 6]. The general procedure was followed using 4-
bromoacetophenone (0.201 g, 1.01 mmol), trans-2-phenylvinylboronic acid (0.224 g, 1.51 
mmol), and NaOH (0.303 g, 7.58 mmol). The product was eluted with hexanes:CH2Cl2:EtOAc 
75:20:5 to yield the title compound as a colorless solid. (0.198 g 88%). 
 
A parallel reaction using 4-bromoacetophenone (0.201 g, 1.01 mmol), 2.10d (0.392 g, 1.51 
mmol) and NaOH (0.308 g, 7.70 mmol) afforded the title compound as a colorless solid. (0.214 
g, 96%). 
Me
O
2.12f  
TLC (hexanes:EtOAc 6:1) 
 Rf = 0.24, visualized by UV (254 and 366 nm) and KMnO4 
 
1H-NMR (400 MHz, CDCl3) 
 δ 7.96 (app. d, J = 8.4, 2H), 7.59 (app. d, J = 8.3, 2H), 7.54 (app. d, J = 7.2, 2H), 7.39 
(app. t, J = 7.2, 2H), 7.31 (app. t, J = 7.2, 1H), 7.23 (d, J = 16, 1H), 7.13 (d, J = 16, 1H), 
2.61 (s, 3H) 
 
13C-NMR (500 MHz, CDCl3) 
 δ 197.4, 142.0, 136.6, 135.9, 131.4, 128.8, 128.8, 128.3, 127.4, 126.8, 126.5, 26.6 
 
HRMS (CI+) 
 Calculated for C16H15O (M+H)+: 223.11230  
Found:     223.11214 
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IR (thin film, cm-1) 
 1676, 1410, 1358, 1333, 1113, 1073, 1020, 965, 953, 867, 820 
 
 
Slow-release cross-coupling of boronic acids and MIDA boronates (Table 2.3). 
 
RR
B(OH)2 or
Pd(OAc)2, SPhos
K3PO4, dioxane:H2O 5:1
60 °C, 6 h
Ot-Bu
Cl
2.4 2.5
MeN
O
OB
O
O
2.14
Ot-Bu
R
2.13
1.0 equiv 1.0 equiv
1 mmol
 
 
General Procedure: 
Under ambient atmosphere, to a 40 mL I-Chem vial equipped with a stir bar was added 1-tert-
butoxy-4-chlorobenzene (2.13) (185 mg, 1.00 mmol), the MIDA boronate or freshly-prepared 
boronic acid (1.00 mmol), 2-dicyclohexylphosphino-2’,6’-dimethoxybiphenyl (S-Phos) (41 mg, 
0.10 mmol) and Pd(OAc)2 (11 mg, 0.050 mmol). The vial was sealed with a PTFE-lined septum 
screw-cap and was placed under argon atmosphere. To the vial was added dioxane (12.5 mL) 
and the resulting mixture was stirred at 23 °C for 10 min. To the vial was then added aq K3PO4 
(3.0 M, 2.5 mL, degassed by sparging with argon for 30 min). The vial was placed in a 60 °C oil 
bath with stirring for 6 h. After cooling to room temperature the mixture was transferred to a 60 
mL separatory funnel and was diluted with aq NaOH (1.0 M, 10 mL) and Et2O (10 mL). The 
mixture was shaken and the phases were separated. The aqueous phase was extracted with Et2O 
(3 × 10 mL). The combined organic fractions were dried over MgSO4, filtered, and concentrated 
in vacuo. The crude residue was adsorbed onto Celite and the resulting powder was subjected to 
flash-chromatography on silica gel (hexanes:EtOAc). 
 
 
2-(4-tert-butoxyphenyl)furan (2.14a) [Table 2.3, Entry 1]. The general procedure was followed 
using MIDA boronate 2.5a (223 mg, 1.00 mmol) to afford 2.14a as a colorless oil (203 mg, 
94%). 
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A parallel reaction using freshly-prepared boronic acid 2.4a (112 mg, 1.00 mmol) under 
otherwise identical conditions afforded 2.14a as a colorless oil (147 mg, 68%). 
 
Ot-Bu
O
2.14a  
TLC (hexanes:EtOAc 20:1) 
Rf = 0.33, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3)  
δ 7.60 (d, J = 8.5 Hz, 2H), 7.45 (dd, J = 1.5, 0.5 Hz, 1H), 7.04 (d, J = 8.5 Hz, 2H), 6.58 
(d, J = 3.0 Hz, 1H), 6.46 (dd, J = 3.0, 1.5 Hz, 1H), 1.38 (s, 9H) 
 
13C-NMR (125 MHz, CDCl3) 
 δ 154.8, 153.9, 141.6, 126.3, 124.4, 124.3, 111.5, 104.0, 78.7, 28.8 
 
HRMS (CI+) 
 Calculated for C14H16O2 (M)+: 216.1150 
 Found:   216.1151 
 
IR (thin film, cm-1) 
2977, 1612, 1587, 1566, 1512, 1481, 1414, 1390, 1366, 1245, 1162, 1106, 1078, 1007, 
904, 895, 854, 798, 730, 667, 594 
 
 
2-(4-tert-butoxyphenyl)benzofuran (2.14b) [Table 2.3, Entry 2]. The general procedure was 
followed using MIDA boronate 2.5b (273 mg, 1.00 mmol) to afford 2.14b as a colorless solid 
(246 mg, 92%).  
 
A parallel reaction using freshly-prepared boronic acid 2.4b (162 mg, 1.00 mmol) under 
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otherwise identical conditions afforded 2.14b as a pale yellow solid (134 mg, 50%). 
 
Ot-Bu
O
2.14b  
TLC (hexanes:EtOAc 20:1) 
Rf = 0.28, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3)  
δ 7.83 (d, J = 8.5 Hz, 2H), 7.62 (d, J = 8.0 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.33 (t, J = 
7.0 Hz, 1H), 7.29 (t, J = 7.0 Hz, 1H), 7.14 (d, J = 8.5 Hz, 2H), 6.96 (s, 1H), 1.46 (s, 9H) 
 
13C-NMR (125 MHz, CDCl3) 
δ 156.0, 156.9, 154.7, 129.3, 125.6, 125.5, 124.1, 123.8, 122.8, 120.6, 111.0, 110.3, 78.9, 
28.8 
 
HRMS (EI+) 
 Calculated for C18H18O2 (M)+: 266.1307 
 Found:   266.1303 
 
IR (thin film, cm-1) 
2978, 1609, 1499, 1451, 1364, 1298, 1239, 1209, 1157, 1099, 1029, 1007, 918, 893, 853, 
806, 750, 713 
  
 
2-(4-tert-butoxyphenyl)thiophene (2.14c) [Table 2.3, Entry 3]. The general procedure was 
followed using MIDA boronate 2.5c (239 mg, 1.00 mmol) to afford 2.14c as a pale yellow solid 
(217 mg, 94%). 
 
A parallel reaction using freshly-prepared boronic acid 2.4c (128 mg, 1.00 mmol) under 
otherwise identical conditions afforded 2.14c as a pale yellow oil (87 mg, 37%). 
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Ot-Bu
S
2.14c  
TLC (hexanes:EtOAc (10:1) 
Rf = 0.50, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3)  
δ 7.52 (d, J = 7.0 Hz, 2H), 7.24 (s, 1H), 7.23 (d, J =1.0 Hz, 1H), 7.06 (dd, J = 5.0, 4.0 Hz, 
1H), 7.00 (d, J = 8.5 Hz, 2H), 1.37 (s, 9H) 
 
13C-NMR (125 MHz, CDCl3) 
δ 154.9, 144.1, 129.6, 127.9, 126.4, 124.4, 124.2, 122.4, 78.7, 28.8 
 
HRMS (EI+) 
 Calculated for C14H16OS (M)+: 232.0922 
 Found:   232.0921 
 
IR (thin film, cm-1) 
2978, 1604, 1534, 1498, 1432, 1366, 1243, 1164, 1102, 922, 895, 850, 819, 694, 606, 540 
 
 
5'-(4-tert-butoxyphenyl)-4-methyl-2,2'-bithiophene (2.14d) [Table 2.3, Entry 4]. The general 
procedure was followed using MIDA boronate 2.5d (335 mg, 1.00 mmol) to afford 2.14d as a 
yellow solid (317 mg, 96%). 
 
A parallel reaction using freshly-prepared boronic acid 2.4d (224 mg, 1.00 mmol) under 
otherwise identical conditions afforded 2.14d as a yellow solid (158 mg, 45%; yield corrected for 
residual 2.13). 
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S
S
Me Ot-Bu
2.14d  
TLC (hexanes:EtOAc 10:1) 
Rf = 0.41, visualized by UV (λ = 254 and 366 nm) 
 
1H-NMR (500 MHz, CDCl3)  
δ 7.50 (d, J = 8.5 Hz, 2H), 7.14 (d, J = 4.0 Hz, 1H), 7.10 (d, J = 4.0 Hz, 1H), 7.01 (m, 
3H), 6.79 (s, 1H), 2.27 (s, 3H), 1.39 (s, 9H) 
 
13C-NMR (125 MHz, CDCl3) 
δ 155.0, 142.6, 138.3, 137.1, 136.3, 129.2, 126.0, 125.6, 124.3, 124.2, 123.0, 119.4, 78.7, 
28.7, 15.6 
 
HRMS (EI+) 
 Calculated for C19H20OS2 (M)+: 328.0956  
 Found:   328.0958 
 
IR (thin film, cm-1) 
2973, 1502, 1466, 1365, 1246, 1160, 1106, 897, 850, 836, 804, 733, 717, 589, 528 
 
 
N-(tert-butoxycarbonyl)-2-(4-tert-butoxyphenyl)pyrrole (2.14e) [Table 2.3, Entry 5]. The 
general procedure was followed using MIDA boronate 2.5e (322 mg, 1.00 mmol) to afford 2.14e 
as a pale yellow solid (284 mg, 90%).  
 
A parallel reaction using freshly-prepared boronic acid 2.4e (211 mg, 1.00 mmol) under 
otherwise identical conditions afforded 2.14e as a pale yellow oil (192 mg, 61%). 
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Boc
N
Ot-Bu
2.14e  
TLC (hexanes:EtOAc 10:1) 
Rf = 0.37, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3)  
δ 7.36 (dd, J = 3.0, 1.5 Hz, 1H), 7.23 (d, J = 8.5 Hz, 2H), 6.97 (d, J = 8.5 Hz, 2H), 6.22 
(t, J = 1.5 Hz, 1H), 6.15 (dd, J = 3.5, 2.0 Hz, 1H), 1.38 (s, 9H), 1.34 (s, 9H) 
 
13C-NMR (125 MHz, CDCl3) 
δ 154.5, 149.5, 134.6, 129.7, 129.6, 123.1, 122.3, 114.2, 110.4, 83.5, 78.4, 28.8, 27.6 
 
HRMS (CI+) 
 Calculated for C19H25O3N (M)+: 315.1834 
 Found:   315.1834 
 
IR (thin film, cm-1) 
2978, 2934, 1739, 1511, 1474, 1392, 1369, 1337, 1314, 1238, 1162, 1074, 1040, 975, 
897, 855, 814, 773, 7.29 
 
 
N-phenylsulfonyl-2-(4-tert-butoxyphenyl)indole (2.14f) [Table 2.3, Entry 6]. The general 
procedure was followed using MIDA boronate 2.5f (412 mg, 1.00 mmol). Purification by flash 
chromatography (SiO2 hexanes:EtOAc 100:0 → 80:20 followed by C18 silica gel (H2O:MeCN 
1:1 → 1:9) afforded 2.14f as a colorless solid (376 mg, 93%). 
 
A parallel reaction using freshly-prepared boronic acid 2.4f (301 mg, 1.00 mmol) under 
otherwise identical reaction and purification conditions afforded 2.14f as a colorless solid (59 
mg, 14%). 
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N
SO2Ph
Ot-Bu
2.14f  
TLC (hexanes:EtOAc 10:1) 
Rf = 0.20, visualized by UV (λ = 254 and 366 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 8.32 (d, J = 8.5 Hz, 1H), 7.43 (m, 2H), 7.34 (m, 5H), 7.25 (m, 3H), 7.01 (d, J = 9.0 Hz, 
2H), 6.50 (s, 1H), 1.43 (s, 9H) 
 
13C-NMR (125 MHz, CDCl3) 
δ 156.1, 141.8, 138.2, 137.7, 133.4, 131.1, 130.4, 128.5, 126.7, 126.6, 124.6, 124.2, 
122.6, 120.5, 116.5, 112.9, 78.8, 28.9 
 
HRMS (EI+) 
 Calculated for C24H23O3NS (M)+: 405.13987 
 Found:   405.13919 
 
IR (thin film, cm-1) 
2979, 2971, 1496, 1446, 1367, 1256, 1238, 1217, 1182, 1171, 1163, 1152, 1120, 1087, 
1055, 992, 899, 858, 822, 756, 729, 682, 593, 568, 547 
 
 
1-tert-butoxy-4-vinylbenzene (2.14g) [Table 2.3, Entry 7]. The general procedure was followed 
using MIDA boronate 2.5g (183 mg, 1.00 mmol) with the modification that the reaction was run 
at 100 ºC to afford 2.14g as a pale yellow liquid (172 mg, 98%). 
 
A parallel reaction using freshly-prepared boronic acid 2.4g (72 mg, 1.0 mmol) under otherwise 
identical conditions afforded 2.14g as pale yellow liquid (0.17 g, 79%; yield corrected for 
residual 3a). 
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Ot-Bu
2.14g  
TLC (hexanes:EtOAc 10:1) 
Rf = 0.51, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3)  
δ 7.34 (d, J = 8.5 Hz, 2H), 6.97 (d, J = 8.5 Hz, 2H), 6.70 (dd, J = 18, 11 Hz, 1H), 5.67 (d, 
J = 18 Hz, 1H), 5.19 (d, J = 11 Hz, 1H), 1.37 (s, 9H) 
 
13C-NMR (125 MHz, CDCl3) 
δ 155.2, 136.3, 132.7, 126.7, 124.1, 112.4, 78.5, 28.8 
 
HRMS (CI+) 
 Calculated for C12H16O (M)+: 176.1201  
 Found:   176.1198 
 
IR (thin film, cm-1) 
2978, 2931, 1630, 1603, 1505, 1473, 1390, 1366, 1243, 1161, 1107, 989, 923, 898, 858, 
840 
 
 
1-tert-butoxy-4-cyclopropylbenzene (2.14h) [Table 2.3, Entry 8]. The general procedure was 
followed using MIDA boronate 2.5h (183 mg, 1.00 mmol) with the modification that the 
reaction was run at 100 ºC to afford 2.14h as a pale yellow liquid (183 mg, 96%). 
 
A parallel reaction using freshly-prepared boronic acid 2.4h (86 mg, 1.0 mmol) under otherwise 
identical conditions afforded 2.14h as pale yellow liquid (0.18 g, 95%). 
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Ot-Bu
2.14h  
TLC (hexanes:EtOAc 10:1) 
Rf = 0.51, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3)  
δ 6.98 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.5 Hz, 2H), 1.87 (m, 1H), 1.34 (s, 9H), 0.94 (m, 
2H), 0.67 (m, 2H) 
 
13C-NMR (125 MHz, CDCl3) 
δ 152.9, 138.6, 125.9, 124.1, 78.0, 28.7, 14.8, 8.9 
 
HRMS (CI+) 
 Calculated for C13H18O (M)+: 190.1358  
 Found:   190.1357 
 
IR (thin film, cm-1) 
3082, 2977, 2932, 1609, 1510, 1474, 1460, 1389, 1365, 1239, 1164, 1105, 1046, 1015, 
923, 900, 845, 813 
 
 
Scope of slow-release cross-coupling conditions (Table 2.4). 
 
Pd(OAc)2, SPhos, K3PO4
dioxane:H2O 5:1, 60 °C, 6 h 2.16
MeN
O
OB
O
O
2.15Cl
2.5  
 
General Procedure: 
Under ambient atmosphere, to a 40 mL I-Chem vial equipped with a stir bar was added the aryl 
chloride (1.00 mmol), the MIDA boronate (1.20 mmol), dicyclohexylphosphino-2’,6’-
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dimethoxy-1,1’-biphenyl  (S-Phos) (41 mg, 0.10 mmol) and Pd(OAc)2 (11 mg, 0.050 mmol). 
The vial was sealed with a PTFE-lined septum screw-cap, and then placed under an argon 
atmosphere. To the vial was added dioxane (12.5 mL) and the resulting mixture was stirred at 23 
°C for 10 min. To the vial was added aq K3PO4 (3.0 M, 2.5 mL, degassed by sparging with argon 
for 30 min). The vial was placed in a 60 °C oil bath with stirring for 6 h. The mixture was cooled 
to room temperature, and was then transferred to a 60 mL separatory funnel and diluted with aq 
NaOH (1.0 M, 10 mL). The mixture was extracted with Et2O (3 x 10 mL). The combined organic 
fractions were dried over MgSO4, filtered, and then concentrated in vacuo. The resulting residue 
was adsorbed onto Celite (app. 10 g). The resulting powder was subjected to flash-
chromatography on silica gel (hexanes:EtOAc). 
 
2-(2,4-dimethoxyphenyl)furan (2.16a) [Table 2.4, Entry 1]. The general procedure was 
followed using 1-chloro-2,4-dimethoxybenzene (2.15a) (173 mg, 1.00 mmol), 2-furan MIDA 
boronate (2.5a) (267 mg, 1.20 mmol), S-Phos (41 mg, 0.10 mmol) and Pd(OAc)2 (12 mg, 0.052 
mmol) to afford 2.16a as a pale orange liquid (202 mg, 99%). 
 
O
MeO OMe
2.16a  
TLC (hexanes:EtOAc 9:1) 
Rf = 0.36, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 7.74 (d, J = 8.5 Hz, 1H), 7.41 (d, J = 1.0 Hz, 1H), 6.79 (d, J = 3.5 Hz, 1H), 6.55 (dd, J = 
8.5, 2.5 Hz, 1H), 6.52 (d, J = 2.0 Hz, 1H), 6.46 (q, J = 2.0 Hz, 1H), 3.89 (s, 3H), 3.82 (s, 
3H) 
 
13C-NMR (125 MHz, CDCl3) 
 δ 159.9, 156.5, 150.4, 140.4, 126.8, 113.4, 111.4, 107.8, 104.6, 98.7, 55.4 (2 carbons) 
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HRMS (EI+) 
 Calculated for C12H12O3 (M)+: 204.0787 
 Found:   204.0790 
 
IR (thin film, cm-1) 
 3002, 2960, 2937, 2836, 1614, 1585, 1514, 1468, 1418, 1307, 1288, 1270, 1208, 1160, 
1054, 1029, 1003, 827, 798, 735 
 
 
2-(2,4,6-trimethylphenyl)furan (2.16b) [Table 2.4, Entry 2]. The general procedure was 
followed using mesityl chloride (2.15b) (154 mg, 1.00 mmol), 2-furyl MIDA boronate (2.5a) 
(267 mg, 1.20 mmol), S-Phos (42 mg, 0.10 mmol) and Pd(OAc)2 (11 mg, 0.049 mmol) to afford 
2.16b as a colorless crystalline solid (181 mg, 97%). 
 
O
Me Me
Me
2.16b  
TLC (hexanes) 
Rf = 0.40, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 7.46 (s, 1H), 6.90 (s, 2H), 6.44 (t, J = 3.0 Hz, 1H), 6.23 (d, J = 3.0 Hz, 1H), 2.28 (s, 
3H), 2.15 (s, 6H) 
 
13C-NMR (125 MHz, CDCl3) 
 δ 152.4, 141.4, 138.3, 138.3, 128.2, 128.2, 110.3, 109.0, 21.0, 20.4 
 
HRMS (EI+) 
 Calculated for C13H14O (M)+: 186.1045 
 Found:   186.1043 
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IR (thin film, cm-1) 
 2975, 2954, 2919, 1612, 1505, 1473, 1440, 1373, 1257, 1212, 1169, 1148, 1028, 1005, 
898, 863, 743 
 
 
5-(2-furanyl)-2-methylbenzoxazole (2.16c) [Table 2.4, Entry 3]. The general procedure was 
followed using 5-chloro-2-methylbenzoxazole (2.15c) (168 mg, 1.00 mmol), 2-furyl MIDA 
boronate (2.5a) (266 mg, 1.19 mmol), S-Phos (41 mg, 0.10 mmol) and Pd(OAc)2 (11 mg, 0.049 
mmol) to afford 2.16c as a pale orange crystalline solid (198 mg, 99%). 
 
O N
O
Me
2.16c  
TLC (hexanes:EtOAc 3:1) 
Rf = 0.30, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 7.93 (d, J = 1.0 Hz, 1H), 7.61 (dd, J = 8.5, 1.5 Hz, 1H), 7.47 (d, J = 1.0 Hz, 1H), 7.44 
(d, J = 8.5 Hz, 1H), 6.63 (d, J = 3.5 Hz, 1H), 6.47 (dd, J = 3.5, 2.0 Hz, 1H), 2.62 (s, 3H) 
 
13C-NMR (125 MHz, CDCl3) 
 δ 164.5, 153.7, 150.3, 141.9, 141.9, 127.6, 120.8, 114.6, 111.6, 110.3, 104.6, 14.5 
 
HRMS (EI+) 
 Calculated for C12H9NO2 (M)+: 199.0633 
 Found:   199.0634 
 
IR (KBr, cm-1) 
 2934, 2857, 1576, 1504, 1458, 1383, 1300, 1269, 1228, 1170, 1011, 885, 811 
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3-(2-furanyl)-2,5-dimethylpyrazine (2.16d) [Table 2.4, Entry 4]. The general procedure was 
followed using 3-chloro-2,5-dimethylpyrazine (2.15d) (143 mg, 1.00 mmol), 2-furyl MIDA 
boronate (2.5a) (267 mg, 1.20 mmol), S-Phos (41 mg, 0.10 mmol) and Pd(OAc)2 (11 mg, 0.049 
mmol) to afford 2.16d as a golden liquid (159 mg, 91%). 
 
O
N
NMe
Me
2.16d  
TLC (hexanes:EtOAc 3:1) 
Rf = 0.28, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 8.20 (s, 1H), 7.61 (d, J = 1.0 Hz, 1H), 7.00 (d, J = 3.5 Hz, 1H), 6.54 (dd, J = 3.0, 1.5 
Hz, 1H), 2.74 (s, 3H), 2.54 (s, 3H) 
 
13C-NMR (125 MHz, CDCl3) 
 δ 151.7, 150.2, 146.5, 143.9, 142.5, 141.2, 112.3, 111.7, 23.3, 21.2 
 
HRMS (EI+) 
 Calculated for C10H10N2O (M)+: 174.0793 
 Found:   174.0799 
 
IR (thin film, cm-1) 
 3116, 3038, 2966, 2926, 2858, 2359, 2228, 1553, 1537, 1449, 1446, 1389, 1357, 1289, 
1255, 1220, 1203, 1174, 1149, 1095, 1061, 1012, 973, 928, 886, 867, 821, 735, 596 
 
 
2-(2,4-dimethoxyphenyl)benzofuran (2.16e) [Table 2.4, Entry 5]. The general procedure was 
followed using 1-chloro-2,4-dimethoxybenzene (2.15a) (172 mg, 1.00 mmol), 2-benzofuranyl 
MIDA boronate (2.5b) (328 mg, 1.20 mmol), S-Phos (41 mg, 0.10 mmol) and Pd(OAc)2 (12 mg, 
0.051 mmol) to afford 2.16e as a colorless liquid (239 mg, 94%) 
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OMe
MeO
O
2.16e  
TLC (hexanes:EtOAc 9:1) 
Rf = 0.25, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS) 
δ 7.97 (d, J = 8.5 Hz, 1H), 7.56 (d, J = 7.5 Hz, 1H), 7.48 (d, J = 7.5 Hz, 1H), 7.24-7.17 
(m, 3H), 6.60 (dd, J = 8.5, 2.5 Hz, 1H), 6.55 (d, J = 2.0 Hz, 1H), 3.95 (s, 3H), 3.84 (s, 
3H) 
 
13C-NMR (125 MHz, CDCl3) 
δ 160.8, 157.7, 153.6, 152.4, 130.0, 127.9, 123.5, 122.5, 120.7, 112.7, 110.6, 104.8, 
104.2, 98.7, 55.4, 55.4 
 
HRMS (EI+) 
 Calculated for C16H14O3 (M)+: 254.0943 
 Found:   254.0941 
 
IR (thin film, cm-1) 
  3002, 2960, 2937, 2834, 1611, 1586, 1503, 1452, 1291, 1255, 1211, 1160, 1050, 1032, 
1013 
 
 
5-(2-benzofuranyl)indole (2.16f) [Table 2.4, Entry 6]. The general procedure was followed 
using 5-chloroindole (2.15e) (153 mg, 1.01 mmol), 2-benzofuranyl MIDA boronate (2.5b) (329 
mg, 1.20 mmol), S-Phos (41 mg, 0.10 mmol) and Pd(OAc)2 (12 mg, 0.053 mmol). The 
extraction step was modified to use Et2O (10 mL), then EtOAc (2 x 10 mL). Benzofuran 2.16f 
was isolated as a pale yellow solid (220 mg, 94%). 
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O
NH
2.16f  
TLC (hexanes:EtOAc 3:1) 
Rf = 0.31, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, acetone-d6)  
δ 10.44 (br s, 1H), 8.23 (s, 1H), 7.74 (dd, J = 8.5, 1.5 Hz, 1H), 7.59 (d, J = 7.0 Hz, 1H), 
7.56 (app. d, J = 8.5 Hz, 2H), 7.41 (t, J = 3.0 Hz, 1H), 7.26 (td, J = 7.5, 1.0 Hz, 1H), 7.22 
(td, J = 7.5, 1.0 Hz, 1H), 7.13 (s, 1H), 6.62 (t, J = 2.0 Hz, 1H) 
 
13C-NMR (125 MHz, acetone-d6) 
δ 158.7, 155.4, 137.4, 130.7, 129.2, 126.9, 124.3, 123.6, 122.6, 121.3, 119.7, 118.0, 
112.7, 111.5, 103.1, 100.0 
 
HRMS (EI+) 
 Calculated for C16H11NO (M)+: 233.0841 
 Found:   233.0843 
 
IR (KBr, cm-1) 
 3439, 1582, 1475, 1458, 1444, 1417, 1332, 1295, 1254, 1020, 1006, 890, 877, 807, 753, 
728, 594, 487, 442, 410 
 
 
5-(2-benzofuranyl)-2-pyridinamine (2.16g) [Table 2.4, Entry 7]. The general procedure was 
followed using 2-amino-5-chloropyridine (2.15f) (128 mg, 1.00 mmol), 2-benzofuranyl MIDA 
boronate (2.5b) (359 mg, 1.50 mmol), S-Phos (41 mg, 0.10 mmol) and Pd(OAc)2 (12 mg, 0.052 
mmol). The extraction step was modified to use Et2O (10 mL), then EtOAc (2 x 10 mL). 
Benzofuran 2.16g was isolated as a pale orange solid (180 mg, 85%). 
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NO
NH2
2.16g  
TLC (EtOAc) 
Rf = 0.45, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, acetone-d6)  
δ 8.57 (d, J = 2.0 Hz, 1H), 7.89 (dd, J = 9.0, 2.5 Hz, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.50 
(d, J = 8.5 Hz, 1H), 7.24 (td, J = 7.5, 1.5 Hz, 1H), 7.20 (td, J = 7.5, 1.5 Hz, 1H), 7.03 (d, 
J = 1.0 Hz, 1H), 6.66 (d, J = 8.5 Hz, 1H), 5.85 (br s, 2H) 
 
13C-NMR (125 MHz, acetone-d6) 
 δ 160.8, 155.9, 155.3, 146.1, 134.6, 130.4, 124.4, 123.8, 121.3, 116.6, 111.5, 108.8, 99.4 
 
HRMS (EI+) 
 Calculated for C13H10N2O (M)+: 210.0793 
 Found:   210.0793 
 
IR (KBr, cm-1) 
 3436, 3308, 3114, 3106, 2964, 1650, 1614, 1574, 1500, 1451, 1399, 1352, 1321, 1294, 
1271, 1254, 1207, 1151, 1142, 1040, 1007, 934, 918, 835, 806, 747, 532, 515, 450, 412 
 
 
2-(3-thienyl)benzofuran (2.16h) [Table 2.4, Entry 8]. The general procedure was followed 
using 3-chlorothiophene (2.15g) (119 mg, 1.01 mmol), 2-benzofuranyl MIDA boronate (2.5b) 
(360 mg, 1.50 mmol), S-Phos (41 mg, 0.10 mmol) and Pd(OAc)2 (11 mg, 0.050 mmol) to afford 
2.16h as a colorless solid (171 mg, 85%). 
 
O S
2.16h  
TLC (hexanes:EtOAc 9:1) 
Rf = 0.53, visualized by UV (λ = 254 nm) 
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1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 7.67 (d, J = 1.5 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.40 (d, J = 
4.5 Hz, 1H), 7.32 (dd, J = 4.5, 3.0 Hz, 1H), 7.24 (t, J = 7.5 Hz, 1H), 7.19 (t, J = 7.5 Hz, 
1H), 6.77 (s, 1H) 
 
13C-NMR (125 MHz, CDCl3) 
 δ 154.5, 152.6, 132.2, 129.0, 126.5, 125.0, 124.0, 122.9, 121.4, 120.8, 111.0, 101.0 
 
HRMS (EI+) 
 Calculated for C12H8OS (M)+: 200.0296 
 Found:   200.0295 
 
IR (KBr, cm-1) 
  3100, 1607, 1452, 1280, 1255, 1041, 944, 854, 807, 785, 749, 601, 436 
 
 
2-(2,4-dimethoxyphenyl)thiophene (2.16i) [Table 2.4, Entry 9]. The general procedure was 
followed using 1-chloro-2,4-dimethoxybenzene (2.15a) (173 mg, 1.00 mmol), 2-thiophenyl 
MIDA boronate (2.5c) (285 mg, 1.19 mmol), S-Phos (41 mg, 0.10 mmol) and Pd(OAc)2 (11 mg, 
0.051 mmol) to afford 2.16i as a pale golden liquid (215 mg, 98%). 
 
S
MeO OMe
2.16i  
TLC (hexanes:EtOAc 9:1) 
Rf = 0.27, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 7.53 (d, J = 9.5 Hz, 1H), 7.37 (d, J = 3.5 Hz, 1H), 7.25 (d, J = 5.5 Hz, 1H), 7.05 (t, J = 
4.5 Hz, 1H), 6.53-6.51 (m, 2H), 3.88 (s, 3H), 3.82 (s, 3H) 
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13C-NMR (125 MHz, CDCl3) 
 δ 160.1, 156.7, 139.6, 129.3, 126.7, 124.3, 124.2, 116.5, 105.0, 98.9, 55.5, 55.4 
 
HRMS (EI+) 
 Calculated for C12H12O2S (M)+: 220.0558 
 Found:   220.0563 
 
IR (thin film, cm-1) 
 3102, 3069, 3000, 3959, 3937, 2835, 1610, 1577, 1528, 1464, 1432, 1417, 1354, 1303, 
1273, 1242, 1210, 1160, 1114, 1031, 959, 927, 848, 824, 798, 697, 577 
 
 
2-methyl-5-(2-thienyl)benzoxazole (2.16j) [Table 2.4, Entry 10]. The general procedure was 
followed using 5-chloro-2-methylbenzoxazole (2.15c) (168 mg, 1.00 mmol), 2-thiophenyl MIDA 
boronate (2.5c) (287 mg, 1.20 mmol), S-Phos (41 mg, 0.10 mmol) and Pd(OAc)2 (11 mg, 0.051 
mmol) to afford 2.16j as a crystalline pale yellow solid (213 mg, 99%). 
 
S N
O
Me
2.16j  
TLC (hexanes:EtOAc 3:1) 
Rf = 0.35, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 7.85 (d, J = 1.0 Hz, 1H), 7.50 (dd, J = 8.0, 1.5 Hz, 1H), 7.39 (d, J = 8.5 Hz, 1H), 7.26 
(d, J = 3.0 Hz, 1H), 7.24 (d, J = 5.0 Hz, 1H), 7.04 (dd, J = 5.0, 3.5 Hz, 1H), 2.59 (s, 3H) 
 
13C-NMR (125 MHz, CDCl3) 
 δ 164.4, 150.3, 144.0, 142.1, 130.9, 127.9, 124.6, 123.0, 122.8, 116.6, 110.2, 14.4 
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HRMS (EI+) 
 Calculated for C12H9NOS (M)+: 215.0405 
 Found:   215.0403 
 
IR (KBr, cm-1) 
 3098, 3064, 1622, 1577, 1473, 1428, 1380, 1271, 1160, 1050, 923, 867, 798 
 
 
2-(2-thienyl)quinoxaline (2.16k) [Table 2.4, Entry 11]. The general procedure was followed 
using 1-chloroisoquinoline (2.15h) (165 mg, 1.00 mmol), 2-thiophenyl MIDA boronate (2.5c) 
(287 mg, 1.20 mmol), S-Phos (41 mg, 0.10 mmol) and Pd(OAc)2 (11 mg, 0.050 mmol) to afford 
2.16k as a yellow solid (206 mg, 97%). 
 
S
N
N
2.16k  
TLC (hexanes:EtOAc 3:1) 
Rf = 0.42, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 9.20 (s, 1H), 8.04 (app d, J = 8.0 Hz, 2H), 7.82 (s, 1H), 7.71 (t, J = 7.0 Hz, 1H), 7.66 (t, 
J = 7.0 Hz, 1H), 7.52 (d, J = 4.0 Hz, 1H), 7.17 (s, 1H) 
 
13C-NMR (125 MHz, CDCl3) 
 δ 147.2, 142.1, 142.0, 141.9, 141.2, 130.3, 129.7, 129.1, 129.0, 129.0, 128.3, 126.8 
 
HRMS (EI+) 
 Calculated for C12H8N2S (M)+: 212.0408 
 Found:   212.0407 
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IR (thin film, cm-1) 
  3118, 3093, 1573, 1547, 1491, 1428, 1321, 1238, 1208, 1134, 1054, 998, 941, 926, 852 
 
 
N-(tert-butoxycarbonyl)-2-(2,3-dimethoxyphenyl)pyrrole (2.16l) [Table 2.4, Entry 12]. The 
general procedure was followed using 1-chloro-2,4-dimethoxybenzene (2.15a) (87 mg, 0.51 
mmol), 2-(N-tert-butoxycarbonyl)pyrrole MIDA boronate (2.5e) (196 mg, 0.61 mmol), S-Phos 
(20 mg, 0.048 mmol), Pd(OAc)2 (6 mg, 0.03 mmol), K3PO4 (3.0 M, 1.25 mL) and dioxane (6.0 
mL) to afford 2.16l as a very pale yellow oil (124 mg, 81%). 
 
Boc
N
OMe
OMe
2.16l  
TLC (hexanes:EtOAc 3:1) 
Rf = 0.59, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 7.32 (s, 1H), 7.17 (d, J = 8.0 Hz, 1H), 6.48 (d, J = 8.5 Hz, 1H), 6.45 (s, 1H), 6.22 (t, J = 
3.0 Hz, 1H), 6.10 (s, 1H), 3.82 (s, 3H), 3.72 (s, 3H), 1.36 (s, 9H) 
 
13C-NMR (125 MHz, CDCl3) 
δ 160.7, 158.3, 149.4, 131.1, 130.6, 121.6, 117.0, 113.5, 110.2, 103.4, 98.2, 82.6, 55.3, 
55.2, 27.6 
 
HRMS (EI+) 
 Calculated for C17H21NO4 (M)+: 303.1471 
 Found:   303.1469 
 
IR (thin film, cm-1) 
2976, 2938, 2834, 1736, 1617, 1584, 1512, 1464, 1437, 1419, 1394, 1370, 1341, 1316, 
1209, 1159, 1127, 1034, 974, 840, 726 
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5-(N-tert-butoxycarbonyl-pyrrole)-2-methylbenzoxazole (2.16m) [Table 2.4, Entry 13]. The 
general procedure was followed using 5-chloro-2-methylbenzoxazole (2.15c) (84 mg, 0.50 
mmol), 2-(N-tert-butoxycarbonyl)pyrrole MIDA boronate (2.5e) (195 mg, 0.61 mmol), S-Phos 
(21 mg, 0.050 mmol), Pd(OAc)2 (6 mg, 0.03 mmol), K3PO4 (3.0 M, 1.25 mL) and dioxane (6.0 
mL) to afford 2.16m as a very pale yellow oil (146 mg, 98%). 
 
Boc
N N
O
Me
2.16m  
TLC (hexanes:EtOAc 3:1) 
Rf = 0.42, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 7.63 (s, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.36 (s, 1H), 7.28 (d, J = 8.5 Hz, 1H), 6.23 (t, J = 
3.0 Hz, 1H), 6.20 (s, 1H), 2.64 (s, 3H), 1.34 (s, 9H) 
 
13C-NMR (125 MHz, CDCl3) 
δ 164.2, 150.2, 149.1, 140.9, 134.4, 130.6, 126.1, 122.4, 120.0, 114.7, 110.4, 109.0, 83.5, 
27.5, 14.5 
 
HRMS (EI+) 
 Calculated for C17H18N2O3 (M)+: 298.1318 
 Found:   298.1317 
 
IR (thin film, cm-1) 
2982, 1739, 1584, 1584, 1456, 1395, 1365, 1370, 1336, 1313, 1264, 1166, 1140, 985, 
906, 836, 809 
 
 
N-phenylsulfonyl-2-(2,3-dimethoxyphenyl)indole (2.16n) [Table 2.4, Entry 14]. The general 
procedure was followed using 1-chloro-2,4-dimethoxybenzene (2.15a) (173 mg, 1.00 mmol), 1-
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(phenylsulfonyl)indole-2-MIDA boronate (2.5f) (495 mg, 1.20 mmol), S-Phos (42 mg, 0.10 
mmol) and Pd(OAc)2 (11 mg, 0.049 mmol) to afford 2.16n as an off-white solid (382 mg, 97%). 
 
OMe
MeO
N
SO2Ph
2.16n  
TLC (hexanes:EtOAc 3:1) 
Rf = 0.37, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, acetone-d6)  
δ 8.19 (d, J = 8.0 Hz, 1H), 7.57-7.53 (m, 3H), 7.50 (d, J = 7.5 Hz, 1H), 7.43 (t, J = 7.5 
Hz, 2H), 7.32 (dt, J = 7.0, 1.0 Hz, 1H), 7.23 (t, J = 7.5 Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 
6.62 (d, J = 2.0 Hz, 1H), 6.58 (dd, J = 8.0, 2.0 Hz, 1H), 6.56 (s, 1H), 3.87 (s, 3H), 3.72 (s, 
3H) 
 
13C-NMR (125 MHz, acetone-d6) 
δ 163.0, 160.6, 139.4, 139.3, 138.1, 134.5, 133.2, 131.3, 129.8, 127.4, 125.0, 124.5, 
121.5, 116.1, 115.0, 113.0, 104.7, 98.8, 55.7, 55.7 
 
HRMS (EI+) 
 Calculated for C12H19NO4S (M)+: 393.1035 
 Found:   393.1036 
 
IR (KBr, cm-1) 
 3000, 2978, 2938, 2842, 1617, 1501, 1449, 1445, 1360, 1284, 1239, 1187, 1163, 1121, 
1093, 1069, 1048, 832, 752, 728, 681, 582, 559 
 
 
5-(N-phenylsulfonyl-indole)-2-methylbenzoxazole (2.16o) [Table 2.4, Entry 15]. The general 
procedure was followed using 5-chloro-2-methylbenzoxazole (2.15c) (168 mg, 1.00 mmol), 1-
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(phenylsulfonyl)indole-2-MIDA boronate (2.5f) (495 mg, 1.20 mmol), S-Phos (41 mg, 0.10 
mmol) and Pd(OAc)2 (12 mg, 0.052 mmol) to afford 2.16o as an off-white solid (366 mg, 93%). 
 
N
SO2Ph
N
O Me
2.16o  
TLC (hexanes:EtOAc 1:1) 
Rf = 0.36, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, acetone-d6)  
δ 8.27 (d, J = 8.5 Hz, 1H), 7.78 (d, J = 1.0 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.55 (t, J = 
7.5 Hz, 1H), 7.51 (d, J = 8.0 Hz, 2H), 7.45 (app. d, J = 8.0 Hz, 2H), 7.39 (app. t, J = 8.0 
Hz, 3H), 7.28 (dt, J = 7.0, 1.0 Hz, 1H), 6.75 (s, 1H), 2.65 (s, 3H) 
 
13C-NMR (125 MHz, acetone-d6) 
δ 165.6, 152.3, 142.9, 142.4, 139.3, 138.6, 134.8, 131.7, 129.9, 129.6, 128.2, 127.5, 
125.8, 125.4, 122.0, 121.9, 117.3, 114.9, 110.1, 14.4 
 
HRMS (EI+) 
 Calculated for C22H16N2O3S (M)+: 388.0882 
 Found:   388.0880 
 
IR (thin film, cm-1) 
 3063, 3012, 1712, 1623, 1581, 1477, 1449, 1432, 1365, 1262, 1220, 1177, 1157, 1122, 
1092, 1065, 1021, 999, 921, 823 
 
 
2,4,6-trimethylstyrene (2.16p) [Table 2.4, Entry 16]. The general procedure was followed using 
mesityl chloride (2.15b) (155 mg, 1.01 mmol), vinyl MIDA boronate (2.5g) (220 mg, 1.20 
mmol), S-Phos (41 mg, 0.10 mmol) and Pd(OAc)2 (12 mg, 0.051 mmol). The reaction time and 
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temperature were modified so that the reaction mixture was heated to 100 °C for 2 h. Styrene 
2.16p was isolated as a colorless liquid (150 mg, 91%; yield corrected for residual 2.15b). 
 
MeMe
Me
2.16p  
TLC (hexanes) 
Rf = 0.64, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 6.86 (s, 2H), 6.66 (dd, J = 18.0, 11.5 Hz, 1H), 5.50 (dt, J = 11.5, 2.0 Hz, 1H), 5.23 (dt, J 
= 18.0, 2.0 Hz, 1H), 2.27 (s, 6H), 2.26 (s, 3H) 
 
13C-NMR (125 MHz, CDCl3) 
 δ 136.1, 135.7, 135.0, 134.8, 128.5, 119.0, 20.9, 20.8 
 
HRMS (EI+) 
 Calculated for C11H14 (M)+: 146.1096 
 Found:   146.1098 
 
IR (thin film, cm-1) 
  3080, 2999, 2952, 2918, 2856, 1631, 1612, 1481, 1442, 1376, 994, 919, 850 
 
 
2-vinylquinoxaline (2.16q) [Table 2.4, Entry 17]. The general procedure was followed using 2-
chloroquinoxaline (2.15h) (165 mg, 1.00 mmol), vinyl MIDA boronate (2.5g) (219 mg, 1.20 
mmol), S-Phos (41 mg, 0.10 mmol) and Pd(OAc)2 (11 mg, 0.051 mmol). The reaction time and 
temperature were modified so that the reaction mixture was heated to 100 °C for 2 h. Following 
the aqueous workup, the crude residue was subjected to purification on C18 silica gel (43g 
RediSep column) eluting with H2O:THF (95:5 → 55:45, 24 mL/min over 25 min) to afford 
2.16q as an orange oil (133 mg, 87%). 
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N
N
2.16q  
TLC (hexanes:EtOAc 3:1) 
Rf = 0.31, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 9.00 (s, 1H), 8.08 (app. t, J = 9.0 Hz, 2H), 7.77-7.70 (m, 2H), 7.04 (dd, J = 17.5, 11.0 
Hz, 1H), 6.48 (d, J = 17.5 Hz, 1H), 5.79 (d, J = 11.0 Hz, 1H) 
 
13C-NMR (125 MHz, CDCl3) 
 δ 150.4, 143.5, 142.1, 141.7, 134.8, 130.2, 129.5, 129.3, 129.1, 122.1 
 
HRMS (ESI+) 
 Calculated for C10H9N2 (M+H)+: 157.0766 
 Found:   157.0768 
 
IR (thin film, cm-1) 
 3064.0, 3018, 2928, 2847, 1631, 1596, 1546, 1492, 1466, 1414, 1365, 1342, 1331, 1303, 
1282, 1258, 1212, 1185, 1121, 1065, 1014, 989, 972, 927, 762 
 
 
2-amino-5-vinylpyridine (2.16r) [Table 2.4, Entry 18]. The general procedure was followed 
using 2-amino-5-chloropyridine (2.15f) (129 mg, 1.00 mmol), vinyl MIDA boronate (2.5g) (220 
mg, 1.20 mmol), S-Phos (42 mg, 0.10 mmol) and Pd(OAc)2 (11 mg, 0.050 mmol). The reaction 
time and temperature were modified so that the reaction mixture was heated to 100 °C for 2 h. 
The extraction step was modified to use Et2O (10 mL), then EtOAc (2 x 10 mL). Pyridine 2.16r 
was isolated as a pale orange crystalline solid (91 mg, 76%). 
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N NH2
2.16r  
TLC (EtOAc) 
Rf = 0.48, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 8.05 (s, 1H), 7.56 (dd, J = 8.5, 2.0 Hz, 1H), 6.58 (dd, J = 17.5, 11.0 Hz, 1H), 6.48 (d, J 
= 9.0 Hz, 1H), 5.56 (d, J = 17.5 Hz, 1H), 5.11 (d, J = 11.0 Hz, 1H), 4.60 (br s, 2H) 
 
13C-NMR (125 MHz, CDCl3) 
 δ 157.9, 147.0, 134.4, 133.3, 124.0, 111.2, 108.5 
 
HRMS (EI+) 
 Calculated for C7H8N2 (M)+: 120.0688 
 Found:   120.0688 
 
IR (KBr, cm-1) 
 3448, 3296, 3128, 1631, 1599, 1509, 1388, 1324, 1274, 1144, 1002, 888, 828 
 
 
5-vinyl-2-methylbenzoxazole (2.16s) [Table 2.4, Entry 19]. The general procedure was 
followed using 5-chloro-2-methylbenzoxazole (2.15c) (167 mg, 1.01 mmol), vinyl MIDA 
boronate (2.5g) (218 mg, 1.19 mmol), S-Phos (42 mg, 0.10 mmol) and Pd(OAc)2 (11 mg, 0.050 
mmol). The reaction time and temperature were modified so that the reaction mixture was heated 
to 100 °C for 2 h. Benzoxazole 2.16s was isolated as a pale golden liquid (152 mg, 96%). 
 
N
O
Me
2.16s  
TLC (hexanes:EtOAc 3:1) 
Rf = 0.46, visualized by UV (λ = 254 nm) 
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1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 7.67 (s, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 6.79 (dd, J = 17.5, 11.0 
Hz, 1H), 5.74 (d, J = 17.5 Hz, 1H), 5.24 (d, J = 11.0 Hz, 1H), 2.61 (s, 3H) 
 
13C-NMR (125 MHz, CDCl3) 
 δ 164.3, 150.6, 141.9, 136.5, 134.2, 122.9, 116.8, 113.4, 109.9, 14.5 
 
HRMS (EI+) 
 Calculated for C10H9NO (M)+: 159.0684 
 Found:   159.0685 
 
IR (thin film, cm-1) 
 3087, 3006, 2984, 2928, 1623, 1622, 1578, 1477, 1433, 1381, 1335, 1262, 1179, 1114, 
1040, 989, 918, 881, 840, 815 
 
 
2,4,6-trimethyl-cyclopropylbenzene (2.16t) [Table 2.4, Entry 20]. The general procedure was 
followed using mesityl chloride (2.15b) (155 mg, 1.00 mmol), cyclopropyl MIDA boronate 
(2.5h) (296 mg, 1.50 mmol), S-Phos (42 mg, 0.10 mmol) and Pd(OAc)2 (11 mg, 0.047 mmol). 
The reaction time and temperature were modified so that the reaction mixture was heated to 100 
°C for 24 h. The title compound was isolated as a colorless liquid (127 mg, 79%). 
 
Me
Me
Me
2.16t  
TLC (hexanes) 
Rf = 0.66, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 6.81 (s, 2H), 2.38 (s, 6H), 2.24 (s, 3H), 1.64 (m, 1H), 0.96 (m, 2H), 0.49 (m, 2H) 
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13C-NMR (125 MHz, CDCl3) 
 δ 138.8, 136.0, 135.5, 128.6, 20.8, 20.5, 11.7, 8.0 
 
HRMS (EI+) 
 Calculated for C12H16 (M)+: 160.1252 
 Found:   160.1252 
 
IR (thin film, cm-1) 
 3080, 3003, 2969, 2954, 2918, 2859, 1612, 1485, 1457, 1375, 1223, 1057, 1025, 901, 
850, 814 
 
 
2,4-dimethoxy-cyclopropylbenzene (2.16u) [Table 2.4, Entry 21]. The general procedure was 
followed using 1-chloro-2,4-dimethoxybenzene (2.15a) (173 mg, 1.00 mmol), cyclopropyl 
MIDA boronate (2.5h) (236 mg, 1.20 mmol), S-Phos (41 mg, 0.10 mmol) and Pd(OAc)2 (11 mg, 
0.048 mmol). The reaction temperature was modified so that the reaction mixture was heated to 
100 °C for 6 h. The title compound was isolated as a colorless liquid (175 mg, 97%). 
 
OMeMeO
2.16u  
TLC (hexanes:EtOAc 9:1) 
Rf = 0.65, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 6.77 (d, J = 8.5 Hz, 1H), 6.44 (d, J = 2.5 Hz, 1H), 6.39 (dd, J = 8.5, 2.5 Hz, 1H), 3.83 
(s, 3H), 3.77 (s, 3H), 2.03 (m, 1H), 0.85 (m, 2H), 0.57 (m, 2H) 
 
13C-NMR (125 MHz, CDCl3) 
 δ 159.2, 158.6, 125.7, 124.2, 103.8, 98.4, 55.5, 55.3, 9.0, 6.9 
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HRMS (EI+) 
 Calculated for C11H14O2 (M)+: 178.0994 
 Found:   178.0995 
 
IR (thin film, cm-1) 
 3080, 3000, 2955, 2940, 2835, 1615, 1585, 1510, 1464, 1439, 1416, 1370, 1319, 1290, 
1261, 1209, 1172, 1158, 1117, 1062, 1037, 938, 884, 834, 823, 799 
 
 
Synthesis of 2-pyridyl MIDA boronate (Table 2.5, entry 3). 
 
N Br B(Oi-Pr)3
n-BuLi
THF
N B(Oi -Pr)3
- HO i-Pr
DMSO
HO N OH
O Me O MeN
O
OB
O
ON
Li
2.18 2.19(via distillation)2.17  
 
2-pyridyl MIDA boronate (2.19). In an unoptimized procedure, to a 250 mL Schlenk flask 
equipped with a stir bar was added 2-bromopyridine (6.00 mL, 62.9 mmol), triisopropylborate 
(15.0 mL, 65.2 mmol) and THF (100 mL). The solution was cooled to -78 °C. To the stirred 
solution was added dropwise n-BuLi (25.0 mL, 2.5M in hexanes) at a rate sufficiently slow as to 
avoid the accumulation of a red color in the mixture (app. 20 minutes). The resulting beige 
mixture was stirred for 30 min and then was allowed to warm to room temperature with stirring 
overnight (12 h). The mixture was concentrated in vacuo onto Celite (10 g) to afford a free-
flowing powder. Separately, a 500 mL 3-neck round-bottom flask equipped with a stir bar was 
charged with N-methyliminodiacetic acid (15.77 g, 107.2 mmol) and DMSO (100 mL). To one 
neck of the flask was fitted a solid addition funnel charged with the Celite-adsorbed lithium 
triisopropyl 2-pyridylborate. To a second neck was fitted a short-path distillation apparatus 
connected to vacuum. The third neck of the flask was sealed with a septum. The system was 
placed under vacuum (1 Torr) and the mixture was heated to 75 °C upon which the DMSO began 
to distill. The lithium triisopropyl 2-pyridylborate was added to the distilling mixture portion-
wise over 1 h. The mixture was further distilled to near dryness (1 h). The resulting residue was 
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suspended in acetone, and then concentrated in vacuo onto additional Celite (10 g). The resulting 
powder was lyophilized for 3 days to remove additional DMSO, and then was subjected to flash 
chromatography on silica gel (40 g silica gel cartridge, Et2O:MeCN, 100:0 → 0:100). The 
product thus obtained was suspended in acetone (5 mL) and then diluted with Et2O (100 mL) to 
promote crystallization. The mixture was filtered to isolate 2.19 as an off-white crystalline solid 
(4.024 g, 27%). 
 
MeN
O
OB
O
ON
2.19  
TLC (MeCN) 
 Rf = 0.26, visualized by UV (λ = 254 nm) and KMnO4 stain 
 
1H-NMR (500 MHz, CD3CN)  
 δ 8.67 (ddd, J = 2.5, 1.5, 1.0 Hz, 1H), 7.70 (td, J = 7.5, 1.5 Hz, 1H), 7.62 (dt, J = 7.5, 1.0 
Hz, 1H), 7.28 (ddd, J = 8.5, 1.5 Hz, 1H), 8.67 (ddd, J = 4.5, 1.5, 1.0 Hz, 1H), 4,09 (d, J = 
17 Hz, 2H), 3.98 (d, J = 17 Hz, 2H), 2.55 (s, 3H) 
 
13C-NMR (125 MHz, CD3CN) 
 δ 169.6, 150.8, 135.8, 128.1, 124.3, 62.9, 47.6 
 
11B-NMR (96 MHz, CD3CN) 
 δ 10.3 
 
HRMS (CI+) 
 Calculated for C10H12O4N2B (M+H)+: 235.0890 
 Found:      235.0895 
 
IR (KBr, cm-1) 
3004, 2956, 1774, 1749, 1633, 1590, 1466, 1340, 1289, 1279, 1214, 1152, 1095, 1054, 
1045, 998, 964, 894, 866, 775, 754, 708, 683 
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Cross-coupling reactions of 2-pyridyl MIDA boronate (Table 2.7). 
 
MeN
O
OB
O
ON
2.19
Cu(OAc)2, K2CO3
DMF:IPA 4:1, 100 °C, 4 h
N
2.21
2.20X
Pd2(dba)3, X-Phos
 
 
General Procedure.  Under ambient atmosphere, to a 15 mL vial equipped with a stir bar was 
added the halide (1.0 mmol), 2-pyridyl MIDA boronate (2.19) (1.5 mmol), K2CO3 (5.0 mmol) 
and Cu(OAc)2 (0.50 mmol). In a glove box, to the vial was added a DMF mixture of 2-
dicyclohexylphosphino-2’,4’,6’-triisopropylbiphenyl (X-Phos) (0.06 mmol) and Pd2dba3 (0.015 
mmol) (8.0 mL DMF, pre-mixed and incubated for 5 min at 100 °C, then transferred at ~40 °C to 
avoid incomplete solubility at room temperature.) The reaction mixture was stirred at 100 °C for 
4 h. The mixture was cooled to room temperature and then was transferred to a 60 mL separatory 
funnel and was diluted with aq NaOH (1.0 M, 10 mL). The mixture was extracted with Et2O (3 × 
10 mL). The combined organics were dried over MgSO4, filtered and concentrated in vacuo. The 
crude residue was adsorbed onto Celite and the resulting powder was subjected to flash-
chromatography on silica gel (hexanes:EtOAc). 
 
 
4-(2-pyridinyl)acetophenone (2.21a) [Table 2.8, Entry 1]. The general procedure was followed 
using 4-chloroacetophenone (2.20a) (155 mg, 1.00 mmol), 2-pyridyl MIDA boronate (2.19) (349 
mg, 1.49 mmol), K2CO3 (694 mg, 5.02 mmol) and Cu(OAc)2 (90 mg, 0.50 mmol). Flash 
chromatography on silica gel (hexanes:EtOAc, 100:0 → 80:20) afforded 2.21a as a colorless 
solid (142 mg, 72%). 
N
Me
O
2.21a  
TLC (hexanes:EtOAc 1:1) 
Rf = 0.47, visualized by UV (λ = 254 nm) 
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1H-NMR (500 MHz, CDCl3)  
δ 8.73 (d, J = 5.0 Hz, 1H), 8.10 (d, J = 8.5 Hz, 2H), 8.06 (d, J = 8.5 Hz, 2H), 7.79 (m, 
2H), 7.29 (q, J = 4.5 Hz, 1H), 2.65 (s, 3H) 
 
13C-NMR (125 MHz, CDCl3) 
δ 197.8, 156.0, 149.9, 143.5, 137.1, 136.9, 128.8, 127.0, 122.9, 121.0, 26.7 
 
HRMS (CI+) 
 Calculated for C13H12ON (M+H)+: 198.0919  
 Found:   198.0919 
 
IR (KBr, cm-1) 
3048, 2999, 1679, 1604, 1584, 1574, 1558, 1466, 1434, 1400, 1356, 1315, 1266, 1156, 
1113, 1013, 989, 960, 849, 785, 723, 696, 618, 600, 592 
 
 
4-(2-pyridinyl)benzonitrile (2.21b) [Table 2.8, Entry 2]. The general procedure was followed 
using 4-chlorobenzonitrile (2.20b) (137 mg, 1.00 mmol), 2-pyridyl MIDA boronate (2.19) (352 
mg, 1.50 mmol), K2CO3 (693 mg, 5.01 mmol) and Cu(OAc)2 (91 mg, 0.50 mmol). Flash 
chromatography on silica gel (hexanes:EtOAc, 9:1) afforded 2.21b as a pale yellow solid (109 
mg, 60%). 
N
CN
2.21b  
TLC (hexanes:EtOAc 1:1) 
Rf = 0.59, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3)  
δ 8.73 (d, J = 5.0 Hz, 1H), 8.11 (d, J = 9.0 Hz, 2H), 7.81 (td, J = 7.5, 1.5 Hz, 1H), 7.75 
(m, 3H), 7.31 (ddd, J = 7, 4.5, 1 Hz, 1H) 
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13C-NMR (125 MHz, CDCl3) 
δ 155.2, 150.0, 143.4, 137.1, 132.5, 127.4, 123.3, 121.0, 118.8, 112.5 
 
HRMS (CI+) 
 Calculated for C12H9N2 (M+H)+: 181.0766  
 Found:   181.0765 
 
IR (KBr, cm-1) 
2228, 1588, 1466, 1433, 1393, 1303, 1152, 1152, 990, 852, 776, 738, 718, 620, 563, 518 
 
 
2-(2-pyridinyl)quinoxaline (2.21c) [Table 2.8, Entry 3]. The general procedure was followed 
using 2-chloroquinoxaline (2.20c) (165 mg, 1.00 mmol), 2-pyridyl MIDA boronate (2.19) (353 
mg, 1.51 mmol), K2CO3 (693 mg, 5.01 mmol) and Cu(OAc)2 (91 mg, 0.50 mmol). Flash 
chromatography on silica gel (hexanes:EtOAc, 100:0 → 80:20) afforded 2.21c as a pale orange 
solid (164 mg, 79%). 
N
N
N
2.21c  
TLC (hexanes:EtOAc (1:1) 
Rf = 0.56, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3)  
δ 9.95 (s, 1H), 8.77 (ddd, J = 5.0, 1.5, 1.0 Hz, 1H), 8.58 (d, J = 8.0 Hz, 1H), 8.15 (m, 
2H), 7.88 (td, J = 7.5, 1.5 Hz, 1H), 7.77 (m, 2H), 7.39 (ddd, J = 7.5, 4.5, 1.0 Hz, 1H) 
 
13C-NMR (125 MHz, CDCl3) 
δ 154.5, 150.1, 149.4, 144.1, 142.5, 141.7, 137.1, 130.1, 130.0, 129.7, 129.3, 124.6, 122.0 
 
HRMS (CI+) 
 Calculated for C13H10N3 (M+H)+: 208.0875 
 Found:   208.0871 
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IR (KBr, cm-1) 
3050, 3004, 1591, 1548, 1492, 1479, 1457, 1437, 1403, 1367, 1143, 1131, 1059, 1043, 
996, 961, 806, 785, 772, 742, 716, 670, 556 
 
 
2,5-dimethyl-3-(2-pyridinyl)pyrazine (2.21d) [Table 2.8, Entry 4]. The general procedure was 
followed using 3-chloro-2,5-dimethylpyrazine (2.20d) (142 mg, 1.00 mmol), 2-pyridyl MIDA 
boronate (2.19) (352 mg, 1.50 mmol), K2CO3 (694 mg, 5.02 mmol) and Cu(OAc)2 (90 mg, 0.50 
mmol). The aqueous phase was extracted an additional time with EtOAc (10 mL). Flash 
chromatography on silica gel (hexanes:EtOAc, 100:0 → 55:45) afforded 2.21d as a pale amber 
liquid (96 mg, 52%). 
N
N
NMe
Me
2.21d  
TLC (hexanes:EtOAc 1:1) 
Rf = 0.39, visualized by UV (λ = 254 nm) 
 
1H-NMR (500 MHz, CDCl3 w/ TMS)  
δ 8.72 (d, J = 3.5 Hz, 1H), 8.38 (s, 1H), 7.83 (m, 2H), 7.33 (m, 1H), 2.73 (s, 3H), 2.59 (s, 
3H) 
 
13C-NMR (125 MHz, CDCl3) 
δ 157.2, 150.2, 149.9, 149.4, 148.7, 142.6, 136.6, 124.1, 123.0, 120.1, 22.6, 21.0 
 
HRMS (CI+) 
 Calculated for C11H12N3 (M+H)+: 186.1031 
 Found:   186.1034 
 
IR (thin film, cm-1) 
3055, 2927, 1693, 1589, 1561, 1474, 1452, 1422, 1371, 1292, 1171, 1071, 1048, 995, 
804, 752, 744 
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1-(2-pyridinyl)isoquinoline (2.21e) [Table 2.8, Entry 5]. The general procedure was followed 
using 1-chloroisoquinoline (2.20e) (164 mg, 1.00 mmol), 2-pyridyl MIDA boronate (2.19) (350 
mg, 1.49 mmol), K2CO3 (697 mg, 5.05 mmol) and Cu(OAc)2 (89 mg, 0.49 mmol). The aqueous 
phase was extracted an additional time with EtOAc (10 mL). Flash chromatography on silica gel 
(hexanes:EtOAc, 70:30 → 30:70) afforded 2.21e as an off-white solid (152 mg, 74%). 
 
 
N
N
2.21e  
TLC (EtOAc) 
Rf = 0.47, visualized by UV (λ = 254 and 366 nm) 
 
1H-NMR (500 MHz, CDCl3)  
δ 8.79 (ddd, J = 5.0, 1.5, 1.0 Hz, 1H), 8.63 (d, J = 5.5 Hz, 1H), 8.60 (d, J = 8.5 Hz, 1H), 
7.99 (dt, J = 8.0 Hz, 1.0 Hz, 1H), 7.91 (td, J = 7.5, 2.0 Hz, 1H), 7.87 (d, J = 8.0 Hz, 1H), 
7.70 (d, J = 5.5 Hz, 1H), 7.69 (ddd, J = 8.0, 7.0, 1.5, 1H), 7.59 (ddd, J = 8.5, 7.0, 1 Hz, 
1H), 7.40 (ddd, J = 7.5, 5.0, 1.0 Hz, 1H) 
 
13C-NMR (125 MHz, CDCl3) 
δ 158.2, 157.6, 148.6, 141.8, 137.0, 136.9, 130.0, 127.7, 127.6, 126.8, 126.6, 125.2, 
123.2, 121.2 
 
HRMS (CI+) 
 Calculated for C14H11N2 (M+H)+: 207.0922 
 Found:   207.0926 
IR (KBr, cm-1) 
3051, 3012, 1581, 1562, 1551, 1470, 1455, 1434, 1379, 1350, 1322, 1245, 1129, 1095, 
992, 979, 966, 826, 811, 780, 753, 742, 713, 674, 644, 618, 573, 465, 441 
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Synthesis of 2-pyridyl MIDA boronate derivatives (Table 2.8). 
 
N Br
n-BuLi, B(i-PrO)3
THF, -78 °C
MeN
O
OB
O
ON
2.23
MIDA, DMSO
115 °C
RR
2.22  
 
General procedure for the synthesis of MIDA boronates. To a 50 mL Schlenk flask equipped 
with a stir bar was added halide (8.6 mmol), triisopropyl borate (2.4 mL, 10 mmol), and THF (17 
mL). The resulting stirred solution was cooled to -78 °C. To the cooled solution was added 
dropwise n-butyllithium (2.5 M in hexanes, 8.5 mmol) (ca. 0.25 mL/min). Following the 
addition, the reaction was stirred at -78 °C for 1 h, then warmed to 23 °C with stirring for 3 h. 
Separately, to a 3-neck 100 mL flask equipped with a 50 mL pressure equalizing addition funnel, 
a water-cooled short-path distillation apparatus, a thermometer and a stir bar was added N-
methyiminodiacetic acid (2.151 g, 14.62 mmol) and DMSO (17 mL). The mixture was heated 
with stirring to an internal temperature of 115 °C. The borate mixture contained in the Schlenk 
flask was transferred to the addition funnel, washing with a THF (9 mL). To the hot, stirred 
DMSO solution was added dropwise the borate solution at a rate necessary to maintain the 
internal temperature at 110-120 °C (ca. 1 h). During the addition the THF was rapidly distilled 
(distillate temperature of app. 85 °C). Following the addition, the mixture was cooled to 50 °C 
and the DMSO was removed via distillation (250 mTorr at 50 °C). The resulting residue was 
cooled to 23 °C and then was adsorbed onto Celite from an acetonitrile suspension and placed 
under vacuum for 12 h to further remove residual DMSO. The Celite mixture was then subjected 
to column chromatography on SiO2 to afford the purified product. Product mixtures containing 
undesired MIDA boronate byproducts could be recrystallized to afford the pure product as 
follows: The isolated product was dissolved in hot MeCN (app. 4 mL/mmol product), cooled to 
room temperature, and precipitated by the dropwise addition of CH2Cl2 (app. 16 mL/mmol) to 
the stirred solution, followed by dropwise addition of Et2O (app. 50 mL/mmol). 
 
2-pyridyl MIDA boronate (2.19) [Table 2.9, Entry 1]. The general procedure was followed 
using 2-bromopyridine (0.860 mL, 8.82 mmol), triisopropyl borate (2.4 mL, 10 mmol), n-BuLi 
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(4.15 mL, 2.29 M in hexanes), and N-methyliminodiacetic acid (2.463 g, 16.74 mmol). The 
product was purified via SiO2 chromatography (Et2O:MeCN 95:5 → 0:100) to afford 2.19 as an 
off-white crystalline solid (1.212 g, 59%). Spectral characterization was consistent with literature 
data.93 
 
N B
O
O
MeN
O
O
2.19  
See Table 2.6 for characterization data. 
 
MIDA boronate (2.23a) [Table 2.9, Entry 2]. The general procedure was followed using 2-
bromo-6-methylpyridine (0.98 mL, 8.6 mmol), triisopropyl borate (2.0 mL, 8.7 mmol), n-BuLi 
(3.75 mL, 2.29 M in hexanes), and N-methyliminodiacetic acid (2.311 g, 15.71 mmol). The 
product was purified by SiO2 chromatography (EtOAc:MeCN 100:0 → 45:55) to afford 2.23a as 
an off-white crystalline solid (1.243 g, 58%). 
 
N B
O
O
MeN
O
OMe
2.23a  
TLC (MeCN) 
 Rf = 0.54, visualized by UV (λ = 254 nm) and KMnO4 stain 
 
1H-NMR (400 MHz, CD3CN)  
 δ 7.57 (app t, J = 7.6 Hz, 1H), 7.40 (d, J = 7.2, 1H), 7.14 (d, J = 7.6 Hz, 1H), 4.07 (d, J = 
17 Hz, 2H), 4.00 (d, J = 17 Hz, 2H), 2.55 (s, 3H), 2.48 (s, 3H) 
13C-NMR (100 MHz, DMSO-d6) 
 δ 169.3, 157.6, 135.0, 124.1, 122.5, 61.9, 46.8, 24.5 
 
11B-NMR (128 MHz, DMSO-d6) 
 δ 9.6 
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HRMS (ES+) 
 Calculated for C11H14O4N2B (M+H)+: 249.1047 
 Found:      249.1051 
 
 
MIDA boronate (2.23b) [Table 2.9, Entry 3]. The general procedure was followed using 2-
bromo-5-methylpyridine (1.489 g, 8.655 mmol), triisopropyl borate (2.4 mL, 10 mmol), n-BuLi 
(4.15 mL, 2.29 M in hexanes), and N-methyliminodiacetic acid (2.227 g, 15.14 mmol). The 
product was purified via SiO2 chromatography (Et2O:MeCN 95:5 → 0:100) to afford 2.23b as an 
off-white crystalline solid (1.090 g, 51%). 
B O
O O
O
MeN
N
Me
2.23b  
TLC (MeCN) 
 Rf = 0.43, visualized by UV (λ = 254 nm) and KMnO4 stain 
 
1H-NMR (500 MHz, CD3CN)  
 δ 8.53 (s, 1H), 7.51 (s, 2H), 4.07 (d, J = 17 Hz, 2H), 3.96 (d, J = 17 Hz, 2H), 2.53 (s, 3H), 
2.31 (s,3H) 
 
13C-NMR (100 MHz, DMSO-d6) 
 δ 169.3, 150.2, 135.1, 132.2, 126.6, 61.9, 46.8, 18.0 
 
11B-NMR (128 MHz, DMSO-d6) 
 δ 9.6 
HRMS (ES+) 
 Calculated for C11H14O4N2B (M+H)+: 249.1047 
 Found:      249.1039 
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MIDA boronate (2.23c) [Table 2.9, Entry 4]. The general procedure was followed using 2-
bromo-4-methylpyridine (0.960 mL, 8.62 mmol), triisopropyl borate (2.4 mL, 10 mmol), n-BuLi 
(4.15 mL, 2.29 M in hexanes), and N-methyliminodiacetic acid (2.264 g, 15.39 mmol). The 
product was purified by SiO2 chromatography (Et2O:MeCN 95:5 → 0:100) to afford 2.23c as an 
off-white crystalline solid (897 mg, 42%). 
 
B O
O O
O
MeN
N
Me 2.23c  
TLC (MeCN) 
 Rf = 0.29, visualized by UV (λ = 254 nm) and KMnO4 stain 
 
1H-NMR (500 MHz, CD3CN)  
 δ 8.51 (d, J = 5.0 Hz, 1H), 7.47 (s, 1H), 7.11 (d, J = 5.0 Hz, 1H), 4.08 (d, J = 17 Hz, 2H), 
3.97 (d, J = 17 Hz, 2H), 2.54 (s, 3H), 2.33 (s,3H) 
 
13C-NMR (125 MHz, DMSO-d6) 
 δ 169.3, 149.5, 145.2, 128.0, 123.9, 62.0, 46.8, 20.6 
 
11B-NMR (128 MHz, DMSO-d6) 
 δ 9.8 
 
HRMS (ES+) 
 Calculated for C11H14O4N2B (M+H)+: 249.1047 
 Found:      249.1052 
MIDA boronate (2.23d) [Table 2.9, Entry 5]. The general procedure was followed using 2-
bromo-6-methoxypyridine (1.05 mL, 8.55 mmol), triisopropyl borate (2.0 mL, 8.7 mmol), n-
BuLi (6.3 mL, 1.37 M in hexanes), and N-methyliminodiacetic acid (2.437 g, 16.56 mmol). The 
product was purified via SiO2 chromatography (EtOAc:MeCN 100:0 → 60:40). The isolated 
product was dissolved in hot MeCN (20 mL), cooled to room temperature, and precipitated by 
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the dropwise addition of Et2O (200 mL) to the stirred solution. The crystals were collected to 
afford 2.23d as an off-white crystalline solid (1.830 g, 81%). 
 
B O
O O
O
MeN
N
Me 2.23d  
TLC (EtOAc) 
 Rf = 0.34, visualized by UV (λ = 254 nm) and KMnO4 stain 
 
1H-NMR (500 MHz, CD3CN)  
 δ 7.60 (dd, J = 7.5, 7 Hz, 1H), 7.22 (d, J = 7.0 Hz, 1H), 6.70 (d, J = 8 Hz, 1H), 4.09 (d, J 
= 17 Hz, 2H), 3.99 (d, J = 16.5 Hz, 2H), 3.83 (s, 3H), 2.60 (s, 3H) 
 
13C-NMR (100 MHz, DMSO-d6) 
 δ 169.2, 163.1, 138.0, 120.4, 110.4, 61.8, 52.6, 46.5 
 
11B-NMR (128 MHz, DMSO-d6) 
 δ 9.3 
 
HRMS (ES+) 
 Calculated for C11H14O5N2B (M+H)+: 265.0996 
 Found:      265.0989 
 
 
 
MIDA boronate (2.23e) [Table 2.9, Entry 6]. The general procedure was followed using 2-
bromo-6-trifluoromethylpyridine (1.951g, 8.633 mmol), triisopropyl borate (2.4 mL, 10 mmol), 
n-BuLi (4.15 mL, 2.29 M in hexanes), and N-methyliminodiacetic acid (2.293 g, 15.58 mmol). 
The product was purified via SiO2 chromatography (hexanes:EtOAc 100:0 → 0:100) to afford 
2.23e as a tan crystalline solid (2.328 g, 89%). 
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N B
O
O
MeN
O
OF3C
2.23e  
TLC (EtOAc) 
 Rf = 0.57, visualized by UV (λ = 254 nm) and KMnO4 stain 
 
1H-NMR (400 MHz, CD3CN)  
 δ 7.95 (app t, J = 7.6 Hz, 1H), 7.88 (d, J = 7.2 Hz, 1H), 7.72 (dd, J = 7.6, 0.8 Hz, 1H), 
4.13 (d, J = 17 Hz, 2H), 3.98 (d, J = 17 Hz, 2H), 2.57 (s, 3H) 
 
13C-NMR (125 MHz, DMSO-d6) 
 δ 169.1, 146.7 (q, J = 33 Hz), 137.1, 130.4, 121.8 (q, J = 270 Hz), 120.0 (d, J = 2.8 Hz), 
62.1, 47.1 
 
11B-NMR (128 MHz, DMSO-d6) 
 δ 9.5 
 
HRMS (ES+) 
 Calculated for C11H11O4N2BF3 (M+H)+: 303.0764 
 Found:      303.0753 
 
MIDA boronate (2.23f) [Table 2.9, Entry 7]. The general procedure was followed using 2-
bromo-5-trifluoromethylpyridine (1.936 g, 8.567 mmol), triisopropyl borate (2.0 mL, 8.7 mmol), 
n-BuLi (3.35 mL, 2.56 M in hexanes), and N-methyliminodiacetic acid (2.222 g, 15.10 mmol). 
The product was purified via SiO2 chromatography (EtOAc:MeCN 100:0 → 90:10). The isolated 
product was dissolved in hot MeCN (8 mL), cooled to room temperature, and precipitated by the 
dropwise addition of Et2O (80 mL) to the stirred solution. The crystals were collected to afford 
2.23f as an off-white crystalline solid (1.448 g, 56%). 
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B O
O O
O
MeN
N
F3C
2.23f  
TLC (EtOAc) 
 Rf = 0.43, visualized by UV (λ = 254 nm) and KMnO4 stain 
 
1H-NMR (500 MHz, CD3CN)  
 δ 8.99 (s, 1H), 8.00 (dd, J = 8.0, 1.5Hz, 1H), 7.82 (d, J = 8.0 Hz, 1H), 4.13 (d, J = 17 Hz, 
2H), 4.00 (d, J = 17 Hz, 2H), 2.56 (s, 3H) 
 
13C-NMR (125 MHz, DMSO-d6) 
 δ 169.2, 145.9, 132.1, 127.2, 124.3 (q, J = 32 Hz), 123.9 (q, J = 270 Hz), 62.1, 47.0 
 
11B-NMR (128 MHz, DMSO-d6) 
 δ 8.3 
 
HRMS (ES+) 
 Calculated for C11H11O4N2BF3 (M+H)+: 303.0764 
 Found:      303.0755 
 
 
MIDA boronate (2.23g) [Table 2.9, Entry 8]. The general procedure was followed using 2-
bromo-4-trifluoromethylpyridine (1.05 mL, 8.49 mmol), triisopropyl borate (2.0 mL, 8.7 mmol), 
n-BuLi (6.3 mL, 1.37 M in hexanes), and N-methyliminodiacetic acid (2.418g, 16.43 mmol). 
[Note: The triisopropylborate mixture was transferred to the addition funnel using DMSO (43 
mL) rather than THF.] The product was purified via SiO2 chromatography (Et2O:MeCN 95:5 → 
75:25 → 50:50). The isolated product was dissolved in hot MeCN (5 mL), cooled to room 
temperature, and precipitated by the dropwise addition of Et2O (50 mL) to the stirred solution. 
The precipitation procedure was repeated to afford 2.23g as an off-white crystalline solid (1.350 
g, 53%). 
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B O
O O
O
MeN
N
CF3 2.23g  
TLC (EtOAc) 
 Rf = 0.17, visualized by UV (λ = 254 nm) and KMnO4 stain 
 
1H-NMR (500 MHz, CD3CN)  
 δ 8.92 (d, J = 5.0 Hz, 1H), 7.86 (s, 1H), 7.57 (d, J = 5.0 Hz, 1H), 4.13 (d, J = 17 Hz, 2H), 
4.00 (d, J = 17 Hz, 2H), 2.56 (s, 3H) 
 
13C-NMR (125 MHz, DMSO-d6) 
 δ 169.2, 151.2, 135.3 (q, J = 33 Hz), 123.3 (q, J = 270 Hz), 121.8, 118.5, 62.2, 47.1 
 
11B-NMR (128 MHz, DMSO-d6) 
 δ 9.5 
 
HRMS (ES+) 
 Calculated for C11H11O4N2BF3 (M+H)+: 303.0764 
 Found:      303.0750 
 
 
MIDA boronate (2.23h) [Table 2.9, Entry 9]. The general procedure was followed using 2,6-
dibromopyridine (2.036g, 8.594 mmol), triisopropyl borate (2.0 mL, 8.7 mmol), n-BuLi (3.4 mL, 
2.54 M in hexanes), and N-methyliminodiacetic acid (2.2049 g, 14.99 mmol). The product was 
purified via SiO2 chromatography (hexanes:EtOAc 25:75 → 0:100). The isolated product was 
dissolved in hot MeCN (3.5 mL), cooled to room temperature, and precipitated by the dropwise 
addition of CH2Cl2 (15 mL) to the stirred solution, followed by dropwise addition of Et2O (40 
mL). The crystals were collected to afford 2.23h as a white crystalline solid (1.269 g, 47%). 
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N B
O
O
MeN
O
OBr
2.23h  
TLC (EtOAc) 
 Rf = 0.46, visualized by UV (λ = 254 nm) and KMnO4 stain 
 
1H-NMR (400 MHz, CD3CN)  
 δ 7.61 (m, 2H), 7.49 (m, 1H), 4.10 (d, J = 17 Hz, 2H), 3.96 (d, J = 17 Hz, 2H), 2.58 (s, 
3H) 
 
13C-NMR (100 MHz, DMSO-d6) 
 δ 169.1, 142.2, 138.5, 127.6, 126.9, 62.0, 47.2 
 
11B-NMR (128 MHz, DMSO-d6 ) 
 δ 9.3 
 
HRMS (ES+) 
 Calculated for C10H11O4N2BBr (M+H)+: 312.9995 
 Found:      312.9996 
 
 
MIDA boronate (2.23i) [Table 2.9, Entry 10]. The general procedure was followed using 2,5-
dibromopyridine (2.042 g, 8.620 mmol), triisopropyl borate (2.0 mL, 8.7 mmol), n-BuLi (3.35 
mL, 2.58 M in hexanes), and N-methyliminodiacetic acid (2.260 g, 15.36 mmol). The product 
was purified via SiO2 chromatography (Et2O:MeCN 95:5 → 50:50). The isolated product was 
dissolved in hot MeCN (3.5 mL), cooled to room temperature, and precipitated by the dropwise 
addition of CH2Cl2 (15 mL) to the stirred solution, followed by the dropwise addition of Et2O 
(40 mL). The crystals were collected to afford 2.23i as a white crystalline solid (1.856 g, 69%). 
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N B
O
O
MeN
O
O
Br
2.23i  
TLC (EtOAc) 
 Rf = 0.24, visualized by UV (λ = 254 nm) and KMnO4 stain 
 
1H-NMR (500 MHz, CD3CN)  
 δ 8.42 (d, J = 1.5 Hz, 1H), 7.73 (dd, J = 8 Hz, 1.5  Hz, 1H), 7.54 (d, J = 8 Hz, 1H), 4.09 
(d, J = 17 Hz, 2H), 3.96 (d, J = 17 Hz, 2H), 2.56 (s, 3H) 
 
13C-NMR (125 MHz, DMSO-d6) 
 δ 169.1, 154.3, 143.8, 142.8, 127.4, 62.0, 47.8 
 
11B-NMR (128 MHz, DMSO-d6) 
 δ 11.0 
 
HRMS (ES+) 
 Calculated for C10H11O4N2BBr (M+H)+: 312.9995 
 Found:      312.9998 
 
 
Synthesis of 5-thiazolyl and 2-pyrazinyl MIDA boronate (Scheme 2.5). 
 
5-thiazolyl MIDA boronate (2.25). The general procedure was followed using 5-bromothiazole (0.270 
mL, 3.02 mmol), triisopropyl borate (0.670 mL, 2.91 mmol), n-BuLi (1.2 mL, 2.58 M in hexanes), and N-
methyliminodiacetic acid (775 mg, 5.27 mmol). The product was purified via SiO2 chromatography 
(Et2O:MecN 95:5 → 0:100). The isolated product was dissolved in hot MeCN (5 mL), cooled to room 
temperature, and precipitated by the dropwise addition of CH2Cl2 (20 mL) to the stirred solution, followed 
by dropwise addition of Et2O (60 mL). The crystals were collected to afford 2.25 as a tan crystalline solid 
(213 mg, 30%). 
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MeN
O
OB
O
O
N
S
2.25  
TLC (MeCN) 
 Rf = 0.67, visualized by UV (λ = 254 nm) and KMnO4 stain 
 
1H-NMR (500 MHz, CD3CN)  
 δ 9.03 (s, 1H), 7.98 (s, 1H), 4.10 (d, J = 18 Hz, 2H), 3.93 (d, J = 18 Hz, 2H), 2.63 (s, 3H) 
 
13C-NMR (125 MHz, CD3CN) 
 δ 168.8, 158.1, 150.0, 62.6, 48.5 
 
11B-NMR (128 MHz, DMSO-d6) 
 δ 10.7 
 
HRMS (ES+) 
 Calculated for C8H10O4N2BS (M+H)+: 241.0454 
 Found:     241.0452 
 
2-pyrazinyl MIDA boronate (2.27). The general procedure was followed using 2-bromopyrazine (0.275 
mL, 2.96 mmol), triisopropyl borate (0.690 mL, 3.00 mmol), n-BuLi (1.2 mL, 2.54 M in hexanes), and N-
methyliminodiacetic acid (774 mg, 5.26 mmol). The product was purified via SiO2 chromatography 
(Et2O:MeCN 95:5 → 0:100) to afford 2.27 as an orange crystalline solid (300 mg, 43%). 
 
MeN
O
OB
O
ON
N
2.27  
TLC (MeCN) 
 Rf = 0.56, visualized by UV (λ = 254 nm) and KMnO4 stain 
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1H-NMR (500 MHz, CD3CN)  
 δ 8.77 (d, J = 1.5 Hz, 1H), 8.67 (dd, J = 2.0, 1.5 Hz, 1H), 8.53 (d, J = 2.5 Hz, 1H), 4.13 (d, J = 17 
Hz, 2H), 3.98 (d, J = 17 Hz, 2H), 2.59 (s, 3H) 
 
13C-NMR (125 MHz, DMSO-d6) 
 δ 169.1, 147.6, 145.4, 144.6, 62.0, 47.2 
 
11B-NMR (128 MHz, DMSO-d6) 
 δ 9.6 
 
HRMS (ES+) 
 Calculated for C9H11O4N3B (M+H)+: 236.0843 
 Found:     236.0840 
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CHAPTER 3 	
 
Attempted Glycosylation of AmB via Intramolecular Aglycone Delivery 
 
 
This chapter describes the design and execution of two separate syntheses targeting a 
mycosamine sugar donor which could be used in the glycosylation of BB2 as part of the ICC 
approach to the AmB total synthesis. The second of these syntheses successfully yielded a 
mycosamine donor which was used to investigate the feasibility of a glycosylation approach 
known as intramolecular aglycone delivery (IAD) to attach the mycosamine sugar appendage to 
BB2 with the requisite stereochemistry. Ultimately, this IAD approach did not yield a practical 
solution to this important problem. Ian Dailey prepared compounds 3.5, 3.51a, 3.51b, and 
contributed the results presented in Scheme 3.8. Justin Struble prepared compound 3.42 and 
contributed to the development of the mycosamine synthesis detailed in Schemes 3.5–3.6. 
 
3-1 BACKGROUND 
In the context of our goal of obtaining single-deletion derivatives of AmB, the synthesis 
and attachment of the mycosamine sugar is of particular significance. The mycosamine sugar has 
been shown to be critical AmB’s ability to bind ergosterol and its activity against yeast cells.1 To 
further probe the specific mechanistic role of the sugar, three of the derivatives targeted by our 
laboratory involve its modification. This demands flexibility in any proposed mycosamine sugar 
synthesis. In addition, a “wild type” sugar donor is also necessary to complete each of the 
remaining derivatives lacking a hydroxyl group on the macrolactone ring. Despite its importance, 
attempts to date at installing mycosamine donors onto polyene macrolides have not produced 
satisfactory results, in large part due to the fact that the mycosamine is bound to AmB 
macrolactone by a 1,2-cis linkage, which is notoriously difficult to form.2-3 This difficulty in 
glycosylation arises primarily due to the axial orientation of the alcohol substituent at the C2’ 
position of the mycosamine sugar. This axial substituent shields the β-face of the sugar, leading 
primarily to α-selective glycosylation.  
Various methods have been developed to overcome this inherent challenge, including 
SN2-type displacement of anomeric halides,4-5 use of participating solvents,6 long-range 
substituent participation,7-8 and steric direction.9-11 Unfortunately, these methods still often lead 
to anomeric mixtures of products. More recently, the strategy of “intramolecular aglycone 
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delivery” (IAD) has emerged.12-15 The general strategy is shown in Figure 3.1, in which the 
nucleophile is tethered to the sugar donor, and upon activation at the anomeric position 
nucleophilic attack proceeds in an intramolecular, stereospecific manner, with the stereochemical 
outcome determined by the configuration at C2. IAD reactions generally proceed with complete 
stereocontrol, and currently represent the state of the art in the formation of 1,2-cis glycosidic 
linkages, though limitation still remain with respect to the generality of activating conditions and 
formation of undesired byproducts.16 
 
OPO
PO
OH
L
PO
ROH
tethering
OPO
PO
O
L
PO X OR OPO
PO
OHPO
OR
stereospecific
intramolecular
glycosidation
P = protecting group 1,2-cis glycoside
2
 
Figure 3.1. Intramolecular aglycone delivery (IAD) enables direct formation of 1,2-cis glycosides. After tethering of 
the nucleophile to a neighboring hydroxyl via a linker, X, subsequent delivery of the nucleophile upon activation of 
the leaving group proceeds stereospecifically from the tethered face of the sugar.  
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Figure 3.2.  Neighboring group participation (also known as anchimeric assistance) provides excellent stereocontrol 
for the formation of 1,2-trans glycosides. In this strategy, a participating protecting group, such as the acetate 
shown, coordinates to the anomeric carbon following activation, thus blocking top face of the sugar from 
nucleophilic attack. Note that alternative attack directly onto the acetoxonium ion produces an undesired ortho ester 
byproduct. 
 
In his classic 1988 synthesis of AmB, Nicolaou and coworkers addressed the problem of 
the 1,2-cis glycosidic bond in AmB by instead initially glycosylating their AmB aglycone with a 
C2’-epimycosamine donor (3.2), using neighboring group participation.17 As seen in Figure 3.2 
in this approach activation of the anomeric tricholoroacetimidate leads to a cyclic oxonium ion, 
in which the C2-acetate group effectively blocks one face of the sugar, leading to very selective 
formation of the 1,2-trans glycosidic bond.6,16 Subsequent inversion of the C2 substituent 
provides the desired 1,2-cis configuration. Unfortunately, despite the excellent stereoselectivity 
obtained, this approach suffered from a low overall yield due to poor conversion in the 
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glycosylation reaction, as well as a significant amount of ortho ester byproduct (Scheme 3.1).17 
In a later synthesis of C35deOAmB methyl ester, Carreira and coworkers refined this approach 
to somewhat improve the overall yield, but were unable to solve the problem of competing ortho 
ester formation, which in this case proved inseparable from the successfully glycosylated 
product.18 Underscoring the difficulty inherent to this glycosylation, Rychnovsky and coworkers 
struggled to attach the sugar to the rimocidin agylcone.19 Attempting to utilize the Stork variant 
of the IAD approach, they concluded that the rimocidin aglycone was too poor of a nucleophile 
to form the desired glycosidic bond with this approach. 
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Scheme 3.1. Nicolaou’s glycosylation strategy. The low yield in the glycosylation step was due to both poor 
conversion of 3.1 and formation of an undesired ortho ester byproduct. 
 
With this precedent in mind we decided to attempt to utilize the more recently developed 
paramethoxybenzyl (PMB) variant of the IAD reaction.20 In this approach, developed by Ito and 
coworkers, the sugar and nucleophile are tethered by a PMB-acetal linker. Yields for the PMB 
IAD variant are generally superior to those for the Hindsgaul and Stork approaches.16 
Additionally, the PMB linker provides a handle to tune the electronics of the system, in that 
placement of additional electron donating groups on the benzyl ring can improve the 
glycosylation yield.21 Further, to maximize the overall efficiency and modularity of the AmB 
synthesis, we decided to incorporate the sugar not onto the AmB aglycone at the conclusion of 
the synthesis, but rather as part of BB2 (Scheme 3.2) prior to assembly of the building blocks via 
ICC (Figure 3.3). We believed this would also serve to address the known problem of poor 
nucleophilicity of the AmB aglycone by allowing us to use the smaller, less electron deficient 3.5 
in our glycosylation reaction. 
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Scheme 3.2. Proposed IAD strategy for glycosylation of BB2. 
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Figure 3.3.  AmB retrosynthesis by ICC. 
 
3-2 1ST GENERATION MYCOSAMINE SYNTHESIS 
Rather than synthesize the necessary glycoside donor for this procedure from a naturally 
occurring sugar, we elected to design a de novo synthesis to maximize its flexibility and the 
ability to access functionally deficient derivatives. Retrosynthetic analysis (Figure 3.4) of the 
target donor 3.6 starts with opening of the ring to aldehyde 3.12. We noted that 3.12 could be 
accessed by periodate cleavage of diol 3.13. This critical complexity-generating transform allows 
most of the stereocenters to be established through the stereoselective installation and opening of 
epoxides, directed by the adjacent hydroxyl groups. This brings us back to the relatively simple 
diene 3.16, which can be accessed via SMC reaction from two relatively simple building blocks 
3.17 and 3.18. This synthetic plan was also anticipated to facilitate access to derivatives lacking 
functional groups targeted for deletion. Specifically, C3’deaminomycosamine could be accessed 
by a hydride mediated opening of epoxide 3.15, while C4’deoxymycosamine could be accessed 
by desilylation and subsequent Barton deoxygenation of 3.6. 
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Figure 3.4. 1st generation mycosamine retrosynthesis. 
 
To investigate the feasibility of the proposed route, an initial racemic synthesis of 3.6 
commenced with the construction of coupling partners ±3.18 and 3.19 (Scheme 3.3). Silylation 
of propargyl alcohol and subsequent hydroboration with catecholborane provided 
catacholboronic ester 3.19 as a viscous oil. Iodination of commercially available 3-butyn-2-ol, 
followed by syn-reduction of the alkyne with potassium azodicarboxylate (PADC) afforded the 
(Z)-vinyl iodide ±3.18 in 84% yield. ±3.18 and 3.19 were then cross-coupled with Pd(PPh3)4 to 
give diene ±3.20, effectively completing the carbon framework of  the sugar.  
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Pd(PPh3)4
K2CO3, 3.19
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B
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Scheme 3.3. (A) Synthesis of building block 3.19 (B) Synthesis of diene ±3.20. 
 
Encouraged by these initially auspicious results, we proceeded forward with the planned 
functionalization 3 As seen in Figure 3.5A, treatment of diene ±3.20 with m-CPBA resulted in a 
diastereo- and regioselective epoxidation, directed by the allylic hydroxyl group, to afford the 
threo epoxyalcohol, which was then inverted by a Parikh-Doering oxidation of the alcohol to the 
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corresponding ketone and a subsequent selective reduction with Zn(BH4)2 to afford the erythro 
epoxy alcohol ±3.21.22-23 In the initial design of the route, the amine on the sugar was to be 
installed and carried through the synthesis as an azide, and in fact the opening of the epoxide 
with NaN3 at 0 °C proceeded smoothly, installing the nitrogen with excellent selectivity at the 
allylic position to give ±3.22. However, upon warming the reaction solution to room 
temperature, the resulting ±3.22 underwent an unanticipated [3,3]-sigmatropic rearrangement to 
afford ±3.23 (Figure 3.5A). Despite the reversibility of this process, the undesired constitutional 
isomer was heavily favored, and the rearrangement was fast at room temperature. To avoid this 
rearrangement the route was modified by instead opening epoxide ±3.21 with ammonia and 
protecting the resulting secondary amine as the Fmoc carbamate, ±3.24 (Figure 3.5B). 
Ketalization of ±3.24 with 2,2-dimethoxypropane and catalytic PPTS, followed by 
desilylation with HF·pyridine yielded the racemic allylic alcohol ±3.25. Subsequent Sharpless 
epoxidation proceeded smoothly giving a 1:1 mixture of diastereomeric products 3.26 and 3.27 
(the diastereomeric mixture being the expected result of performing the catalyst controlled, 
asymmetric epoxidation on a racemic substrate), but the resulting epoxy alcohol appeared 
recalcitrant to opening with PMBOH and Ti(O-i-Pr)4, despite literature precedent suggesting the 
facility of this transformation.24-26 The use of ZnCl2 and various other solvents were similarly 
ineffective, while temperatures above 60 °C resulted in rapid Fmoc deprotection. Additionally, it 
was observed that while Fmoc group was stable at or below 40 °C, at these temperatures 3.26 
and 3.27 rapidly decomposed to a variety of unidentified products, with no desired product 
observed even by mass spectrometry. We hypothesized that the unanticipated addition of an 
adjacent carbamate may have interfered with proper Lewis acid complexation, as in the absence 
of a Lewis acid catalyst, alcohols are known to be ineffective nucleophiles for this 
transformation.27 
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Figure 3.5. (A) Azide opening of epoxide ±3.21 resulted in a [3,3]-sigmatropic rearrangement. (B) Substitution of 
Fmoc for azide enabled isolation of the desired protected amino alcohol ±3.24. Unfortunately, with the amine thus 
protected all attempts at opening epoxides 3.26 and 3.27 were unsuccessful. 
 
3-3 2ND GENERATION MYCOSAMINE SYNTHESIS 
 Our inability to access 3.28 prompted us to consider alternative routes to mycosamine 
donor 3.6. We were inspired by a recent publication by the White group, in which they 
demonstrated a streamlining of Trost and coworkers’ 1987 synthesis of acosamine28 through the 
use of a novel Pd-catalyzed diastereoselective allylic C-H amination reaction (Figure 3.6).29 As 
acosamine differs from mycosamine only in that is lacks oxygenation at C2’, we reasoned that 
we could adapt this new, efficient route to target 3.6. As seen in Figure 3.6B, we reasoned that 
substitution of a Sharpless asymmetric dihydroxylation reaction30 for the known hydroboration 
in the Trost route would afford 3.33, which contains the necessary oxygenation at the carbon that 
ultimately becomes C2’ in mycosamine.  
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Figure 3.6. (A) A new diastereoselective C-H amination reaction allows rapid access to ent-3.30, which has been 
elaborated by Trost and coworkers to the sugar acosamine. (B) Substitution of a dihydroxylation reaction for the 
hydroboration in the Trost route was envisioned to afford a sugar, 3.32, with the desired oxygenation at C2’. 
 
 In the forward direction, synthesis of 3.32 began with commercially available D-ethyl 
lactate (3.34) (Scheme 3.4) Protection of the alcohol as the TBS ether, followed by DIBAL-H 
reduction of the ethyl ester to the aldehyde set up a Brown allylation to afford homoallylic 
alcohol 3.35. Subsequent formation of the N-tosylcarbamate, followed by allylic C-H oxidation 
with the White catalyst provided the key intermediate, oxazolidinone 3.37, in a 9:1 d.r. and 75% 
yield. Column chromatography, followed by recrystallization from Et2O provided 3.37 as a 
diastereomerically pure, colorless, and air-stable solid. This sequence proved not only efficient 
but also quite scalable, enabling the isolation of 170 g of 3.36, and the subsequent White 
oxidation could be run on 25 g scale. The efficient isolation of 3.37 enabled us to test the 
proposed dihydroxylation.  
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PhBQ, 75%
Me CO2Et
OH
1. TBSCl, imidazole, 89%
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3.
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O
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Scheme 3.4. Initial sequence toward the key intermediate, oxazolidinone 3.37, from D-ethyl lactate.  
 
As seen in Figure 3.7, deprotection of 3.37 with sodium naphthalide, as per the Trost 
route, provided oxazolidinone 3.30 in very high yield. However, subsequent dihydroxylation was 
142 
 
essentially unselective, giving products 3.33 and 3.38 with a d.r. of 1:1. We hypothesized that the 
neighboring unprotected nitrogen might be accelerating a background, ligand-free reaction, and 
found that performing the dihydroxylation prior to deprotection of the N-tosylate gave excellent 
selectivity, providing the desired diol 3.39 as a single diastereomer. The use of acetone as a co-
solvent was found to be necessary due to the insolubility of both the chincona alkaloid ligand and 
substrate in mixtures of t-BuOH:H2O. Additionally, despite literature reports of the superiority of 
the pyrazine-based ligands for terminal olefin substrates,31-32 we found that the phthalazine based 
ligand (DHQ)2PHAL gave equally selectivity, while also being much more soluble, and giving 
higher yields with a substantially reduced reaction time. 
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Figure 3.7. Dihydroxylation of 3.30 gave a 1:1 mixture of diastereomeric products 3.33 and 3.38. Alternatively, 
dihydroxylation of 3.37, prior to deprotection of the N-tosylate, gave the desired diol 3.39 as a single diastereomer, 
with a much faster reaction and superior yields observed using the phthalazine-based dihydroxylation catalyst. 
  
 Interestingly, unlike the corresponding reaction with olefin 3.37, attempts to deprotect the 
N-tosylate of diol 3.39 with sodium naphthalide proceeded with extremely variable yields, 
ranging from 19–84%. Alternately as seen in Scheme 3.5, we found that 3.39 could be 
deprotected with magnesium powder in MeOH with much more reproducible results, though 
here the reaction was heavily dependent on the conditions selected. Specifically, sonication was 
found to be essential, and the use of 325-mesh magnesium at 0 °C maximized conversion while 
limiting undesired side products, allowing isolation of the product on 10 g scale in a very 
acceptable 90% yield (Scheme 3.5). Selective protection of the secondary alcohol as a PMB 
ether was effected by first forming PMP ketal 3.40, followed by treatment of 3.40 with DIBAL-
H, which opens the ketal from the less hindered terminal position, giving the desired secondary 
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PMB-protected alcohol (3.41) in 61% yield after chromatography. Oxidation of the remaining 
primary alcohol under Swern conditions, and subsequent reaction with CSA and 
trimethylformate afforded 3.42, with the dimethyl acetal serving as a masked aldehyde. Finally, 
treatment of 3.42 with aqueous sodium hydroxide, which achieved hydrolysis of the 
oxazolidinone with concomitant deprotection of the TBS-ether, followed by protection of the 
resulting secondary amine with imidazolyl azide reagent 3.4333-34 gave the linear intermediate 
3.44, ready for acid-mediated cyclization. 
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Scheme 3.5. 2nd generation synthesis of mycosamine, part 2. 
 
 Treatment of 3.44 with CSA effectively promoted cyclization (Scheme 3.6). However, 
after TBS-protection of the remaining alcohol and installation of the C1’-sulfide via Hanessian’s 
conditions,35 an X-ray crystal structure obtained for 3.46 identified it as the five-membered 
furanose sugar, rather than the desired pyranose. Treatment of 3.44 instead with HCl in methanol 
provided the desired pyranose sugar 3.47, albeit with concomitant loss of the C2’-PMB group. 
After TBS protection of the C2’ and C4’ alcohols, installation of the sulfide at C1’ was in this 
case found to be more efficient through the intermediacy of an acetate, which was then converted 
to phenylsulfide 3.48 in nearly quantitative yield. The C2’ and C4’ positions were then re-
differentiated by desilylation with HF·pyr, followed by a selective monosilylation at C4’ using 1 
equivalent of TBSCl to finally provide mycosamine sugar donor 3.49.  
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Scheme 3.6. 2nd generation synthesis of mycosamine part 3. 
 
3-4 ATTEMPTS AT INTRAMOLECULAR AGLYCONE DELIVERY 
 While isolation of furanose glycosyl donor 3.46 was not useful in the long run for the 
synthesis of BB2 or AmB, it did provide an opportunity to initially investigate the feasibility of 
the IAD strategy while a route to the desired pyranose glycosyl donor was being pursued. To this 
end, 3.46 was exposed to BB2 aglycone 3.5 under a variety of oxidative conditions in an attempt 
to form the corresponding linked benzylidene acetal (Scheme 3.7). However, in no case was 
successful linkage observed due to the facile oxidation of the BB2 acceptor to enone 3.50. 
 
BO
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NMe O
O OTBS
CO2TMSE
OH
BO
OO
O
NMe O
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CO2TMSE
O
DDQ, NBS,
or Ce(NH4)2(NO3)6
+ 3.46
3.5 3.50  
Scheme 3.7. Attempts to link 3.5 and 3.46 for IAD revealed the sensitivity of the dienyl alcohol 3.5 to oxidation.  
 
 With these results in mind, upon successful isolation of pyranose 3.49, which contains a 
free hydroxyl at C2’, we decided to, rather than reinstall the lost PMB group, instead attempt 
linkage with benzylated acceptors 3.51a, reasoning that an allylic benzyl ether might be less 
prone to oxidation than 3.5. Thus, we exposed 3.51a to 3.49 in the presence of DDQ (Scheme 
3.8). Again, none of the desired linked product was detected, though we did observe significant 
loss of the benzyl ether from 3.51a. Similar results were observed with benzylated BB2 acceptor 
3.51b.  
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Scheme 3.8. Attempts to link mycosamine donor 3.49 to benzylated BB2 acceptors 3.51a and 3.51b were 
unsuccessful, with the primary product of the reaction being allylic alcohol 3.5 and enone 3.50. 
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Scheme 3.9. The use of DTBMP to buffer the linkage reaction enabled formation of 3.7 and 3.52. However, these 
acetals were found to be too unstable to isolate, and all attempts at glycosyl transfer on the crude linkage products 
were unsuccessful, only yielding hemiacetal 3.53, suggestive of the poor nucleophilicity of 3.5. 
 
The observation of significant debenzylation of 3.51a and 3.51b suggested that activation of 
the benzyl ether was not the problem, and we hypothesized that the desired benzylidene acetal 
product might be unstable to the acidic byproducts of DDQ oxidation. Thus we investigated 
running these reactions in the presence of an amine base. As seen in Scheme 3.9, exposure of 
mycosamine donor 3.49 to benzylated BB2 donors 3.51a and 3.51b in the presence of DDQ and 
DTBMP, clean conversion to the desired benzylidene acetal was finally observed by mass 
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spectrometry. However, clean isolation of this intermediate was not possible due to its instability 
to chromatography. Further, all attempts to initiate glycosyl transfer by activation of the C1’ 
sulfide following linkage were unsuccessful (Scheme 3.9). Isolation of hemiacetal 3.53 as a 
byproduct of attempted glycosylation reactions suggested that activation of the anomeric position 
was successful, but that transfer of the allylic alcohol was not. Collectively, these results led us 
to finally conclude that the IAD strategy for glycosylation of BB2 aglycone would not be 
possible, due to both the instability of the intermediate benzylidene acetal, and the poor 
nucleophilicity of the BB2 acceptor. Chapter 4 details the development of an alternative 
approach which ultimately enabled successful glycosylation of BB2 and the AmB aglycone. 
 
3-5 EXPERIMENTAL SECTION 
Materials.   
Commercial reagents were purchased from Sigma-Aldrich, Fisher Scientific, Alfa Aesar, 
TCI America Frontier Scientific, Oakwood Products or Combi-Blocks and were used without 
further purification unless otherwise noted. Solvents were purified via passage through packed 
columns as described by Pangborn and coworkers36 (THF, Et2O, MeCN, DCM: dry neutral 
alumina; hexane, benzene, and toluene: dry neutral alumina and Q-5 reactant (copper(II) oxide 
on alumina); DMSO, DMF: activated molecular sieves). All water was deionized prior to use. 
Triethylamine, diisopropylamine, diethylamine, pyridine, and 2,6-lutidine were freshly distilled 
under an atmosphere of nitrogen from CaH2. The following compounds were prepared according 
to procedures reported in the literature: 3.30,28 3.35,29,37-38 3.36,29 3.37,29 3.43,33-34 
 
General Experimental Procedures.   
 Unless otherwise noted, all reactions were performed in flame-dried glassware under 
argon. Organic solutions were concentrated via rotary evaporation under reduced pressure with a 
bath temperature of 35-40 ºC. Reactions were monitored by analytical thin layer chromatography 
(TLC) performed using the indicated solvent on E. Merck silica gel 60 F254 plates (0.25mm). 
Compounds were visualized by: exposure to a UV lamp (λ = 254 or 366 nm), incubation in a 
glass chamber containing iodine, and/or treatment with a solution of KMnO4, an acidic solution 
of p-anisaldehyde or a solution of ceric ammonium molybdate (CAM) followed by brief heating 
with a Varitemp heat gun. MIDA boronates are compatible with standard silica gel 
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chromatography, including standard loading techniques. Column chromatography was performed 
using standard methods39 or with a Teledyne-Isco CombiFlash Rf purification system. Both 
methods were performed using Merck silica gel grade 9385 60 Å (230-400 mesh).  
 
Structural analysis.   
1H-NMR spectra were recorded at 23 °C on a Varian Unity or a Varian Unity Inova 500 
MHz spectrometer. Chemical shifts () are reported in parts per million (ppm) downfield from 
tetramethylsilane and referenced to residual protium in the NMR solvent (CHCl3, = 7.26; 
CD2HCN, = 1.93, center line; acetone-d6 = 2.04, center line). Alternatively, NMR-solvents 
designated as “w/ TMS” were referenced to tetramethylsilane (δ = 0.00 ppm) added as an 
internal standard. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, quint = quintet, sept = septet, m = multiplet, br = broad, app = 
apparent), coupling constant (J) in Hertz (Hz), and integration.  13C NMR spectra were recorded 
at 23 °C on a Varian Unity 500 MHz spectrometer. Chemical shifts () are reported in ppm 
downfield from tetramethylsilane and referenced to carbon resonances in the NMR solvent 
(CDCl3, = 77.0, center line; CD3CN, = 1.30, center line, acetone-d6 = 29.80, center line) or 
to added tetramethylsilane (= 0.00). Carbons bearing boron substituents were not observed 
(quadrupolar relaxation). 11B NMR were recorded using a General Electric GN300WB 
instrument and referenced to an external standard of (BF3·Et2O). High resolution mass spectra 
(HRMS) were acquired by Furong Sun and Dr. Steve Mullen at the University of Illinois School 
of Chemical Sciences Mass Spectrometry Laboratory.  Infrared spectra were collected from a 
thin film on NaCl plates or as KBr pellets on a Perkin-Elmer Spectrum BX FT-IR spectrometer, 
a Mattson Galaxy Series FT-IR 5000 spectrometer or a Mattson Infinity Gold FT-IR 
spectrometer.  Absorption maxima (max) are reported in wavenumbers (cm-1). 
 
Synthesis of compounds. 
OH
Me
OH
Me
I
nBuLi
THF, -78 °C;
I2  
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To a solution of 3-butyn-2-ol (4.11 g, 58.7 mmol) stirring in THF (125 mL) at -78 °C was 
added n-BuLi (1.6 M in hexanes, 76 mL, 122 mmol) dropwise. The solution was stirred at -78 °C 
for 30 min. Iodine (14.835 g, 58.8 mmol), dissolved in 7 mL THF was added dropwise to the 
stirring solution. The reaction solution was allowed to warm to r.t., and the reaction was 
quenched by the addition of 10 mL H2O. The reaction was diluted with an additional 50 mL 
H2O. The aqueous phase was extracted with Et2O (2X) and the combined organic fractions were 
concentrated in vacuo. The resulting brown residue was taken up in Et2O (30 mL) and washed 
with sat’d aq. NaHCO3, aq. NaHSO3 (2x) and brine. The organic phase was then dried over 
Na2SO4, filtered, and concentrated in vacuo. The resulting brown oil purified by column 
chromatography (SiO2, hexanes:EtOAc 3:1 + 1% Et3N) to give a brown oil (9.4 g, 83%) 
contaminated with a small amount of Et3N. 
 
 
TLC (hex:EtOAc 5:1) 
 Rf = 0.24 visualized by p-anisaldehyde 
 
1H-NMR (400 MHz, CDCl3) 
 δ 4.60 (q, J = 6.4 Hz, 1H), 1.41 (d, J = 6.4 Hz, 3H). 
 
 
OH
Me
I
I OH
Me
PADA
AcOH
MeOH
r.t. 3.18  
 
To a solution of alkynyl iodide (8.229 g, 36.5 mmol) in MeOH (80 mL) stirring at r.t. as 
added potassium azodicarboxylate (PADA) (10.638 g, 54.8 mmol). AcOH (6.5 mL) was added 
dropwise via syringe pump over 1 h. The reaction was stirred for an additional 1 h. A second 
addition of PADA (10.636 g, 54.8 mmol) was made under argon flow.  6.0 mL AcOH as then 
added dropwise over 1 h. by syringe pump, and the reaction was allowed to stir for an additional 
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1 h. A third addition of PADA (10.629 g, 54.7 mmol) was made under argon flow, and an 
additional 6.7 mL AcOH was added dropwise over 1 h. The reaction was allowed to stir at room 
temp for a final 2 h. The reaction was diluted with Et2O (100 mL) and 5% aq. HCl (100 mL). 
The aqueous layer as extracted with Et2O (3 x 50 mL). The combined organic fractions were 
washed with brine (2 x 40 mL) and 40% aqueous Me2NH (30 mL) The aqueous layer from the 
amine wash was extracted with ether, and the extract was then back washed with brine. All Et2O 
fractions were dried over Na2SO4, filtered and conc. in vacuo to give a yellow oil. This crude 
material was purified by column chromatography (SiO2, hex:acetone 5:1) to give the purified 
product as a pale yellow liquid (6.04 g, 84%). 
 
I OH
Me
±3.18  
TLC (hex:EtOAc 1:1) 
 Rf = 0.48 visualized by KMnO4 
 
1H-NMR (400 MHz, CDCl3) 
 δ 6.23 (m, 2H), 4.50 (m, 1H), 3.00 (d, J = 3.2 Hz, 1H), 1.24 (d, J = 6.4 Hz, 3H). 
 
 
HO TBDPSO
TBDPSCl
imidazole
DMF
r.t.  
 
To a stirring solution of propargyl alcohol (0.963 g, 17.2 mmol) in DMF (30 mL) was 
added imidazole (1.841 g, 27.0 mmol), followed by tert-butyldiphenylchlorosilane (4.5 mL, 17.3 
mmol). The resulting solution was stirred at r.t. for 17 h. The reaction was diluted with Et2O (200 
mL) and washed with water (75 mL), 5% aq. HCl (75 mL), water (75 mL), and brine (75 mL). 
The organic phase was then concentrated in vacuo. The resulting liquid was purified by passage 
through a plug of silica with hexanes (4.35 g, 86%). 
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TLC (hex:EtOAc 1:1) 
 Rf = 0.78 visualized by KMnO4 
 
1H-NMR (400 MHz, CDCl3) 
 δ 7.78 (m, 4H), 7.46 (m, 6H), 4.37 (d, J = 2.4 Hz, 2H), 2.43 (t, J = 2.4 Hz, 1H), 1.14 (s, 
9H) 
 
 
TBDPSO O
B
O
H
70 °C
TBDPSO B
O
O
3.19  
 
To a dry 10 mL flask equipped with a stir bar was added alkyne (1.516 g, 5.15 mmol) and 
catecholborane (0.66 mL, 6.19 mmol). The resulting mixture was stirred at 70 °C for 8 h. After 
cooling to r.t., the resulting viscous oil was used without further purification. 
 
TBDPSO B
O
O
3.19  
TLC (hex:EtOAc 1:1) 
 Rf = 0.5 (streaks) visualized by KMnO4 
 
1H-NMR (400 MHz, CDCl3) 
 δ 7.72 (m, 4H), 7.43 (m, 6H), 7.26 (m, 2H), 7.11 (m, 2H), 6.36 (dt, J = 18, 2.4 Hz, 1H), 
4.42 (dd, J = 3.6, 2.4 Hz, 2H), 1.14 (s, 9H) 
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I OH
Me
3.18
+
TBDPSO
Me
OH
Pd(PPh3)4
K2CO3
THF:H2O
60 °C, 24h 3.20  
 
Catecholboronic ester 3.19 (1.859 g, 4.5 mmol) was transferred to a 40 mL IChem vial 
with 15 mL THF. Vinyl iodide ±3.18 (0.602 g, 3.0 mmol) was added to the vial by syringe, 
followed by K2CO3 (1.240 g, 9.0 mmol). The vial was thoroughly flushed with argon, sealed 
with a PTFE-lined septum screw cap, and brought into the glovebox. In the glovebox, Pd(PPh3)4 
(0.0695 g, 0.06 mmol) was massed into a 7 mL vial, and quantitatively transferred to the reaction 
vial with 3 mL THF. The reaction vial was sealed, and removed from the glovebox. H2O (15 
mL) was added via syringe. The resulting mixture was maintained with stirring at 60 °C for 24 h. 
After cooling to r.t., the reaction was transferred to a separatory funnel and the aqueous layer 
was removed. The organic layer was washed with brine, and then H2O. The organic fraction was 
then concentrated in vacuo, and purified by column chromatography (SiO2, hexanes:EtOAc 3:1) 
to give ±3.20 as a colorless liquid (0.981 g, 94%).  
 
TBDPSO
Me
OH
±3.20  
TLC (hex:EtOAc 1:1) 
 Rf = 0.58 visualized by KMnO4 
 
1H-NMR (400 MHz, CDCl3) 
 δ 7.70 (m, 4H), 7.42 (m, 6H), 6.61 (m, 1H), 6.02 (t, J = 10.8 Hz, 1H), 5.82 (dt, J = 15, 4.8 
Hz, 1H), 5.44 (m, 1H), 4.79 (quint, J = 6 Hz, 1H), 4.29 (dd, J = 4.8, 1.6 Hz, 1H), 1.29 (d, 
J = 6.4 Hz, 3H), 1.09 (s, 9H) 
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TBDPSO
Me
OH
TBDPSO
Me
OH
O
m-CPBA
NaHCO3
DCM, 0 °C
3.20   
 
To mixture of ±3.20 (0.689 g, 1.88 mmol), and sodium bicarbonate (0.315 g, 3.75 mmol), 
stirring at 0 °C in CH2Cl2 (12 mL) was added solid m-CPBA (0.566 g, 2.46 mmol). The reaction 
was stirred at 0 °C for 1 h. Me2S (70 μL) was added, and the reaction was allowed to stir for an 
additional 5 min. The reaction mixture was diluted with Et2O and sat’d aq. NaHCO3. The 
aqueous phase was extracted once with ether. The combined organic fractions were washed with 
brine, dried over Na2SO4 and concentrated in vacuo. The resulting crude material was purified by 
column chromatography (SiO2, hexanes:EtOAc 2:1 , 0.5% Et3N) to give pure product (0.428 g, 
60%). 
 
TBDPSO
Me
OH
O
(±)  
TLC (hex:EtOAc 1:1) 
 Rf = 0.48 visualized by p-anisaldehyde 
 
1H-NMR (500 MHz, CDCl3) 
 δ 7.66 (m, 4H), 7.41 (m, 6H), 6.03 (dt, J = 16, 4 Hz, 1H), 5.70 (qt, J = 16, 8, 2 Hz, 1H), 
4.24 (m, 2H), 3.66 (m, 1H), 3.57 (dd, J = 7.5, 4.5 Hz, 1H), 3.06 (dd, J = 8, 4.5 Hz, 1H), 
2.16 (d, J = 3 Hz, 1H), 1.24 (d, J = 6.5 Hz, 3H), 1.06 (s, 9H) 
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TBDPSO
Me
OH
O
SO3·pyr
DMSO, DCM
Et3N, 0 °C
TBDPSO
Me
O
O
   
 
A flame dried round bottom flask was charged with DCM (4 mL), DMSO (10 mL), and 
alcohol epoxy alcohol substrate (0.335 g, 0.876 mmol). The solution was cooled, stirring, to 0 
°C. In a separate 10 mL pear flask SO3·pyr was suspended in DCM (2.5 mL). DMSO (5 mL) and 
Et3N (0.52 mL) were added to the pear, flask, and after the suspension had become a clear 
solution, the contents of the pear flask were cannulated dropwise into the reaction flask. The pear 
flask was rinsed with DCM (2 mL) and DMSO (5 mL), and this rinse was cannulated over as 
well. The reaction stirred at 0 °C for 6 h. The reaction was poured into 50 mL ether:pentane 1:1 
+ 50 mL ½-sat’d NH4Cl. the Aqueous layer was separated and extracted with ether:pentane 1:1 
(3x). The combined organic fractions were washed with ½ sat’d NH4Cl and with brine, and then 
dried over Na2SO4, filtered and concentrated in vacuo to give a pale yellow oil as the crude 
product. This crude material was purified by column chromatography (SiO2,  hexanes:EtOAc 4:1 
+ 0.5% Et3N). The purified material was isolated from the column (0.197 g, 59%). 
 
TBDPSO
Me
O
O
(±)  
TLC (hex:EtOAc 1:1) 
 Rf = 0.64 visualized by p-anisaldehyde 
 
1H-NMR (400 MHz, CDCl3) 
 δ 7.64 (m, 4H), 7.41 (m, 6H), 6.13 (dt, J = 15.2, 4 Hz, 1H), 5.65 (m, 1H), 4.22 (m, 2H), 
3.72 (m, 2H), 2.21 (s, 3H), 1.05 (s, 9H) 
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HRMS (CI+) 
 Calculated for C23H29O3Si (M+H)+: 381.18861 
Found:     381.18891 
 
 
TBDPSO
Me
O
O
TBDPSO
Me
OH
O
Zn(BH4)2
Et2O, 0 °C
3.21  
 
To a solution of the ketone substrate (0.1648 g, 0.433 mmol) stirring in a solution of Et2O 
(10 mL) was added a dilute solution of Zn(BH4)2 dropwise  until conversion was complete by 
TLC. H2O (2 mL) was immediately added, dropwise via syringe, to quench the remaining 
reagent. The solution was allowed to stir for an additional 20 min before being poured into 10 
mL each of Et2O and sat’d NH4Cl. The organic layer was washed with sat’d aqueous NaHCO3 (1 
x 10 mL) and with brine (1 × 10 mL), dried with Na2SO4, filtered and concentrated. the crude 
product was purified by column chromatography (SiO2, gradient, hexanes:EtOAc 
30:1→20:1→10:1→5:1→3:1). The pure erythro product was thusly obtained (0.146 g, 88%). 
 
TBDPSO
Me
OH
O
±3.21  
TLC (hex:EtOAc 2:1) 
 Rf = 0.34 visualized by p-anisaldehyde 
 
1H-NMR (400 MHz, CDCl3) 
 δ 7.68 (m, 4H), 7.41 (m, 6H), 6.04 (dtd, J = 16, 4.5, 1 Hz, 1H), 5.84 (ddt, J = 16, 7.5, 2 
Hz, 1H), 4.27 (m, 2H), 3.74 (m, 1H), 3.53 (ddd, J = 8, 4, 0.5 Hz, 1H), 3.01 (dd, J = 7.5, 4 
Hz, 1H), 1.68 (d, J = 3.5 Hz, 1H), 1.37 (d, J = 6 Hz, 3H), 1.08 (s, 9H) 
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HRMS (ESI+) 
 Calculated for C23H31O3Si (M+H)+: 383.2042 
 Found:     383.2052 
 
 
TBDPSO
Me
OH
3.21
O
NH2 OH
OH
Me
OTBDPS
FmocHN OH
OH
Me
OTBDPS
NH4OH
dioxane
100 °C
Fmoc-OSu
K2CO3
DMF, H2O
r.t. 3.24(±)
 
By syringe, 1.5 mL dioxane and 750 μL NH4OH were added to 85.8 mg ±3.21 in a 7mL 
vial through. Under an argon funnel, the septum cap as exchanged for a Teflon lined screw cap. 
The reaction was maintained, with stirring, at 100 °C for 12 h. After cooling to r.t., the reaction 
was diluted with EtOAc and poured into 15 mL each of EtOAc and brine. The aqueous layer was 
extracted with EtOAc (2x), and the combined organic fractions were dried over MgSO4, filtered, 
and concentrated in vacuo. The resulting crude material was carried forward without further 
purification. 
 
To a 7 mL septum capped vial containing the crude amine and K2CO3 (0.0625 g, 0.45 
mmol) was added 370 μL H2O by syringe, and this solution was stirred at 0 °C. In a separate 
vial, Fmoc-OSu (101.6 mg) was dissolved in 1.0 mL DMF. 750 μL of this stock solution was 
added to the reaction vial, still at 0 °C, by syringe. Reaction was allowed to warm to room temp 
and stir for 5.5 h. The reaction was transferred into 15 mL each of Et2O and 5% aq. HCl. The 
aqueous layer was extracted with Et2O (3x). The combined organic fractions were washed with 
sat’d NaHCO3, sat’d NaCl, dried over MgSO4, filtered, and concentrated in vacuo. The crude 
product was purified by column chromatography (SiO2, gradient, hexanes:EtOAc 5:1→1:1. 
From this column was isolated 47.8 mg of the purified material, a 34% yield over two steps. 
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FmocHN OH
OH
Me
OTBDPS
±3.24  
TLC (hex:EtOAc 1:1) 
 Rf = 0.38 visualized by UV (254 nm) 
 
1H-NMR (400 MHz, CDCl3) 
 δ 7.78 (d, J = 7.5 Hz, 2H), 7.68 (m, 4H), 7.61 (d, J = 7.5 Hz, 2H), 7.4 (m, 10H), 5.72 (m, 
2H), 5.07 (d, J = 9.5 Hz, 1H), 4.58 (m, 2H), 4.47 (m, 1H), 4.24 (m, 3H), 3.51 (s, 1H), 
3.41, (s, 1H), 3.31 (m, 1H), 1.76 (s, 1H), 1.27 (d, J = 6 Hz, 3H), 1.09 (s, 9H) 
 
HRMS (ESI+) 
 Calculated for C38H44NO5Si (M+H)+: 622.2989 
 Found:      622.2979 
 
 
FmocHN Me
OTBDPS
FmocHN OH
OH
Me
OTBDPS
3.24
Me Me
OMeMeO
PPTS
acetone
O
O
Me
Me
  
 
A 7.5 mL vial was charged with ±3.24 (0.0475 g, 0.0764 mmol), 2,2-dimethoxypropane 
(1.15 mL, 9.35 mmol), and acetone (365 μL). A single crystal of PPTS was added, and after 
flushing and sealing the vial under argon flow, the reaction was stirred at r.t. for 12 h. The 
reaction was directly concentrated and azeotroped with DCM (3x). This crude product was 
purified by column chromatography (SiO2, gradient, hexanes:EtOAc 20:1→3:1, single step with 
a copious 20:1 wash). The desired product was isolated (47.0 mg, 94%). 
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FmocHN Me
OTBDPS
(±)
O
O
Me
Me
 
TLC (hex:EtOAc 5:1) 
 Rf = 0.32 visualized by UV (254 nm) and p-anisaldehyde 
 
1H-NMR (400 MHz, CDCl3) 
 δ 7.78 (d, J =7.5 Hz, 2H), 7.68 (d, J = 8 Hz, 4H), 7.62 (d, J = 7 Hz, 2H), 7.40 (m, 10H), 
5.75 (bs, 2H), 5.17 (bs, 1H), 4.30 (m, 9H?), 1.54 (s, 3H), 1.39 (s, 3H), 1.29 (bs, 3H), 1.08 
(s, 9H) 
 
HRMS (ESI+) 
 Calculated for C41H48NO5Si (M+H)+: 662.3302 
 Found:      662.3307 
 
 
FmocHN Me
OTBDPS
FmocHN Me
OH
HF·pyr
THF
0 °C - r.t.
O
O
Me
Me O
O
Me
Me
3.25  
 
To a 7-mL polyethylene vial containing the silyl ether substrate (0.0234 g, 0.0354 mmol) 
was added 50 μL dry THF via syringe. The substrate was stirred at 0 °C. Into a separate identical 
PE vial as added 500 μL THF and 25 μL HF pyridine solution via a plastic syringe. After stirring 
for an additional 5 min. 150 μL of this diluted HF solution was transferred to the substrate vial. 
The reaction was warmed to r.t. and stirred under argon for 3 h. 1 mL sat’d aq. NaHCO3 was 
added via syringe, and the reaction as stirred at r.t. for an additional 3 h. The reaction was poured 
into a mixture of Et2O and sat’d aq. NaHCO3. The aqueous layer was extracted with Et2O (3X). 
The combined organic fractions were washed with brine, dried over MgSO4, filtered, and 
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concentrated in vacuo. The crude product was purified by column chromatography (SiO2, 
gradient hexanes:EtOAc 4:1→1:6). The yield for this reaction was not noted. 
 
FmocHN Me
OH O
O
Me
Me
3.25  
TLC (hex:EtOAc 1:6) 
 Rf = 0.30 visualized by UV (254 nm) 
 
1H-NMR (400 MHz, CDCl3) 
 δ 7.78 (d, J = 7, 2H), 7.61 (d, J = 7, 2H), 7.42 (t, J = 7.5, 2H), 7.33 (t, J = 7.5, 2H), 5.78 
(m, 2H), 5.23 (bs, 1H), 4.30 (m, 9H), 1.55 (s, 3H), 1.38 (s, 3H), 1.31 (bs, 3H) 
 
HRMS (ESI+) 
 Calculated for C25H30NO5 (M+H)+: 424.2124 
 Found:     424.2107 
 
 
Me
TBSO
NTs
O
O
3.37
K2OsO4, (DHQ)2PHAL
K3Fe(CN)6
K2CO3, NaHCO3
t-BuOH:H2O:acetone
0 °C, 24 h
NTsO
OTBS
O
Me
OH
OH
3.39  
 
 To a 7-mL vial equipped with a stir bar was added (DHQ)2PHAL (0.0260 g, 0.03 mmol), 
K2OsO4·2H2O (0.0022 g, 0.0060 mmol), K2CO3 (0.083 g, 0,601 mmol), NaHCO3, (0.050 g, 
0.595 mmol), K3Fe(CN)6 (0.197 g, 0.598 mmol), t-BuOH (0.4 mL) and H2O (0.95 mL). The 
resulting mixture was stirred vigorously at 23 °C for 10 min, then cooled to 0 °C and stirred an 
additional 10 min. 3.37 was added as a solution in t-BuOH (0.3 mL) and acetone (0.1 mL). t-
BuOH (0.25 mL) was used for quantitative transfer. The reaction was thus stirred at 0 °C for 24 
h. The reaction mixture was diluted with EtOAc (10 mL), and sat’d aq. Na2SO3 (5 mL). The 
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aqueous phases were extracted with EtOAc (3x), and the combined organic fractions were dried 
over MgSO4 and concentrated in vacuo. The resulting crude product was purified by column 
chromatography (SiO2, hex:EtOAc 50:50 → 0:100) to afford the title compound as a colorless 
solid (0.0754 g, 87% yield). 
 
NTsO
OTBS
O
Me
OH
OH
3.39  
TLC (hex:EtOAc 1:1) 
 Rf = 0.35, stained with KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
 δ 7.95 (d, J = 8.5 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 4.44 (app t, J = 2.5 Hz, 1H), 4.39 (dd, 
J = 5, 3 Hz, 1H), 4.29 (m, 1H), 3,80 (m, 1H), 3.64 (m, 2H), 3.24 (d, J = 5 Hz, 1H), 2.61 
(dd, J = 7, 5 Hz, 1H), 2.43 (s, 3H), 1.13 (d, J = 6.5 Hz, 3H), 0.85 (s, 9H), 0.048 (s, 3H), -
0.01 (s, 3H) 
 
13C-NMR (125 MHz, CDCl3) 
 δ 152.2, 145.6, 134.9, 129.8, 128.4, 78.3, 71.3, 68.4, 62.7, 59.5, 53.4, 25.7, 21.6, 19.2, 
18.0, -4.71, -4.84 
 
HRMS (ESI+) 
 Calculated for C20H34NO7SSi (M+H)+: 460.1825  
 Found:      460.1820 
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NTsO
OTBS
O
Me
OH
OH
3.39
NHO
OTBS
O
Me
OH
OH
3.33
Mg, MeOH, 0 °C, 1 h
sonication, 90%
 
 
 In a glovebox, to a 500 mL, flame dried round bottom flask was added magnesium 
powder (2.65 g, 109 mmol). The flask was sealed with a rubber septum and removed from the 
glovebox and charged with MeOH (100 mL) and 3.39 (10.8 g, 23.5 mmol) as a solution in 
MeOH (50 mL), and additional MeOH (50 mL) for quantitative transfer.  The resulting mixture 
was immediately sonicated at 0 °C for 30 min. The reaction mixture was diluted with EtOAc 
(400 mL) and sat’d aq. NH4Cl (200 mL). The aqueous phase was separated and extracted with 
EtOAc (3×100 mL). The combined organic fractions were washed with sat’d aq. NaHCO3 (100 
mL), and the resulting aqueous phase was separated and back extracted with EtOAc (2×50 mL). 
The combined organic fractions were dried over Na2SO4, filtered and concentrated in vacuo to 
give a pale yellow oil. The crude residue was purified by flash column chromatography (SiO2, 
EtOAc → EtOAc + 3% i-PrOH) to afford the title compound as a colorless foam (6.44 g, 90%). 
 
NHO
OTBS
O
Me
OH
OH
3.33  
TLC (EtOAc) 
 Rf = 0.18, stained with KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
 δ 7.03 (s, 1H), 4.62 (s, 1H), 4.36 (app t, J = 3.5 Hz, 1H), 3.99 (m, 2H), 3.79 (app t, J = 4 
Hz, 1H), 3.71 (br s, 1H), 3.58 (m, 2H), 1.13 (d, J = 6.5 Hz, 3H), 0.86 (s, 9H), 0.074 (s, 
3H), 0.062 (s, 3H) 
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13C-NMR (125 MHz, CDCl3) 
 δ 160.6, 81.7, 72.8, 68.6, 62.9, 54.6, 25.7, 18.9, 17.9, -4.6, -4.9 
 
HRMS (ESI+) 
 Calculated for C13H28NO5Si (M+H)+: 306.1737 
 Found:      306.1740 
 
 
NHO
OTBS
O
Me
O
O
PMP
MeO
OMe
OMe
NHO
OTBS
O
Me
OH
OH PPTS, DCM
23 °C, 94%
3.33 3.40  
  
To a 1 L round bottom flask containing 3.33 (6.44 g, 21.1 mmol) and a stir bar under 
argon was added DCM (210 mL), p-anisaldehyde dimethylacetal (7.20 mL,7.20 mmol), and 
PPTS (1.061 g, 4.22 mmol). The resulting solution was stirred at 23 °C for 5 h. The reaction 
mixture was then diluted with Et2O (400 mL) and sat’d aq. NaHCO3 (200 mL). The aqueous 
phase was separated and extracted with Et2O (3 ×100 mL). The combined organic fractions were 
dried over MgSO4, filtered and concentrated in vacuo to give a yellow oil, which was purified by 
column chromatography (SiO2, hex:EtOAc 3:1 → 1:1 → 1:2). Mixed fractions were 
concentrated and re-purified under the same conditions. The title compound was thus obtained as 
a mixture of acetals, and as a colorless foam (8.38 g, 94%). 
 
NHO
OTBS
O
Me
O
O
PMP
3.40  
TLC (hex:EtOAc 1:1), stained with KMnO4 
 Major diastereomer: Rf = 0.33 
 Minor diastereomer: Rf = 0.45 
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1H-NMR (500 MHz, CDCl3) 
 Major diastereomer: δ 7.39 (d, J = 8.5 Hz, 2H), 6.91 (d, J = 8.5 Hz, 2H), 5.73 (s, 1H), 
4.22 (m, 2H), 4.13–4.03 (m, 4H), 3.82 (s, 3H), 1.13 (d, J = 6.5 Hz, 3H), 0.88 (s, 9H), 
0.083 (s, 6H) 
 Minor diastereomer: δ 7.35 (d, J = 9 Hz, 2H), 6.90 (d, J = 7.5 Hz, 2H), 5.97 (s, 1H), 4.15 
(m, 1H), 3.99 (m, 1H), 3.89 (m, 1H), 4.13–4.03 (m, 3H), 3.81 (s, 3H), 1.17 (d, J = 6.5 Hz, 
3H), 0.88 (s, 9H), 0.098 (s, 6H) 
 
 
NHO
OTBS
O
Me
O
O
PMP
3.40
NHO
O
Me
OPMBOTBS
OH
3.41
DIBAL-H, DCM
-78 °C, 76%
 
 
 To a 1 L flask containing 3.40 (8.38g, 19.8 mmol) and a stir bar under argon was added 
DCM (100 mL) . The resulting solution was cooled, stirring, to -78 °C. DIBAL-H (1M in DCM, 
100 mL, 100 mmol) was added via cannulation to the reaction mixture over 10 min. The reaction 
mixture was thus stirred for 8 h. Additional DIBAL-H (20 mL, 20 mmol), was added, and the 
reaction mixture was stirred an additional 1 h. The reaction mixture was quenched by the 
dropwise addition of MeOH (10 mL). The reaction mixture was then allowed to warm to room 
temperature, and thus stirred for 1 h, then was diluted with sat’d aq. Na, K-tartrate (200 mL). 
This mixture was vigorously stirred for 3 h. The aqueous phase was isolated and extracted with 
Et2O (3×100 mL). The combined organic fractions were dried over MgSO4, filtered and 
concentrated in vacuo to give a yellow oil. This crude product was purified by column 
chromatography (SiO2, hex:EtOAc, 50:50 → 0:100). Mixed fractions were concentrated and re-
purified under the same conditions. The pure primary alcohol 3.41, was thus afforded (6.42 g, 
76%). 
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NHO
O
Me
OPMBOTBS
OH
3.41  
TLC (hex:EtOAc 1:1) 
 Rf = 0.15, stained with KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
 δ 7.22 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 9 Hz, 2H), 6.35 (s, 1H), 4.60 (d, J = 11.5 Hz, 1H), 
4.46 (d, J = 11 Hz, 1H), 4.18 (t, J = 3.5 Hz, 1H), 3.95 (m, 1H), 3.89 (m, 1H), 3.79 (s, 
3H), 5.91 (m, 1H), 4.47 (m, 1H), 2.63 (m, 1H), 1.08 (d, J = 6 Hz, 3H), 0.86 (s, 9 H), 
0.061 (s, 6 H) 
 
 
NHO
O
Me
OPMBOTBS
OMe
OMe
3.42
Me OMe
OMe
OPMB
OH
OH
NH2
aq NaOH, MeOH
99%
 
 
 To a 25 mL round bottom flask containing 3.42 (0.2451 g, 0.690 mmol) and a stir bar, 
under ambient air, was added MeOH (3.5 mL). The resulting mixture was stirred to 
homogeneity, and then NaOH (2M aqueous solution, 3.5 mL, 7.0 mmol) was added. The flask 
was equipped with a reflux condenser and stirred under air at 70 °C for 18 h. The reaction was 
then diluted with DCM (20 mL) and brine (20 mL). The aqueous phase was separated and 
extracted with DCM (3×15mL). The combined organic fractions were dried over Na2SO4, 
filtered and concentrated in vacuo to give a colorless oil that was carried forward without further 
purification (0.2258 g, 99%). 
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Me OMe
OMe
OPMB
OH
OH
N3
O
S
O
NN3
NH Cl
3.44
3.43Me OMe
OMe
OPMB
OH
OH
NH2 CuSO4, K2CO3
MeOH, 94%
 
 
 To a 20 mL vial containing 3.42 (0.2258 g, 0.76 mmol) and a stir bar was added MeOH 
(4.0 mL), K2CO3 (0.2117 g, 1.53 mmol), CuSO4·5H2O (0.0039 g, 0.016 mmol), and azide 
transfer reagent 3.43 (0.2081 g, 0.99 mmol). The resulting heterogeneous mixture was stirred at 
room temperature for 2 h. The reaction mixture was then diluted with EtOAc (10 mL) and H2O 
(10 mL). the aqueous phase was separated and extracted with EtOAc (3x). The combined organic 
fractions were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated in 
vacuo. The resulting crude product was purified by column chromatography (SiO2, hex:EtOAc 
2:1 → 1:1) to obtain the title compound as a colorless oil (0.1564 g, 64%). 
 
Me OMe
OMe
OPMB
OH
OH
N3
3.44  
TLC (hex:EtOAc 1:1) 
 Rf = 0.30, stained with KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
 δ 7.29 (d, J = 8.5 Hz, 2H), 6.87 (d, J = 8.5 Hz, 2H), 4.76 (d, J = 11 Hz, 1H), 4.63 (d, J = 
10.5 Hz, 1H), 4.44 (d, J = 5.5 Hz, 1H), 3.87 (s, 1H), 3.84 (m, 2H), 3.79 (s, 3H), 3.68 (dd, 
J = 7.5, 1.5 Hz, 1H), 3.51 (s, 3H), 3.45 (s, 3H), 1.26 (d, J = 6.5 Hz, 3H) 
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Me OMe
OMe
OPMB
OH
OH
N3
HCl, MeOH
70 °C, 73%
3.44
OMeO
HO
N3
Me
OH
3.47  
 
 To a 7 mL vial containing 3.44 (0.0348 g, 0.098 mmol) under N2 was added MeOH (1.0 
mL) and HCl (3M in MeOH, 0.033 mL, 0.098 mmol) by syringe. The resulting mixture was 
stirred at 70 °C for 4 h. The reaction mixture was diluted with EtOAc (1 mL) and sat’d aq. 
NaHCO3 (1mL). The aqueous phase was separated and extracted with EtOAc (3x). The 
combined organic fractions were dried over Na2SO4, filtered and concentrated in vacuo. The 
crude reaction product thus obtained was purified by column chromatography (hex:EtOAc 2:1 → 
1:1) to afford the pyranose sugar 3.47 as a mixture of anomers (14.6 mg, 73% yield). 
 
OMeO
HO
N3
Me
OH
3.47  
TLC (hex:EtOAc 1:1), stained with KMnO4 
 Major anomer: Rf = 0.37 
 Minor anomer: Rf = 0.26 
 
1H-NMR (500 MHz, CDCl3) 
 Major anomer: δ 4.64 (d, J = 1.5 Hz, 1H), 3.96 (m, 1H), 3.92 (s, 1H), 3.72–3.59 (m, 2H), 
1.34 (d, J = 6 Hz, 3H)  
  Minor anomer: δ 4.39 (s, 1H), 4.08 (d, J = 2.5 Hz, 1H), 3.94 (m, 1H), 3.27 (dd, J = 9.5, 3 
Hz), 1.39 (d, J = 6 Hz, 3H) 
 
HRMS (EI+) 
 Calculated for C7H13N3O4 (M+Na)+: 226.0800   
 Found:     226.0804 
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OMeO
TBSO
N3
Me
OTBS
OMeO
HO
N3
Me
OH
3.47
TBSCl
imidazole
DMF, 45 °C
81%
 
 To a 2 mL vial containing 3.47 (0.0086g, 0.042 mmol) and a stir bar was added DMF 
(0.42 mL), imidazole (0.0638 g, 0.94 mmol), and TBSCl (0.0637 g, 0.42 mmol). The resulting 
mixture was stirred at 45 °C for 14 h. The reaction was diluted with Et2O (5 mL) and H2O (5 
mL). The aqueous phase was extracted with Et2O (5 mL). The combined organic fraction were 
washed with sat’d aq. NaHCO3 (2 mL) and brine (2 mL), then dried with MgSO4, filtered, 
concentrated and purified by column chromatography (SiO2, hex:EtOAc, 20:1 isocratic) to afford 
the bis-TBS ether as a colorless oil (0.0148 g, 81%). 
 
OMeO
TBSO
N3
Me
OTBS
 
TLC (hex:EtOAc 10:1) 
 Rf = 0.5, stained with Anisaldehyde 
 
1H-NMR (500 MHz, CDCl3) 
 δ 4.47 (d, J = 1.5 Hz, 1H), 3.97 (app t, J = 2 Hz, 1H), 3.58 (m, 1H), 3.50 (dd, J = 9, 2.5 
Hz, 1H), 3.37 (s, 3H), 1.27 (d, J = 5.5 Hz, 3H), 0.93 (s, 18H), -0.20 (s, 3H), -0.16 (s, 3H), 
-0.12 (s, 3H), -0.10 (s, 3H) 
 
 
OAcO
TBSO
N3
Me
OTBS
Ac2O, H2SO4
0 °C - r.t., 84%
OMeO
TBSO
N3
Me
OTBS
 
 
 To a stirring solution of the methyl acetal substrate (0.110 g, 0.25 mmol) in Ac2O (1.2 
mL) at 0 °C was added a solution of H2SO4 in Ac2O (0.020 mL, prepared by addition of 0.175 
mL conc. H2SO4 in 0.50 mL Ac2O). After stirring at 0 °C for 20 min, the reaction mixture was 
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poured into a mixture of sat’d aq. NaHCO3 (50 mL) and Et2O (50 mL). This mixture was 
allowed to stir at room temperature for 1 h. The aqueous phase was separated and extracted with 
Et2O (30 mL). The combined organic phases were washed with sat’d aq. NaHCO3 (25 mL), dried 
over Na2SO4, filtered, and concentrated in vacuo. The resulting crude product was purified by 
column chromatography (SiO2 hex:EtOAc, 25:1 isocratic) to afford the anomeric acetate (0.098 
g, 84% yield). 
 
OAcO
TBSO
N3
Me
OTBS
 
TLC (hex:EtOAc 10:1) 
 Rf = 0.40, stained with CAM 
 
1H-NMR (500 MHz, CDCl3) 
 δ 5.83 (d, J = 2 Hz, 1H), 3.96 (t, J = 2.5 Hz, 1H), 3.68 (m, 1H), 3.63 (m, 1H), 3.48 (dd, J 
= 9.5, 2.5 Hz, 1H), 2.12 (s, 3H), 1.26 (d, J = 6 Hz, 3H), 0.923 (s, 9H), 0.915 (s, 9H), 
0.197 (s, 3H), 0.151 (s, 3H), 0.119 (s, 3H), 0.113 (s, 3H) 
 
 
OPhS
TBSO
N3
Me
OTBS
OAcO
TBSO
N3
Me
OTBS
ZnI2, PhSTMS
DCM, TBAI
45 °C, 99%
3.48  
 In the glovebox, o a 7 mL vial was added ZnI2 (0.201 g, 0.63 mmol), TBAI (0.093 g, 0.25 
mmol), and a stir bar. The vial was sealed with a PTFE-lined septum-cap and removed from the 
box. To the vial was then added the acetate substrate (0.097 g, 0.21 mmol) as a solution in DCM 
(2.1 mL), followed by PhSTMS (0.4 mL, 2.1 mmol). The resulting mixture was stirred at 45 °C 
for 15 min. The reaction mixture was diluted with Et2O (10 mL) and sat’d aq. NaHCO3 (10 mL). 
The aqueous phase was separated and extracted with Et2O (3x). The combined organic fractions 
were dried over MgSO4, filtered and concentrated in vacuo. The resulting crude product was 
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purified by column chromatography (hex:EtOAc 20:1 isocratic) to afford the anomeric sulfide 
3.48 as a mixture of anomers (0.1072 g, 99%). 
 
OPhS
TBSO
N3
Me
OTBS
3.48  
TLC (hex:EtOAc 10:1) 
 Rf = 0.55, stained with KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
 Major anomer: δ 7.49 (m, 2H), 7.32(m, 3H), 5.24 (d, J = 1.5 Hz, 1H), 4.23 (dd, J = 2.5, 2 
Hz, 1H), 4.06 (m, 1H), 3.65 (t, 9 Hz, 1H), 3.50 (dd, J = 9.5, 2.5 Hz, 1H), 1.27 (d, J = 6.5 
Hz, 3H), 0.932 (s, 9H), 0.899 (s, 9H), 0.199 (s, 3H), 0.140 (s, 3H), 0.118 (s, 3H), 0.061 
(s, 3H) 
 
 
OPhS
TBSO
N3
Me
OTBS
OPhS
HO
N3
Me
OH
HF·pyr, 60%
3.48  
 To a 12 mL PTFE vial containing 3.48 (0.158 g, 0.310 mmol) and a stir bar under N2 was 
added THF (3 mL), pyridine (0.19 mL, 2.36 mmol), then HF·pyr (0.19 mL, 3.13 mmol). The vial 
was sealed and the solution was maintained with stirring at 50 °C for 36 h. The reaction was 
quenched by the addition of sat’d aq NaHCO3 (added dropwise until bubbling ceased) and 
allowed to stir at 23 °C for an additional 30 min. The reaction was then diluted with EtOAc (10 
mL) The aqueous phase was extracted with EtOAc (4x), and the combined organic fractions 
were dried over MgSO4, filtered, and concentrated in vacuo. The resulting crude product was 
purified by column chromatography (SiO2, hex:EtOAc 3:1→2:1) to afford the desired diol as a 
mixture of anomers (52.2 mg, 60%). 
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OPhS
HO
N3
Me
OH
 
TLC (hex:EtOAc 2:1), stained with KMnO4 
 Major anomer: Rf = 0.26 
 Minor anomer: Rf = 0.21 
 
1H-NMR (500 MHz, CDCl3) 
 Major anomer: δ 7.50–7.45 (m, 2H), 7.35–7.28 (m, 3H), 5.45 (s, 1H), 4.25 (m, 1H), 4.20 
(m, 1H), 3.73 (t, J = 9.5 Hz, 1H), 3.68 (dd, J = 10, 3 Hz, 1H), 1.34 (d, J = 6.5 Hz, 3H) 
 Minor anomer: δ 7.50–7.45 (m, 2H), 7.35–7.28 (m, 3H), 4.83 (d, J = 1 Hz, 1H), 4.22 (d, J 
= 3.5 Hz, 1H), 3.72 (t, J = 9.5 Hz, 1H), 3.40 (m, 1H), 3.37 (m, 1H) 
 
 
OPhS
HO
N3
Me
OTBS
OPhS
HO
N3
Me
OH
TBSOTf
2,6-lutidene
DCM, 0 °C, 52%
3.49  
 To a 7 mL vial containing the diol substrate (0.0522 g, 0.186 mmol) and a stir bar under 
N2 was added DCM (1.9 mL). The resulting solution was cooled to 0 °C. 2,6-lutidene (0.032 mL, 
0.275 mmol), and then TBSOTf (0.049 mL, 0.213 mmol) was added. The solution stirred at 0 °C 
for 3 h. The reaction was diluted with sat’d aq NaHCO3 (10 mL) and Et2O (10 mL). The aqueous 
phase was extracted with Et2O (3x), and the combined organic fractions were dried over MgSO4, 
filtered and concentrated in vacuo. The resulting crude product was purified by column 
chromatography (SiO2, hex:EtOAc 5:1, isocratic) to yield 3.49 as a colorless oil (38.4 mg, 52%). 
 
OPhS
HO
N3
Me
OTBS
3.49  
TLC (hex:EtOAc 2:1), stained with KMnO4 
 Major anomer: Rf = 0.58 
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1H-NMR (500 MHz, CDCl3) 
 Major anomer: δ 7.47 (d, J = 4.5 Hz, 2H), 7.3–7.28 (m, 3H), 5.43 (d, J = 1 Hz, 1H), 4.28 
(s, 1H), 4.13 (quint, J = 6 Hz, 1H), 3.59 (m, 2H), 1.28 (d, J = 6.5 Hz, 3H), 0.94 (s, 9H), 
0.22 (s, 3H), 0.13 (s, 3H) 
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CHAPTER 4 	
 
Glycosylation of BB2 and Amphotericin B via TDMB-Mediated Anchimeric Assistance 
 
 
The efforts of the previous chapter toward the application of the IAD strategy in forming 
the 1,2-cis glycosidic linkage found in BB2 reinforced our appreciation for the challenge 
inherent to forming this type of glycosidic bond, especially in the context of large, complex 
small molecules. This chapter describes the development of a different approach toward this 
problem, which ultimately yielded a solution in the form of the discovery of a new directing 
group for use in a neighboring group participation glycosylation strategy. Successful 
glycosylation and completion of BB2 are described, as well as application of this methodology 
toward an efficient glycosylation of the full amphotericin aglycone, a long-standing challenge in 
the chemical literature. Ian Dailey prepared 4.13 and contributed the results presented in 
Schemes 4.3, 4.6, and 4.7. Dr. Justin R. Struble prepared compounds 4.12 and 4.31, contributed 
the results presented in Schemes 4.8 and 4.10, and contributed to the development of the 
mycosamine donor synthesis described below. 
 
4-1 BACKGROUND 
 Our lack of success with the IAD methodology forced us to consider alternative strategies 
for glycosylation of BB2. A survey of the literature brought our attention back to the use of the 
neighboring group participation strategy developed by Nicolaou and later adapted by Carreira.1-3 
We noted that this strategy gave excellent stereoselectivity and had been shown to be compatible 
with large, poor nucleophiles like the AmB aglycone. Further, the necessary inversion of the 
C2’-hydroxyl has been shown to proceed in high yield.1-2 The major problems were low 
conversion and competing ortho ester formation in the glycosyl transfer step. We therefore 
reasoned if these two problems could be addressed, the neighboring group participation strategy 
might provide an efficient route to the glycosylation of BB2 and the AmB aglycone. 
 
4-2 SYNTHESIS OF A NEW MYCOSAMINE DONOR 
 The decision to pursue a neighboring group participation group strategy required us to 
readdress the mycosamine donor synthesis, since our existing route produced a sugar donor with 
the natural S-configuration found in AmB. Neighboring group participation would require this 
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carbon center to be inverted in our new proposed sugar donor, 4.1 (Figure 4.1). While 4.1 might 
be accessible with our current route by employing the pseudoenantiomeric (DHQD)2PYR 
ligands in the dihydroxylation of 3.37 (See Chapter 3, Figure 3.7), targeting a sugar donor with 
an inverted C2’-substituant enabled us to take advantage of substantial existing work already 
done in this area.4-5 As seen in Figure 4.1, 4.1 would be accessed by opening epoxide 4.3 with 
sodium azide, followed by protection of the resulting C2’-hydroxyl and conversion of the 
anomeric PMB group to an appropriate anomeric activating group, such as the 
trichloroacetimidate shown. 4.3 is conveniently accessible from commercially available and 
relatively inexpensive 2-acetylfuran in only 6 steps.5 This route also has the advantage of 
installing the C2’-substituent very late in the synthesis, which would greatly facilitate a survey of 
improved directing groups for neighboring group participation. 
 
O
O
PMBO
OH
Me
O
Me
O
O'Doherty,
Carreira
6 steps
OO
OTBS
Me
RO
N3
Cl3C NH
OPMBO
OTBS
Me
HO
N3
2-acetyl furan
48¢/gram
4.1 4.2 4.3
4.4
2'
3' 4'
 
Figure 4.1. Retrosynthesis of the mycosamine donor 4.1 from commercially available 2-acetylfuran. 
 
 In the forward direction, the synthesis of 4.1 proved to very efficient (Scheme 4.1). In 
brief, Noyori reduction of 2-acetylfuran, followed by Achmatowicz rearrangement and 
diastereoselective Boc-protection provided pyranone 4.6. Subsequent palladium-mediated 
installation of the anomeric OPMB, Luche reduction, and directed m-CPBA epoxidation 
provided 4.3. This route was not only efficient step-wise, but was also found to be very scalable, 
enabling isolation of more than 100 g of epoxy alcohol 4.3. 
 
O
Me
O
O
Me
OH OBocO
O
Me O
O
PMBO
OH
Me
[Cp*RhCl2]2
(R,R)-TsDPEN
, H2ONa O H
O
1. NBS, NaHCO3
NaOAc
THF:H2O, 0 °C
2. Boc2O, DMAP
DCM, -78 °C
48% (3 steps)
1. PMBOH
Pd2dba3, PPh3
DCM, 0 °C, 94%
2. NaBH4, CeCl3
DCM:MeOH, quant.
3. m-CPBA
DCM, 0 °C, 74%
4.4 4.5 4.6 4.3
 
Scheme 4.1. Synthesis of epoxide 4.3 from 2-acetylfuran. This route was both efficient and scalable, enabling the 
isolation of more than 100 g of 4.3. 
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O
O
PMBO
OH
Me O
O
PMBO
OTBS
Me OPMBO
OTBS
Me
HO
N3
TBSCl
imidazole
DCM, 23 °C, 92%
NaN3, LiClO4
MeCN, 80 °C, 25%
4.3 4.7 4.2  
Scheme 4.2. Preparation of azido alcohol 4.2 from epoxide 4.7 proceeded via a low yielding but reliable sodium 
azide opening. The yield for this transformation suffered from poor regioselectivity between the two possible sites of 
attack on epoxide 4.7. 
 
 Following TBS-protection of 4.3, opening of epoxide 4.7 with NaN3 and LiClO4 
proceeded in a modest 25% yield. The poor yield of this epoxide opening was not unexpected, 
due to the poor degree of discrimination between opening at C2’ vs. the desired C3’. Similarly 
low yields have been observed in a very similar TES protected substrate.5 Nevertheless, the yield 
for this reaction was very reproducible, and more than compensated for by the small number of 
steps in the synthesis to this point. Alcohol 4.2 was thus set up for acylation with our choice of 
directing group. For our initial attempts, the chlorodimethylacetyl group utilized by Carreira and 
coworkers seemed to be a logical starting point, and we were curious to see how it would 
perform in glycosylations with BB2. We therefore set out to synthesize 4.10 and attach it to a 
mycosamine sugar donor (Figure 4.2). Synthesis of the carboxylic acid was fairly 
straightforward, beginning with chlorination of isobutyraledhyde, followed by a Pinnick 
oxidation to give 4.10. Completion of our first mycosamine donor for neighboring group 
participation-mediated glycosylation is shown in Figure 4.2. Briefly, acylation with 4.10, 
followed by oxidation cleavage of the anomeric PMB group with DDQ, and installation of a 
trichloroacetimidate gave mycosamine donor 4.12. 
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Me
Me
H
O 1. t-BuNH2, neat23 °C
2. NCS, CHCl3
0-23 °C; HCl
39% (2 steps)
Cl
Me
H
O
Me
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Me
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O Me
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O
Cl
MeMe
O Me
OTBS
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O
PMBO
O
Cl
Me
Me
4.2
4.10
DCC, DMAP
DCM, 40 °C
84%
1. DDQ, DCM
pH 6 phosphate buffer
40 °C
2. Cl3C-CN, Cs2CO3
DCM, 23 °C
79% (2 steps)
4.8 4.9 4.10
4.11 4.12
O
NHCl3C
 
Figure 4.2. (A) Synthesis of chlorodimethylacetic acid (4.10) from isobutyraldehyde. (B) completion of 
mycosamine donor 4.12, designed for neighboring group participation-controlled glycosylation. 
 
For our glycosylation reactions, we chose to use BB2 aglycone 4.13. We hypothesized 
that 4.13 might be a more competent nucleophile than the corresponding dienyl MIDA boronate 
3.15 (See Chapter 3, Scheme 3.9). Additionally, we expected that the MIDA boronate of 3.15 
would be incompatible with the strongly basic conditions necessary for removal of the C2’ 
directing group following glycosylation. As seen in Scheme 4.3, combination of BB2 aglycone 
4.13 and mycosamine donor 4.12 in the presence of CMPT/CMP in hexanes afforded the desired 
product in an estimated ~60% yield, along with an unidentified and inseparable byproduct. 
Unfortunately, subsequent removal of the chlorodimethylacetyl directing group was not possible 
due to the sensitivity of the BB2 lactone to base, with all attempts resulting in decomposition. 
 
O Me
OTBS
N3
O
O
Cl
Me
Me
Et3Ge
OH
O
O OTBS
CO2TMSE
O Me
OTBS
N3
O
O
Cl
MeMe
H
N MeCl
ClH
N MeCl
hexanes, 23 °C, 30 min
~60%
Et3Ge
O
O
O OTBS
CO2TMSE
H
K2CO3
MeOH:THF
23 °C
decomposition
4.13
4.12
4.14
O
NHCl3C
 
Scheme 4.3. Glycosylation of BB2 aglycone 4.13 with 4.12 enabled successful attachment of mycosamine to BB2. 
However, the sensitivity of the BB2 lactone to base prevented subsequent removal of the chlorodimethylacetyl 
directing group. 
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4-3 DESIGN OF A NEW DIRECTING GROUP FOR GLYCOSYLATION 
Despite a less than optimal yield and an inability to remove the directing group, we were 
very encouraged by having finally achieved the desired glycosidic linkage. We next considered 
whether we could improve upon the chlorodimethylacetyl protecting group. In principle, the 
chlorodimethylacetate works well as a directing group because the chloride gives it a steric 
profile similar to a pivolate group, which helps to disfavor ortho ester formation. Inductively,  
the chloride withdraws electron density from the carbonyl, making subsequent deprotection of 
the group more facile. However, this chloride activation likely also contributes to ortho ester 
formation by activation of the carbonyl to nucleophilic attack in the glycosylation step. With 
these principles in mind, we considered several alternative directing groups which maintained a 
quaternary center alpha to the carbonyl, while incorporating additional functionality that would 
promote deprotection following glycosylation without also promoting ortho ester formation 
(Figure 4.3). The 2,2-dimehtylbut-3-enoate protecting group (4.15) developed by Crimmins,6 can 
be removed by hydroboration/oxidation and subsequent lactonization. Similarly, the 4-acetoxy-
2,2-dimethylbutyrate group (4.16) developed by Ensley is removed by acetate saponification and 
lactonication,7 though we were uncertain whether a base-promoted deprotection manifold would 
be productive given the demonstrated instability of the BB2 lactone to base. The 4-tert-
butyldimethylsilyloxy-2,2-dimethylbutyrate (TDMB, 4.17) was seen as potentially the most 
promising, as we expected it to be labile under mildly acidic conditions (Scheme 4.4). This group 
had been previously employed by Trost8 as an alcohol protecting group, but to the best of our 
knowledge, it had never been used in glycosylation reactions. 
 
OH
O
Me Me
OH
O
Me Me
AcO OH
O
Me Me
TBSO
4.15 4.16 4.17  
Figure 4.3. Alternative directing groups considered for use in the glycosylation of BB2. 
 
O
OR
Me
TBSO
O
ORHO
H+
ROH O
O
Me Me Me
Me
Me+
4.17 4.18  
Scheme 4.4. Deprotection of the TDMB group under acidic conditions via desilylation followed by an acid 
catalyzed lactonization. 
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Between these 3 possibilities we were less confident in the compatibility of the BB2 
framework to hydroboration/oxidation or base, so we proceeded initially with 4.17, the synthesis 
of which was previously described.9-10 The synthesis of a mycosamine donor, 4.20 incorporating 
this new directing group is shown in Error! Reference source not found.. In this case, 
functionalization of the C2’ alcohol was achieved very efficiently via a DCC coupling, followed, 
as before, by deprotection of the anomeric PMB group and installation of, in its place, a 
trichloroacetimidate group. Mycosamine donor 4.20 has been shown to be stable to storage for 
greater than a week, though only if frozen in a benzene matrix. In contrast, the hemiketal 
precursor to 4.20 can be stored for greater than six months at -78 °C. 
 
O Me
OTBS
N3
HO
PMBO
O
OH
Me
TBSO
Me
DCC, DMAP
DCM, 40 °C, 82%
O Me
OTBS
N3
TDMBO
PMBO
1. DDQ, DCM
pH 6 phosphate buf fer
40 °C, 52%
2. Cl3C-CN, Cs2CO3
DCM, 23 °C, 76%
O Me
OTBS
N3
TDMBO
O
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4.2 4.19 4.20
4.18
 
Scheme 4.5. Incorporation of the TDMB directing group into the synthesis of the mycosamine donor 4.20. 
 
 To test this alternative directing group, mycosamine donor 4.20 was combined with BB2 
aglycone 4.13 in the presence of CMPT/CMP in hexanes (Scheme 4.6). The TDMB group was 
very effective, providing the desired glycosylated product 4.21 in a remarkable 93% yield as a 
single diastereomer, with no evidence of ortho ester formation. Further, we found that the TDMB 
group could be removed by treatment with anhydrous CSA in MeCN. Under these conditions the 
desired product (4.22) was obtained in 60% yield. Recycling the incompletely reacted starting 
material a single time improved the overall yield to 72%. 
Et3Ge
O
O OTBS
CO2TMSE
O O
H
RO
N3
OTBS
MeEt3Ge
O
O OTBS
CO2TMSE
OH
CSA, MeCN, 23 °C
2 cycles, 72%
O Me
OTBS
N3
TDMBO
O
H
N MeCl
Cl
N MeCl
hexanes, 23 °C, 30 min
93%
+
4.21: R = TDMB
4.22: R = H
4.13 4.20
NHCl3C
 
Scheme 4.6. Successful glycosylation with mycosamine donor 4.20. The use of the TDMB group provided the 
desired product in 93% yield with complete stereoselectivity and no evidence of ortho ester formation. Treatment of 
4.21 with CSA successfully removed the directing group to give the free alcohol 4.22. 
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4-4 COMPLETION OF BB2 
With the glycosylated product 4.22 in hand, we were in a position to finally finish the 
building block, BB2. Inversion of the C2’ hydroxyl was accomplished by treatment with DMP, 
followed by a highly stereoselective reduction with NaBH4 (Scheme 4.7).1-2,11-12 The ketone 
obtained from DMP oxidation (4.23) was fairly unstable, both to chromatography and storage, 
and in the presence of water equilibrated to the hydrate, which was unreactive in the subsequent 
reduction. This phenomenon is consistent with a report by Rychnovsky and coworkers in their 
development of a β-selective glycosylation of cholesterol.12-14 Fortunately, carrying the crude 
oxidation product directly into the reduction reaction allowed isolation of the R-alcohol 4.24 in a 
67% yield over the two steps.  
 
Et3Ge
O
O OTBS
CO2TMSE
O O
H
O
N3
OTBS
Me
4.22 Et3Ge
O
O OTBS
CO2TMSE
O O
H
HO
N3
OTBS
Me
DMP, DCM,
23 °C, 5 h
NaBH4, EtOH
-78 °C, 30 min
67% (2 steps)
4.23 4.242' 2'
 
Scheme 4.7. Inversion of the C2’-hydroxyl following successful glycosylation was accomplished by oxidation with 
DMP, immediately followed by a selective reduction with NaBH4 to give 4.24. 
  
With the correct configuration of the C2’ position established, all that remained was 
extension of the olefin to a dienyl MIDA boronate, and conversion of the lactone to a ketene 
acetyl phosphate, thus installing each of the two cross-coupling handles of our bifunctional 
building block. TBS-protection of the C2’-hydroxyl, followed by iododegermylation,15 cleanly 
gave vinyl iodide 4.25. As seen in Scheme 4.8, we initially envisioned first performing a Stille 
coupling with bis-metallated olefin 4.26,16 followed phosphorylation of the lactone. While the 
Stille coupling proceeded smoothly, subsequent phosphorylation proceeded with concomitant 
hydrolysis of the MIDA boronate. This hurdle was overcome by reprotection of the boronic acid 
with a MIDA anhydride reagent (4.28) developed by Jenna Klubnick,17 thereby completing BB2.  
Although reprotection of the MIDA boronate proceeded smoothly, we wished to 
eliminate this step to improve the efficiency of the route. Predictably, phosphorylation of vinyl 
iodide 4.25 proceeded without incident to give 4.29. We then considered whether the vinyl 
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iodide could be selectively coupled to bis-metallated olefin 4.26 in the presence of the ketene 
acetal phosphate. Indeed, when using PdCl2(MeCN)2 in DMF at 65 °C we were able to achieve 
complete selectivity for the iodide over the ketene acetal phosphate to again give BB2. This 
completed building block has been shown to be stable for greater than 2 months at -78 °C, and is 
ready to be incorporated into an ICC-based selective cross-coupling of the ketene acetal 
phosphate in the presence of the MIDA-boronate. 
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65 °C
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N
OO O
4.28
(PhO)2P(O)Cl
HMPA, THF
-78 °C
55% BRSM
4.26
PdCl2(MeCN)2
DMF, 60 °C, 44%
4.24
BB2
4.25 4.27
4.29
Scheme 4.8. BB2 was completed by Stille coupling of 4.25 and 4.26, followed by phosphorylation of the BB2 
lactone and subsequent reprotection of the MIDA boronate with MIDA anhydride (4.28). An alternative route that 
obviates the MIDA reprotection step was also demonstrated, whereby the lactone was phosphorylated first to give 
4.29, followed by selective Stille coupling  of this iodide to 4.26. 
 
4-5 APPLICATION OF GLYCOSYLATION STRATEGY TO AMPHOTERICIN AGLYCONE 
 The successful use of the TDMB directing group in the glycosylation of BB2 prompted 
us to investigate whether this strategy might provide a solution to the long standing problem of 
glycosylating polyene macrolides. In fact, combining mycosamine donor 4.30 with protected 
amphotericin B aglycone, under our now standard conditions of CMPT/CMP in hexanes 
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provided the desired glycosylated product 4.31 in nearly quantitative yield, again with no 
evidence of ortho ester formation.  
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Scheme 4.9. The TDMB directing group enabled effective glycosylation of the AmB aglycone 
 
This result represents a significant advance over existing methodology, and suggested to 
us an accelerated route to amphotericin derivatives containing modifications to the mycosamine 
sugar, since AmB aglycones like 4.30 are readily accessible via degradation of AmB.18 As 
mentioned in Chapter 1, sugar-based functional group deletion derivatives are of significant 
interest to us, due to clear role that the mycosamine sugar plays in enabling sterol binding. To 
test this approach we pursued a synthesis of the C3’-deaminomycosamine donor. As seen in 
Scheme 4.10, beginning with intermediate 4.7 from our existing mycosamine route, opening of 
the epoxide with DIBAL-H afforded 4.32 in an unoptimized 10% yield, which retains the proper 
stereochemical configuration at C2’ but lacks the nitrogen at C3’.  Protection of the 2’-alcohol as 
a TDMB acetate via DCC coupling, deprotection of the PMB group, and subsequent installation 
of the anomeric trichloroacetimidate proceeded without incident to afford 3’-
deaminomycosamine donor 4.33. 
 
O
O
PMBO
OTBS
Me OPMBO
OTBS
Me
HO
DIBAL-H
DCM, 60 °C
1. 4.17, DCC, DMAP
DCM, 60 °C, 53%
2. DDQ, DCM:H2O
pH=6 phosphate buffer
80%
10%
OO
OTBS
Me
TDMBO
3. Cl3C-CN
Ce2(CO3)3, DCM
68%
NHCl3C
4.334.7 4.32
3'
 
Scheme 4.10. Synthesis of a deaminomycosamine donor  
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 Combination of 4.33 with amphotericin B aglycone 4.30 in the presence of CMPT/CMP 
in hexanes afforded the desired product in an excellent 97% yield. As appears to be typical for 
this directing group, the reaction proceeded with complete stereocontrol, and no ortho ester was 
observed. With the protecting group pattern chosen for amphotericin aglycone 4.30, after 
inversion of the C2’-alcohol only three deprotection steps would be necessary to obtain 
C3’deNAmB, demonstrating the potential of this glycosylation strategy for accessing AmB 
derivatives containing modified sugars. 
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4.34  
Scheme 4.11. Glycosylation of amphotericin aglycone 4.30 with deaminomycosamine donor 4.33 proceeded in an 
outstanding 97% yield, demonstrating the potential of this approach for accessing AmB derivatives containing 
modified sugars. 
 
4-6 SUMMARY 
 This dissertation describes several methodological advances that were stimulated by 
studies toward an efficient and flexible total synthesis of AmB. In response to challenges 
encountered in the construction of the AmB polyene, a new cross-coupling protocol was 
developed whereby MIDA boronates can be used directly in SMC reactions, enabling air-stable 
MIDA boronates to act as surrogates for boronic acids. Additionally, conditions were identified 
under which MIDA boronates could be slowly hydrolyzed in the SMC reaction, enabling an in 
situ “slow-release” of the boronic acid. This slow-release effect enables the efficient cross-
coupling of a variety of otherwise unstable boronic acids. The synthesis and isolation of 2-
pyridyl MIDA boronate and its derivatives demonstrates that even the most unstable boronic 
acids may be rendered stable and competent cross coupling partners by conversion to the 
corresponding MIDA boronates. Further, the use of “fast-release” conditions enabled the 
construction of the AmB heptaene as well as a variety of polyenyl natural products both within 
and outside our research group.  To overcome the challenging 1,2-cis glycosidic bond found in 
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AmB a mycosamine sugar donor synthesis was developed incorporating a new directing group 
for neighboring group participation. The use of this new directing group enabled efficient 
glycosylation of, and ultimately the completion of, BB2, a critical building block in the context 
of the ICC-based synthesis of AmB. The potential of this glycosylation strategy for rapidly 
accessing AmB derivatives was also demonstrated in the synthesis of a C3’deaminomycosamine 
sugar donor and its efficient attachment to a protected amphotericin aglycone. 
 
4-7 EXPERIMENTAL SECTION 
Materials.   
Commercial reagents were purchased from Sigma-Aldrich, Fisher Scientific, Alfa Aesar, 
TCI America Frontier Scientific, Oakwood Products or Combi-Blocks and were used without 
further purification unless otherwise noted. Solvents were purified via passage through packed 
columns as described by Pangborn and coworkers19 (THF, Et2O, MeCN, DCM: dry neutral 
alumina; hexane, benzene, and toluene: dry neutral alumina and Q-5 reactant (copper(II) oxide 
on alumina); DMSO, DMF: activated molecular sieves). All water was deionized prior to use. 
Triethylamine, diisopropylamine, diethylamine, pyridine, and 2,6-lutidine were freshly distilled 
under an atmosphere of nitrogen from CaH2. The following compounds were prepared according 
to procedures reported in the literature: 4.3,5 4.5,4-5 4.6,4-5 4.179-10. 
 
General Experimental Procedures.   
 Unless otherwise noted, all reactions were performed in flame-dried glassware under 
argon. Organic solutions were concentrated via rotary evaporation under reduced pressure with a 
bath temperature of 35-40 ºC. Reactions were monitored by analytical thin layer chromatography 
(TLC) performed using the indicated solvent on E. Merck silica gel 60 F254 plates (0.25mm). 
Compounds were visualized by: exposure to a UV lamp (λ = 254 or 366 nm), incubation in a 
glass chamber containing iodine, and/or treatment with a solution of KMnO4, an acidic solution 
of p-anisaldehyde or a solution of ceric ammonium molybdate (CAM) followed by brief heating 
with a Varitemp heat gun. MIDA boronates are compatible with standard silica gel 
chromatography, including standard loading techniques. Column chromatography was performed 
using standard methods20 or with a Teledyne-Isco CombiFlash Rf purification system. Both 
methods were performed using Merck silica gel grade 9385 60 Å (230-400 mesh). For loading, 
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compounds were adsorbed onto non acid-washed Celite 545 (app. 10 g/mmol crude product) in 
vacuo from an acetone solution. Specifically, in each case the crude residue was 
dissolved/suspended in acetone and to the mixture was added Celite. The mixture was 
concentrated in vacuo to afford a free flowing powder which was then loaded on top of a silica 
gel column. To ensure quantitative transfer, this procedure was repeated with a small amount of 
acetone and Celite to transfer any remaining residue. 
 
Structural analysis.   
1H-NMR spectra were recorded at 23 °C on a Varian Unity or a Varian Unity Inova 500 
MHz spectrometer. Chemical shifts () are reported in parts per million (ppm) downfield from 
tetramethylsilane and referenced to residual protium in the NMR solvent (CHCl3, = 7.26; 
CD2HCN, = 1.93, center line; acetone-d6 = 2.04, center line). Alternatively, NMR-solvents 
designated as “w/ TMS” were referenced to tetramethylsilane (δ = 0.00 ppm) added as an 
internal standard. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, quint = quintet, sept = septet, m = multiplet, br = broad, app = 
apparent), coupling constant (J) in Hertz (Hz), and integration.  13C NMR spectra were recorded 
at 23 °C on a Varian Unity 500 MHz spectrometer. Chemical shifts () are reported in ppm 
downfield from tetramethylsilane and referenced to carbon resonances in the NMR solvent 
(CDCl3, = 77.0, center line; CD3CN, = 1.30, center line, acetone-d6 = 29.80, center line) or 
to added tetramethylsilane (= 0.00).  Carbons bearing boron substituents were not observed 
(quadrupolar relaxation). 11B NMR were recorded using a General Electric GN300WB 
instrument and referenced to an external standard of (BF3·Et2O). High resolution mass spectra 
(HRMS) were performed by Furong Sun and Dr. Steve Mullen at the University of Illinois 
School of Chemical Sciences Mass Spectrometry Laboratory.  Infrared spectra were collected 
from a thin film on NaCl plates or as KBr pellets on a Perkin-Elmer Spectrum BX FT-IR 
spectrometer, a Mattson Galaxy Series FT-IR 5000 spectrometer or a Mattson Infinity Gold FT-
IR spectrometer.  Absorption maxima (max) are reported in wavenumbers (cm-1).   
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Synthesis of compounds. 
 
O
O
PMBO
OH
Me O
O
PMBO
OTBS
MeTBSClimidazole
DCM, 23 °C, 92%
4.3 4.7  
  
 To a 1 L round bottom flask containing 4.3 and stir bar under argon was added DCM 
(325 mL) and DMF (65 mL) and the resulting mixture was stirred to homogeneity. To the 
mixture was then added sequentially imidazole (31.0 g, 491 mmol) and TBSCl (51.4 g, 341 
mmol). The flask was fitted with a reflux condenser and, under argon maintenance, was stirred at 
40 °C for 16 h. The reaction was cooled to room temperature and diluted with Et2O (1 L) and 
sat’d aq NaHCO3 (1 L). The aqueous layer was separated and extracted  with Et2O (500 mL). 
The combined organic fractions were washed with brine, dried over Na2SO4, filtered and 
concentrated in vacuo to give a white solid. The product was purified by DCVC21 (hex:EtOAc, 
20:1 → 3:1) to afford 4.7  as a white solid (40.0 g, 92%). 
 
O
O
PMBO
OTBS
Me
4.7  
TLC (hex:EtOAc 4:1) 
 Rf = 0.35, stained with CAM 
 
1H-NMR (500 MHz, CDCl3) 
 δ 7.30 (d, J = 8.5 Hz, 2H), 6.88 (d, J = 9 Hz, 2H), 4.92 (d, J = 3 Hz, 1H), 4.70 (d, J = 12 
Hz, 1H), 4.54 (d, J = 12 Hz, 1H), 3.85 (m, 1H), 3.81 (s, 3H), 3.61 (dd, J = 8.5, 1.5 Hz, 
1H), 3.41 (app t, J = 4 Hz, 1H), 3.25 (dd, J = 4, 1 Hz, 1H), 1.15 (d, J = 6 Hz, 3H), 0.911 
(s, 9H), 0.140 (s, 3H), 0.110 (s, 3H) 
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HO
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NaN3, LiClO4
DCM, 23 °C, 25%
4.7 4.2  
  
To a 2 L round bottom flask containing 4.7 (79.1 g, 208 mmol) and a stir bar was added 
MeCN. The resulting mixture was stirred to homogeneity. To the mixture was next added NaN3 
(27.05 g, 416 mmol), then LiClO4 (110.67 g, 1040 mmol). The flask was fitted with a reflux 
condenser, and the mixture was stirred at 80 °C under argon maintenance for 24 h. The reaction 
was cooled to room temperature and diluted with Et2O (2 L) and brine (1 L). The aqueous layer 
was separated and extracted with Et2O (3×1 L). The combined organic fractions were dried over 
Na2SO4, filtered and concentrated in vacuo. The resulting crude material was purified in 2 
batches by DCVC (hex:EtOAc 10:1 → 2:1). Mixed fractions were combined and re-purified in 3 
subsequent cycles to yield the desired product as a yellow oil (22.31 g, 25%). 
 
OPMBO
OTBS
Me
HO
N3
4.2  
1H-NMR (500 MHz, CDCl3) 
 δ 7.28 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.5 Hz, 2H), 4.87 (d, J = 4 Hz, 1H), 4.69 (d, J = 
11.5 Hz, 1H), 4.46 (d, J = 11.5 Hz, 1H), 3.82 (s, 3H), 3.73 (m, 1H), 3.53 (m, 1H), 3.43 (t, 
J = 9.5 Hz, 1H), 3.02 (t, J = 9.5 Hz, 1H), 1.22 (d, J = 6.5 Hz, 3H), 0.907 (s, 9H), 0.182 (s, 
3H), 0.097 (s, 3H) 
 
 
Me
Me
H
O 1. t-BuNH2, neat
23 °C
2. NCS, CHCl3
0-23 °C; HCl
39% (2 steps)
Cl
Me
H
O
Me
4.8 4.9  
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 To a 100 mL flask equipped with a stir bar under nitrogen was added isobutyraldehyde 
(4.8) (10 mL, 110 mmol). The substrate was cooled with stirring to 0 °C, and to the flask was 
then added t-BuNH2 (11.5 mL, 110 mmol). The resulting mixture was stirred at room 
temperature for 6 h. Chloroform (100 mL) and Na2SO4 were added, and the mixture was stirred 
for 15 min, then filtered into a 250 mL flask. A stir bar was added and the solution was cooled, 
stirring, to 0 °C. NCS (14.69 g, 110 mmol) was added in a single portion, the mixture was stirred 
at room temperature for 18 h. The reaction was then poured into H2O (100 mL). The organic 
phase was separated and extracted with chloroform (50 mL). The combined organic fractions 
were washed with H2O (50 mL), dried over Na2SO4, filtered and concentrated (rotovap bath at 
23 °C) in vacuo. Conc. HCl (25 mL) was added, and the mixture was vigorously stirred for 6 h at 
room temperature. NaHCO3 (ca. 30 g) was added, followed by chloroform (50 mL) and enough 
H2O to dissolve the NaHCO3 salts. The organic phase was separated, and aqueous phase 
extracted with chloroform (2×20 mL). The combined organic fractions were dried over Na2SO4, 
filtered and distilled at ambient pressure. Note: the desired product co-distills with chloroform, 
so 4.9 was thus isolated as a chloroform solution. 1H NMR enabled a calculation of the 
concentration, and thus the yield: 4.6 g, 39%. This solution of 4.9 was carried directly forward 
into the next reaction without further purification or characterization. 
 
 
Cl
Me
H
O
Me
NaClO2
NaH2PO4
MeOH, CHCl3
H2O, 23 °C
98%
Me
Me
Me
Cl
Me
OH
O
Me
4.9 4.10  
 
 To a 1 L flask containing 4.9 (40.9 mmol in an 87 mL-solution of chloroform) and a stir 
bar was added MeOH (260 mL), H2O (87 mL), 2-methyl-2-butene (43.5 mL), NaH2PO4 (22.588 
g, 164 mmol), and NaClO2 (7.409 g, 81.9 mmol). The resulting mixture was stirred briskly at 
room temperature for 5 h. The reaction was then diluted with 1M HCl (500 mL) and Et2O (500 
mL). The aqueous phase was separated and extracted with Et2O (250 mL). the combined organic 
fractions were extracted with 1M NaOH (500 mL, then 250 mL). The combined basic aqueous 
fractions were then acidified with 3M aq HCl (750 mL) and extracted with Et2O (3×500 mL). the 
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combined Et2O fractions were washed with brine (500 mL), dried over Na2SO4, filtered and 
concentrated in vacuo to afford a pale yellow oil (4.92 g, 98%). 
 
Cl
Me
OH
O
Me
4.10  
Spectroscopic characterization was consistent with literature reports.22 
 
 
O Me
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N3
HO
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Me
DCC, DMAP
DCM, 40 °C, 82%
O Me
OTBS
N3
TDMBO
PMBO
4.2 4.19
4.18
 
 
 To a 250 mL flask containing 4.2 (4.08 g, 9.63 mmol) and a stir bar was added 4.18 (5.33 
g, 19.2 mmol), DCM (32 mL), DCC (9.93 g, 48.1 mmol), and finally DMAP (2.35 g, 19.2 
mmol). The flask was fitted with a reflux condenser and the mixture thus stirred at 40 °C for 36 
h. The reaction was then cooled to room temperature and diluted with hexanes (ca. 250 mL) and 
filtered through a medium fritted glass funnel. The filtrate was washed with sat’d aq NaHCO3 
(50 mL). The aqueous phase was extracted with hexanes (100 mL). The combined organic 
fractions were dried over Na2SO4, filtered and concentrated in vacuo to give a yellow oil. This 
crude product was purified by DCVC (hex:EtOAc 50:1 → 10:1) to afford 4.19 as a colorless oil 
(5.18 g, 82%). 
O Me
OTBS
N3
TDMBO
PMBO
4.19  
TLC (hex:EtOAc 10:1) 
 Rf = 0.40, stained with CAM 
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1H-NMR (500 MHz, CDCl3) 
 δ 7.25 (d, J = 9 Hz, 2H), 6.88 (d, J =8.5 Hz, 2H), 5.03 (d, J = 3.5 Hz, 1H), 4.60 (d, J = 
11.5 Hz, 1H), 4.56 (dd, J = 11, 4 Hz, 1H), 4.39 (d, 11 Hz, 1H), 3.81 (s, 3H), 3.77 (dd, J = 
10.5, 9 Hz, 1H), 3.72 (m, 1H), 3.65 (t, J = 7 Hz, 2H), 3.09 (t, J = 9 Hz, 1H), 1.82 (m, 2H), 
1.22 (m, 9H), 0.905 (s, 9H), 0.873 (s, 9H), 0.171 (s, 3H), 0.098 (s, 3H), 0.029 (s, 3H) 
 
 
O Me
OTBS
N3
TDMBO
PMBO
DDQ, DCM
pH=6 phosphate buffer
40 °C, 52% O Me
OTBS
N3
TDMBO
HO
4.19  
 To a 1 L round bottom flask containing 4.19 (5.04 g, 7.73 mmol) and a stir bar was added 
DCM (135 mL), 1 M pH=6 aq phosphate buffer (27 mL), then DDQ (5.274 g, 23.2 mmol). The 
flask was sealed with a rubber septum and stirred vigorously at 40 °C for 36 h. Additional DDQ 
(1.75 g, 7.71 mmol) was added at 12 h and 24 h. The reaction was cooled to room temperature 
and diluted with sat’d aq NaHCO3 (300 mL) and Et2O (300 mL). The aqueous phase was 
separated and extracted with Et2O (3×400 mL). The combined organic fractions were dried over 
Na2SO4, filtered, and concentrated in vacuo. The crude material thus obtained was purified by 
column chromatography (SiO2, hex:EtOAc 10:1 → 4:1) to afford the hemiacetal as a mixture of 
anomers (2.15 g, 52%). 
O Me
OTBS
N3
TDMBO
HO
 
TLC (hex:EtOAc 5:1) 
 Rf = 0.33: Major anomer, stained with KMnO4 
 Rf = 0.39: Minor anomer 
 
1H-NMR (500 MHz, CDCl3) 
 Major anomer: δ 4.56 (dd, J = 11, 4 Hz, 1H), 4.39 (d, 11 Hz, 1H), 3.81 (s, 3H), 3.77 (dd, 
J = 10.5, 9 Hz, 1H), 3.72 (m, 1H), 3.65 (t, J = 7 Hz, 2H), 3.09 (t, J = 9 Hz, 1H), 1.82 (m, 
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2H), 1.22 (m, 9H), 0.905 (s, 9H), 0.873 (s, 9H), 0.171 (s, 3H), 0.098 (s, 3H), 0.029 (s, 
3H) 
 
 
O Me
OTBS
N3
TDMBO
HO Cl3C-CN, Cs2CO3DCM, 23 °C, 76% O Me
OTBS
N3
TDMBO
O
NHCl3C
4.20  
 To a 250 mL round bottom flask containing the hemiacetal substrate (5.01 g, 9.42 mmol) 
and a stir bar under argon was added DCM (94 mL), trichloroacetonitrile (9.45 mL, 94.2 mmol) 
and Cs2CO3 (1.53 g, 4.69 mmol). The resulting mixture was stirred  at room temperature for 1 h. 
The reaction was directly concentrated, and the resulting crude product purified by column 
chromatography (SiO2, hex:EtOAc 10:1 isocratic) to yield 4.20 as a 2:1 mixture of anomers 
(4.83 g, 76%) 
O Me
OTBS
N3
TDMBO
O
NHCl3C
4.20  
TLC (EtOAc) 
 Rf = 0.33, stained with KMnO4 
 
1H-NMR (500 MHz, CDCl3) 
 Major anomer: δ 8.62 9 (s, 1H), 6.42 (d, J = 3.5 Hz, 1H), 4.82 (dd, J = 10.5, 3.5 Hz, 1H), 
3.87 (m, 1H), 3.78 (t, J = 10.5 Hz, 1H), 3.67–3.62 (m, 3H), 1.90–1.74 (m, 2H), 1.26 (d, J 
= 6 Hz, 3H), 1.21 (m, 6H), 0.91 (s, 9H), 0.87 (s, 9H), 0.10 (s, 3H), 0.03 (s, 3H) 
 
Minor anomer: δ 8.65 (s, 1H), 5.86 (d, J = 8.5 Hz, 1H), 5.11 (dd, 1H), 3.55 (m, 1H), 3.45 
(t, 10 Hz, 1H), 3.30 (t, J = 9 Hz, 1H), 3.20 (t, J = 9.5 Hz, 2H), 1.90–1.74 (m, 2H), 1.32 
(d, J = 6 Hz, 3H), 1.21 (m, 6H), 0.92 (s, 9H), 0.87 (s, 9H), 0.20 (s, 3H), 0.12 (s, 3H) 
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Me
HO
DIBAL-H
DCM, 60 °C
10%
4.7 4.32  
 
To a 40 mL I-Chem vial containing 4.7 (0.286 g, 0.75 mmol) and a stir bar under 
nitrogen was added DCM (15 mL) and DIBAL-H (1M solution in DCM, 2.25 mL, 2.25 mmol). 
The resulting mixture was stirred at 60 °C for 1 h. The reaction was cooled to room temperature, 
diluted with Et2O (30 mL) and sat’d aq Na,K-tartrate (15 mL), then stirred for 3 h. The aq phase 
was separated and extracted with Et2O (3×15 mL). The combined organic fractions were dried 
over MgSO4, filtered, and concentrated in vacuo. The resulting crude product was purified by 
column chromatography (SiO2, hex:EtOAc 5:1 → 3:1) to afford 4.32 as a colorless oil (28.7 mg, 
10% yield). It should be noted that the epoxide opening appears to be completely selective under 
these conditions. The loss of yield is due to competitive desilylation at C4’. 
 
OPMBO
OTBS
Me
HO
4.32  
TLC (hex:EtOAc 3:1) 
 Rf = 0.43, stained with CAM 
 
1H-NMR (500 MHz, CDCl3) 
 δ 7.28 (d, J = 10 Hz, 2H), 6.90 (d, J = 8.5 Hz, 2H), 4.79 (d, J = 3.5 Hz, 1H), 4.70 (d, J = 7 
Hz, 1H), 4.46 (d, J = 11.5 Hz, 1H), 3.81 (s, 3H), 3.67 (dt, J = 12, 4 Hz, 1H), 3.57 (m, 
1H), 3.26 (m, 1H), 2.10 (m, 1H), 1.69 (q, J = 11.5 Hz, 1H), 1.19 (d, J = 6 Hz, 3H), 0.878 
(s, 9H), 0.067 (s, 6H) 
OPMBO
OTBS
Me
HO
4.17
DCC, DMAP
DCM, 60 °C, 53%
OPMBO
OTBS
Me
TDMBO
O
OH
Me
TBSO
Me
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 To a 7 mL vial containing 4.32 (0.0528 g, 0.138 mmol) and a stir bar was added 4.17 
(0.068 g, 0.276 mmol), DCM, DCC (0.142 g, 0.688 mmol), and DMAP (0.034 g, 0.278 mmol). 
The resulting mixture was stirred at 40 °C for 24 h. After cooling to room temperature, the 
reaction was diluted with hexanes (4 mL) and filtered, then concentrated directly to a colorless 
oil, which was column purified (SiO2, hex:EtOAc 40:1 → 20:1) to yield the TDMB-protected 
product as a colorless oil (44.8 mg, 53%). 
 
OPMBO
OTBS
Me
TDMBO  
TLC (hex:EtOAc 1:1) 
 Rf = 0.76, stained with CAM 
 
1H-NMR (500 MHz, CDCl3) 
 δ 7.27 (d, J = 9 Hz, 2H), 6.86 (d, J = 8.5 Hz, 2H), 4.87 (d, J = 3.5 Hz, 1H), 4.73 (m, 1H), 
4.65 (d, J = 12 Hz, 1H), 4.44 (d, J = 11.5 Hz, 1H), 3.80 (s, 3H), 3.61 (m, 3H), 3.34 (q, 7 
Hz, 1H), 1.96 (m, 2H), 1.80 (m, 2H), 1.19 (d, J = 6 Hz, 3H), 1.17 (d, J = 5 Hz, 3H), 0.874 
(s, 9H), 0.865 (s, 9H), 0.067 (s, 3H), 0.063 (s, 3H), 0.015 (s, 6H) 
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